```
     FILE 'REGISTRY' ENTERED AT 09:12:12 ON 19 DEC 2007
L26             STRUCTURE UPLOADED
L27          14 S L26 SAM SUB=L6
L28         506 S L26 SSS FULL SUB=L6
L29        1077 S L6 NOT L28

     FILE 'STNGUIDE' ENTERED AT 09:14:12 ON 19 DEC 2007

     FILE 'CAPLUS' ENTERED AT 09:14:23 ON 19 DEC 2007
L30         105 S L29

     FILE 'REGISTRY' ENTERED AT 09:14:47 ON 19 DEC 2007

=> d l26
L26 HAS NO ANSWERS
L26              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> d his

     (FILE 'HOME' ENTERED AT 08:23:53 ON 19 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 08:23:59 ON 19 DEC 2007
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3                STRUCTURE UPLOADED
L4          993942 S NCSC2/ES
L5              50 S L1 SAM SUB=L4
L6            1583 S L1 SSS FULL SUB=L4
L7              40 S L2 SAM SUB=L6
L8            1101 S L2 SSS FULL SUB=L6
L9             197 S L3 SSS FULL SUB=L6
L10           1163 S L8 OR L9
                   SAV TEM L6 BRD576830/A
                   SAV TEM L10 NAR576830/A

     FILE 'STNGUIDE' ENTERED AT 08:26:31 ON 19 DEC 2007

     FILE 'REGISTRY' ENTERED AT 08:28:44 ON 19 DEC 2007
L11               STRUCTURE UPLOADED
L12               STRUCTURE UPLOADED
L13             2 S L11 SAM SUB=L10
L14             5 S L12 SAM SUB=L10
L15            14 S L11 SSS FULL SUB=L10
L16            32 S L12 SSS FULL SUB=L10
L17            43 S L15 OR L16
                  SAV TEM L17 NA2576830/A

     FILE 'CAPLUS' ENTERED AT 08:30:22 ON 19 DEC 2007
L18            18 S L17

     FILE 'STNGUIDE' ENTERED AT 08:30:43 ON 19 DEC 2007

     FILE 'CAPLUS' ENTERED AT 08:31:19 ON 19 DEC 2007
L19             1 S US200!-576830/APPS
L20             1 S L18 AND L19

     FILE 'REGISTRY' ENTERED AT 08:31:37 ON 19 DEC 2007
L21               STRUCTURE UPLOADED
L22             1 S L21 SAM SUB=L10
L23            14 S L21 SSS FULL SUB=L10

     FILE 'CAPLUS' ENTERED AT 08:32:29 ON 19 DEC 2007
L24             4 S L23
L25             3 S L24 NOT L19

     FILE 'REGISTRY' ENTERED AT 08:33:07 ON 19 DEC 2007

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l11
L11 HAS NO ANSWERS
L11 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l12
L12 HAS NO ANSWERS
L12 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l21
L21 HAS NO ANSWERS
L21 STR



Structure attributes must be viewed using STN Express query preparation.

```
=>
Uploading C:\Program Files\Stnexp\Queries\10576830-broad.str

L1      STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10576830-narrow-1.str

L2      STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10576830-narrow-2.str

L3      STRUCTURE UPLOADED


=>
Uploading C:\Program Files\Stnexp\Queries\10576830-narrow-3.str

L11     STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10576830-narrow-4.str

L12     STRUCTURE UPLOADED


=>
Uploading C:\Program Files\Stnexp\Queries\10576830-narrow-5.str

L21     STRUCTURE UPLOADED
```

C:\Program Files\Stnexp\Queries\10576830-broad.str





chain nodes :
14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
6-14 8-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
6-14 8-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 14:CLASS 15:Atom 17:Atom
Generic attributes :
15:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

Node 15: Limited
    C,C3
    S,S1
    N,N1

C:\Program Files\Stnexp\Queries\10576830-narrow-1.str





chain nodes :
14 15 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
6-14 8-14 15-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
6-14 8-14 15-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 14:CLASS 15:Atom 17:Atom 18:CLASS
Generic attributes :
15:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

```
Node 15: Limited
    C,C3
    S,S1
    N,N1
```

C:\Program Files\Stnexp\Queries\10576830-narrow-2.str





chain nodes :
    14 15 18
ring nodes :
    1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
    6-14 8-14
ring bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
    6-14 8-14
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
    containing 1 : 7 :

Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
    12:Atom 14:CLASS 15:Atom 17:Atom 18:CLASS 19:Atom
Generic attributes :
    15:
    Saturation   : Unsaturated
    Number of Carbon Atoms : less than 7
    Number of Hetero Atoms : 2 or more
    Type of Ring System   : Monocyclic

Element Count :

Node 15: Limited
    C,C3
    S,S1
    N,N1

C:\Program Files\Stnexp\Queries\10576830-narrow-3.str





chain nodes :
    14 15 18 20
ring nodes :
    1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
    6-14 8-14 15-20
ring bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
    6-14 8-14 15-20
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
    containing 1 : 7 :

Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
    12:Atom 14:CLASS 15:Atom 17:Atom 18:CLASS 19:Atom 20:CLASS
Generic attributes :
    15:
    Saturation   : Unsaturated
    Number of Carbon Atoms : less than 7
    Number of Hetero Atoms : 2 or more
    Type of Ring System   : Monocyclic

Element Count :

Node 15: Limited
    C,C3
    S,S1
    N,N1

C:\Program Files\Stnexp\Queries\10576830-narrow-4.str





chain nodes :
7 8 11 12 13
ring nodes :
1 2 3 4 5 6
chain bonds :
2-7 7-11 11-12 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-7
exact bonds :
7-11 11-12 11-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 10:Atom 11:Atom
12:CLASS 13:CLASS
Generic attributes :
8:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

```
Node 8: Limited
    C,C3
    S,S1
    N,N1
```

C:\Program Files\Stnexp\Queries\10576830-narrow-5.str





chain nodes :
7 8 11 12 13 14
ring nodes :
1 2 3 4 5 6
chain bonds :
2-7 7-11 8-14 11-12 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-7 8-14
exact bonds :
7-11 11-12 11-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 10:Atom 11:Atom
12:CLASS 13:CLASS 14:CLASS
Generic attributes :
8:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

```
Node 8: Limited
    C,C3
    S,S1
    N,N1
```

=> d l19 bib abs

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:426430 CAPLUS
DN 142:482037
TI Preparation of substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of cell proliferation
IN Gorczynski, Michael J.; Bushweller, John H.; Brown, Milton L.
PA University of Virginia Patent Foundation, USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005044263	A1	20050519	WO 2004-US35586	20041027
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2007082934	A1	20070412	US 2006-576830	20060424 <--
PRAI	US 2003-514678P	P	20031027		
	WO 2004-US35586	W	20041027		

OS CASREACT 142:482037; MARPAT 142:482037
GI



I

AB The invention discloses compds. which are substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles (shown as I; X = O, S, and NH; and R1, R2, and R3 = H, halo, (C1-C4)alkyl, (C1-C4)alkoxy, aryl, -O-aryl and (CO)OR4; and R4 is H or (C1-C4)alkyl; e.g. [4-[4-(3,4-dichlorophenoxy)phenyl]thiazol-2-yl]ammonium iodide (II)) with anti-cancer activity. The invention further discloses methods of preparing compds. of the invention. For example, II was prepared (75 %) from thiourea, iodine and 4'-(3,4-dichlorophenoxy)acetophenone in EtOH. The invention also discloses methods of inhibiting cell proliferation and tumor growth in a subject by administering compds. of the invention to the subject. Pharmaceutical compns. containing the aminothiazoles and a kit for administering the aminothiazoles are also claimed.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:151244 CAPLUS Full-text
DN 140:368073
TI Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation
AU Gorczynski, Michael J.; Leal, Rachel M.; Mooberry, Susan L.; Bushweller, John H.; Brown, Milton L.
CS Department of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA
SO Bioorganic & Medicinal Chemistry (2004), 12(5), 1029-1036
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 140:368073
AB Several substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles were synthesized and evaluated for cytotoxic activity against estrogen-pos., estrogen-neg., and adriamycin-resistant human breast cancer cell lines. 4-[4'-(3,4-Dichlorophenoxy)-phenyl]-thiazol-2-yl ammonium iodide demonstrated potent activity against both estrogen-pos. and neg. breast cancer cell lines with low micromolar (μM) GI50 values. In addition, we have identified several 2-aminothiazoles that demonstrated selective potency for the adriamycin-resistant and estrogen-neg. breast cancer cell lines. The results suggest that these 2-aminothiazoles represent lead compds. for evaluation in animal models of breast cancer.
IT 684255-35-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity relationship studies of substituted 4-aryloxy- and 4-arylsulfanyl-Ph-2-aminothiazoles as inhibitors of human breast cancer cell proliferation)
RN 684255-35-4 CAPLUS
CN 2-Thiazolamine, 4-[4-(3,4-dichlorophenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:567366 CAPLUS Full-text
DN 113:167366
TI Substituted 2-aminothiazoles as fungicides
IN Ippen, Joachim; Baasner, Bernd; Marhold, Albrecht; Kysela, Ernst; Dutzmann, Stefan; Reinecke, Paul

PA Bayer A.-G., Germany
SO Ger. Offen., 78 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3836161	A1	19900426	DE 1988-3836161	19881024
PRAI DE 1988-3836161		19881024		

OS CASREACT 113:167366; MARPAT 113:167366
GI



AB Substituted 2-aminothiazoles (I, R1 = H, alkyl; R2 = II, III, IV; R3, R4, R5, R6 = H, alkyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, NO2, etc.; X = O, S, SO, SO2; Ar = substituted or unsubstituted alkyl or their addition salts and tautomeric compds.) are fungicides. Thus, spray application of I (R1 = H; R2 = C6H4OPh-4) at 0.025% by weight to wheat in greenhouse expts. gave complete protection against Leptosphaeria nodorum.
IT 129639-88-9P 129675-08-7P 129675-09-8P
129695-19-8P 129735-34-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as fungicide)
RN 129639-88-9 CAPLUS
CN 2-Pyrimidinamine, N-[4-[4-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129675-08-7 CAPLUS
CN 2-Pyrimidinamine, N-[4-[4-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129675-09-8 CAPLUS
CN 2-Pyrimidinamine, N-[4-[2-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129695-19-8 CAPLUS
CN 2-Pyrimidinamine, N-[4-[4-(2,6-dichloro-4-nitrophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129735-34-8 CAPLUS
CN 2-Pyrimidinamine, N-[4-[2-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 129639-92-5

CMF C19 H16 Cl2 N4 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 75-75-2
CMF C H4 O3 S

L25 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:552458 CAPLUS Full-text
DN 113:152458
TI Preparation of 2-(2-tetrahydropyrimidinyl)aminothiazoles as antimycotics
IN Ippen, Joachim; Baasner, Bernd; Marhold, Albrecht; Kysela, Ernst; Schaller, Klaus; Von Bittera, Miklos
PA Bayer A.-G., Germany
SO Ger. Offen., 81 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3839758	A1	19900426	DE 1988-3839758	19881125
EP 365915	A2	19900502	EP 1989-118839	19891011
EP 365915	A3	19900829		
EP 365915	B1	19940420		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4956370	A	19900911	US 1989-419981	19891011
AT 104669	T	19940515	AT 1989-118839	19891011
ES 2051954	T3	19940701	ES 1989-118839	19891011
CA 2001167	A1	19900424	CA 1989-2001167	19891020
CA 2001167	C	19991123		
AU 8943633	A	19900426	AU 1989-43633	19891023
AU 622227	B2	19920402		
JP 02164879	A	19900625	JP 1989-273932	19891023
JP 06037494	B	19940518		

PRAI DE 1988-3836167 A1 19881024
DE 1988-3839758 A 19881125
EP 1989-118839 A 19891011
OS CASREACT 113:152458; MARPAT 113:152458
GI



I

AB The title compds. [I; R1 = H, alkyl; R2 = Ph optionally substituted by o-, m-, or p-XAr and by 1-4 halo, NO2, alkyl(thio), alkoxy(carbonyl), dialkylamino, etc.; Ar = (un)substituted Ph; X = O, S, SO, SO2] and their physiol. compatible acid addition salts, were prepared by cyclocondensation of N-(2-tetrahydropyrimidinyl)thioureas with ω-haloacetophenones. Thus, a mixture of N-(1,4,5,6-tetrahydropyrimidinyl)thiourea and 2-(2,4-dimethylphenoxy)phenacyl chloride was refluxed 2 h in Me2CO to give 91.4% title compound I [R1 = H, R2 = C6H4(OC6H3Me2-2,4)-2]. Another I [R1 = H, R2 = C6H4(OPh)-2], tested in vitro as a phosphate salt, inhibited Candida albicans with a MIC of 4 μg/mL vs. 16 μg/mL for a HCl salt of a known fungicide (I; R1 = H, R2 = C6H3Cl2-2,4).

IT [illegible]
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antimycotic)

RN 129639-87-8 CAPLUS
CN 2-Pyrimidinamine, N-[4-[4-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129639-88-9 CAPLUS
CN 2-Pyrimidinamine, N-[4-[4-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129639-89-0 CAPLUS
CN 2-Pyrimidinamine, N-[4-[4-(2,6-dichloro-4-nitrophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129639-90-3 CAPLUS
CN 2-Pyrimidinamine, N-[4-[2-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 129639-93-6 CAPLUS
CN 2-Pyrimidinamine, N-[4-[2-(2,4-dichlorophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 129639-92-5
CMF C19 H16 Cl2 N4 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 75-75-2
CMF C H4 O3 S

=> fil stng
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.28	406.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'STNGUIDE' ENTERED AT 08:35:20 ON 19 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 18, 2007 (20071218/UP).

=> log hodl
'HODL' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> log hold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	406.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:35:59 ON 19 DEC 2007

=> s l30 not l19
L31 104 L30 NOT L19

=> d l31 tot bib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 548.08 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L31 ANSWER 1 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:1176019 CAPLUS Full-text
DN 147:448778
TI Preparation of thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases for disease treatment
IN Jimenez, Juan-Miguel; Knegtel, Ronald; Robinson, Daniel; Collier, Philip
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 71pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007117692	A2	20071018	WO 2007-US8819	20070411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-791083P	P	20060411		

OS MARPAT 147:448778
GI



I



II

AB The present invention relates to compds. of general formula I (wherein the A ring is thiazole, imidazole, or pyrazole; R1 is a 3-7 membered monocyclic cycloalkyl optionally substituted; R4 is H, C1-6aliph., C3-6cycloaliph., etc.; T1 is a C1-6 aliphatic chain wherein 0-3 methylene units are optionally replaced with -O-, -S-, etc.; R5 is a (un)substituted 5-10 membered aromatic ring containing 0-4 heteroatoms; p is 0-4) useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compns. comprising said compds. and methods of using the compds. and the compns. in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compds. of the inventions. Example compound II was prepared by converting tert-Bu 1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazole-4- carboxylate (preparation given) to the carboxamide. In a Lck inhibition assay, II had a Ki value of 100-500 nM.
IT 952330-70-0P, 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide 952330-74-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases for disease treatment)
RN 952330-70-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-cyclopentyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 952330-74-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-cyclohexyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



IT 952330-68-6P, Methyl 2-cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases for disease treatment)
RN 952330-68-6 CAPLUS
CN 5-Thiazolecarboxylic acid, 2-cyclopentyl-4-(4-phenoxyphenyl)-, methyl ester (CA INDEX NAME)



L31 ANSWER 2 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:1145598 CAPLUS Full-text
DN 147:449083
TI Preparation of pyrrolopyridines and thiazolopyridines, particularly N-[(4-hydroxy-1H-pyrrolo[2,3-c]pyridin-5-yl)carbonyl]glycine and N-(7-hydroxythiazolo[4,5-c]pyridin-6-yl)carbonyl]glycine derivatives, as hypoxia inducible factor hydroxylase modulators
IN Deng, Shaojiang; Wu, Min; Turtle, Eric D.; Ho, Wen-Bin; Arend, Michael P.; Cheng, Heng; Flippin, Lee A.
PA Fibrogen, Inc., USA
SO PCT Int. Appl., 210pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007115315	A2	20071011	WO 2007-US65987	20070404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-789310P	P	20060404		

OS MARPAT 147:449083
GI



I



II

AB The invention is related to compds. I [q = 0-1; A, B = independently :CR7, NH and derivs., :N, S, provided that at least one of the following is present: A = :CR7 and B = NH and derivs.; A = S and B = :N; A = :N and B = S; A = NH and derivs. and B = :CR7; when the bond between A and CR6 is double, the bond between B and CR6 is single and vice-versa; R1 = OH, (un)substituted alkoxyaryloxy, alkylthio, etc.; R2 = H, D, Me; R3 = H, D, (un)substituted alkyl; R4 = H, (un)substituted alkyl; R5,R6 = independently H, halo, CN, OH, (un)substituted heteroaryl, acyl, etc.; or when A or B = CH and derivs., then R6CCR7 = (un)substituted cycloalkenyl, (hetero)aryl] and their pharmaceutically acceptable salts, stereoisomers, esters and prodrugs that modulate the stability and/or activity of hypoxia inducible factor (HIF). Thus, arylation of 2-methyl-1H-pyrrole-3- carboxylic acid Et ester (preparation given) with iodbenzene, bromination with NBS, treatment of 5-bromo-2-bromomethyl-1-phenyl-1H-pyrrole-3-carboxylic acid Et ester with (tert-butoxycarbonylamino)acetic acid Et ester in the presence of NaI in DMF, cyclization in the presence of potassium tert-butoxide in THF/cleavage of tert-butoxycarbonyl group/aromatization (no data for protected tetrahydropyrrolopyridine intermediate), and reaction of the ester with glycine in the presence of NaOMe in methanol gave pyrrolopyridine II. I were active in at least one of the cell-based HIFα stabilization assay, cell-based VEGF and erythropoietin (EPO) ELISA assay, and HIF-PH assay (no data). I are useful for treating, preventing or delaying onset of a condition mediated at least in part by HIF or by EPO.
IT 952395-23-2P, 4-Methyl-2-(4-phenoxyphenyl)thiazole-5-carboxylic acid ethyl ester 952395-24-3P, 4-Bromomethyl-2-(4-phenoxyphenyl)thiazole-5-carboxylic acid ethyl ester 952395-25-4P, 4-[[(2,4-Dimethoxybenzyl)[(ethoxycarbonyl)methyl]amino]methyl]-2-(4-phenoxyphenyl)thiazole-5-carboxylic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of [(pyrrolo[2,3-c]pyridin-5-yl)carbonyl]glycines and [(thiazolo[4,5-c]pyridin-6-yl)carbonyl]glycines as hypoxia inducible factor hydroxylase modulators)
RN 952395-23-2 CAPLUS
CN 5-Thiazolecarboxylic acid, 4-methyl-2-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 952395-24-3 CAPLUS
CN 5-Thiazolecarboxylic acid, 4-(bromomethyl)-2-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 952395-25-4 CAPLUS
CN 5-Thiazolecarboxylic acid, 4-[[[(2,4-dimethoxyphenyl)methyl](2-ethoxy-2-oxoethyl)amino]methyl]-2-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



L31 ANSWER 3 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:963933 CAPLUS Full-text
DN 147:322708
TI Preparation of biaryls compounds, such as hydroxy- and alkoxybiphenyls and biphenyl ethers as inhibitors of 17β-hydroxysteroid dehydrogenase
IN Vicker, Nigel; Allan, Gillian Margaret; Lawrence, Harshani Rithma Ruchiranani; Day, Joanna Mary; Purohit, Atul; Reed, Michael John; Potter, Barry Victor Lloyd
PA Sterix Limited, UK
SO PCT Int. Appl., 187pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2007096647 A2 20070830 WO 2007-GB655 20070226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI GB 2006-3894 A 20060227
GB 2006-15464 A 20060803
OS MARPAT 147:322708
GI



I



II

AB Title compds. I [ring A = (un)substituted (hetero)aryl; X = bond or linker group; at least one of R3-7 = substituted acyl; CN, -CH=N-O-alkyl, -CH=N-OH, alkylheterocycle, alkenylheterocycle, alkylheteroaryl, alkenylheteroaryl, heteroaryl, etc.; or R3-7 together with another of R3-7 forms a (hetero)cyclyl ring; R9 = alkyl or halo; R10 = OH, oxyhydrocarbyl, -OSO2NH2, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of 17β-hydroxysteroid dehydrogenase (17β-HSD). Thus, Suzuki coupling reaction of 5-bromoindan-1-one with (4-benzyloxyphenyl)boronic acid to generate 5-(4-(benzyloxy)phenyl]indan-1- one which undergoes hydrolysis provided II. Select compds. of the invention were evaluated for their inhibitory activity on 17β-HSD (type 1), e.g., II exhibited > 80% inhibition at the concentration of 10 μM.
IT 947548-39-2P, 4-[4-(2-Aminothiazol-4-yl)phenoxy]phenol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryls compds., such as hydroxy- and alkoxybiphenyls and biphenyl ethers as inhibitors of 17β-hydroxysteroid dehydrogenase)
RN 947548-39-2 CAPLUS
CN Phenol, 4-[4-(2-amino-4-thiazolyl)phenoxy]- (CA INDEX NAME)



L31 ANSWER 4 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:938960 CAPLUS Full-text
DN 147:449366
TI Synthesis and characterization of novel polyimides derived from 2-amino-5-[4-(4'-aminophenoxy)phenyl]-thiazole with some of dianhydride monomers
AU Zhao, Xin; Li, Yan-Feng; Zhang, Shu-Jiang; Shao, Yu; Wang, Xiao-Long
CS State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Institute of Biochemical Engineering and Environmental Technology, Lanzhou University, Lanzhou, 730000, Peop. Rep. China
SO Polymer (2007), 48(18), 5241-5249
CODEN: POLMAG; ISSN: 0032-3861
PB Elsevier Ltd.
DT Journal
LA English
AB A new kind of aromatic unsym. diamine monomer containing thiazole ring, 2-amino-5-[4-(4'-aminophenoxy)phenyl]-thiazole (APPT), was synthesized. A series of novel polyimides were prepared by polycondensation of APPT with various aromatic dianhydrides via one-step process. The resulting polyimides held inherent viscosities of 0.40-0.71 dL/g and were easily dissolved in strong dipolar solvents. Meanwhile, strong and flexible polyimide films were obtained, which had thermal stability with the glass transition temps. (T g) of 268.2-328.8 °C in nitrogen, the temperature at 5% weight loss of 452-507 °C in nitrogen and 422-458 °C in air, and the residue at 800 °C of 54.18-63.33% in nitrogen, as well as exhibited outstanding mech. properties with the tensile strengths of 105.4-125.3 MPa, elongation at breakage of 6-13%. These films also held dielec. consts. of 3.01-3.18 (10 MHz) and showed predominantly amorphous revealed by wide-angle X-ray diffraction measurements.
IT 952421-13-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate in monomer synthesis; synthesis and characterization of novel polyimides derived from asym. thiazole moiety-containing diamines and dianhydride comonomers)
RN 952421-13-5 CAPLUS
CN 2-Thiazolamine, 5-[4-(4-nitrophenoxy)phenyl]- (CA INDEX NAME)



IT 952421-14-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; synthesis and characterization of novel polyimides derived

from asym. thiazole moiety-containing diamines and dianhydride comonomers)
RN 952421-14-6 CAPLUS
CN 2-Thiazolamine, 5-[4-(4-aminophenoxy)phenyl]- (CA INDEX NAME)



IT 952421-15-7P 952421-16-8P 952421-17-9P
952421-18-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and characterization of novel polyimides derived from asym. thiazole moiety-containing diamines and dianhydride comonomers)
RN 952421-15-7 CAPLUS
CN 1,3-Isobenzofurandione, 5,5'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-, polymer with 5-[4-(4-aminophenoxy)phenyl]-2-thiazolamine (CA INDEX NAME)

CM 1

CRN 952421-14-6
CMF C15 H13 N3 O S



CM 2

CRN 1107-00-2
CMF C19 H6 F6 O6



RN 952421-16-8 CAPLUS
CN 1,3-Isobenzofurandione, 5,5'-oxybis-, polymer with 5-[4-(4-aminophenoxy)phenyl]-2-thiazolamine (CA INDEX NAME)

CM 1

CRN 952421-14-6
CMF C15 H13 N3 O S



CM 2

CRN 1823-59-2
CMF C16 H6 O7



RN 952421-17-9 CAPLUS
CN 1,3-Isobenzofurandione, 5,5'-carbonylbis-, polymer with 5-[4-(4-aminophenoxy)phenyl]-2-thiazolamine (CA INDEX NAME)

CM 1

CRN 952421-14-6
CMF C15 H13 N3 O S



CM 2

CRN 2421-28-5
CMF C17 H6 O7



RN 952421-18-0 CAPLUS
CN 1H,3H-Benzo[1,2-c:4,5-c']difuran-1,3,5,7-tetrone, polymer with 5-[4-(4-aminophenoxy)phenyl]-2-thiazolamine (CA INDEX NAME)

CM 1

CRN 952421-14-6
CMF C15 H13 N3 O S



CM 2

CRN 89-32-7
CMF C10 H2 O6



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 5 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:932937 CAPLUS Full-text
DN 147:301160
TI Preparation of thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors.
IN Ferrigno, Federica; Jones, Philip; Muraglia, Ester; Ontoria Ontoria, Jesus Maria; Scarpelli, Rita; Schultz-Fademrecht, Carsten
PA Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy
SO PCT Int. Appl., 70pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007093827	A1	20070823	WO 2007-GB50061	20070214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI GB 2006-3041	A	20060215		

OS MARPAT 147:301160
GI



I

AB Title compds. [I; a, b = 0-3; c = 0-2; A = CH, N; X = (substituted) aryl, heteroaryl, heterocyclyl; Y = bond, O, CO, S, SO, SO2, CONR2; R2 = H, alkyl; Z = H, halo, cyano, OH, alkyl, haloalkyl, alkoxy, NO2, amino, (substituted) cycloalkyl, aryl, heterocyclyl; Q = Z(CH2)aY(CH2)b(CH:CH)c], were prepared Thus, 5-trifluoroacetylthiophene-2-carboxylic acid in DMF was stirred with carbonyldiimidazole followed after 30 min. by addition of 2-[(4-fluorobenzyl)sulfonyl]-N-hydroxyethanimidamide in DMF and stirring overnight. The resulting intermediate was microwaved with carbonyldiimidazole in in DMF to give 2,2,2-trifluoro-1-[5-[3-[[[4- fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl]-2-thienyl]ethanone. I inhibited HDAC with IC50 <10 μM.
IT 946501-35-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophene and thiazole substituted trifluoroethanone derivs.
as HDAC inhibitors)
RN 946501-35-5 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[2-(4-phenoxyphenyl)-5-thiazolyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:793568 CAPLUS Full-text
DN 147:189168
TI Preparation of thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
IN Gillespie, Paul; Goodnow, Robert Alan; Kowalczyk, Agnieszka; Le, Kang; Zhang, Qiang
PA USA
SO U.S. Pat. Appl. Publ., 66pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2007167622	A1	20070719	US 2007-650645	20070108
WO 2007082808	A2	20070726	WO 2007-EP50141	20070108
WO 2007082808	A3	20070913		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,				

RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2006-759676P P 20060118
OS MARPAT 147:189168
GI



I



II

AB Title compds. I [R1 = 5- to 8-membered cycloalkyl, Ph, 9- or 10-membered bicyclic unsatd. or partially unsatd. ring, etc.; one of R2 and R3 is H or alkyl, the other is alkyl, -CH2-Ph, mono-, bi- or tricyclic 5- to 10-membered carbocyclic ring; R2 and R3, together with the N atom to which they are attached, may form a saturated or partially unsatd. 6- to 8-membered monocyclic or 7- to 10-membered bicyclic ring] and their pharmaceutically acceptable salts were prepared For example, HATU mediated amidation of 2-(2,3-dichlorophenyl)thiazole-4-carboxylic acid with decahydroquinoline afforded compound II [R11 = Cl; R21 = decahydroquinolin-1-yl]. In 11β-HSD1 inhibition assays, compound II [R11 = H; R21 = azocan-1-yl] exhibited the IC50 value of 0.05 μM. Compds. I are claimed useful for the treatment of type II diabetes mellitus and metabolic syndrome.

IT 944273-88-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase for treatment of type II diabetes mellitus and metabolic syndrome)

RN 944273-88-5 CAPLUS

CN Methanone, (octahydro-1(2H)-quinolinyl)[2-(2-phenoxyphenyl)-4-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 7 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:731135 CAPLUS Full-text

DN 147:166353

TI Diamine derivatives as inhibitors of leukotriene A4 hydrolase and their preparation, pharmaceutical compositions and use in the treatment of inflammatory disorders

IN Arnaiz, Damian; Brown, Greg; Claret, Emmanuel; Cleve, Arwed; Davey, David; Guilford, William; Khim, Seock-Kyu; Kirkland, Thomas; Kochanny, Monica J.; Liang, Amy; Light, David; Parkinson, John; Vogel, David; Wei, Guo Ping; Ye, Bin

PA Schering Aktiengesellschaft, Germany

SO U.S. Pat. Appl. Publ., 97pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2007155726	A1	20070705	US 2006-644244	20061222
WO 2007079078	A1	20070712	WO 2006-US49273	20061222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-755421P P 20051229
US 2006-835819P P 20060804

OS MARPAT 147:166353

GI



I



II

AB This invention is directed to compds. of formula I, as single stereoisomers or as mixts. of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compns. comprising the compds. of the invention and methods of preparing the compds. of the invention are also disclosed. Compds. of formula I wherein R is (un)substituted Ph, (un)substituted fluoroalkyl, and (un)substituted heteroaryl; m is 0 - 4; n is 0 - 2; R2 us H, (halo)alkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, (un)substituted cycloalkyl, etc.; R3 is a bond, O, alkoxy, oxyalkoxy, (un)branched alkylene, etc.; R5a, R5b, R5c, R6a, R6b, and R6c are independently H, (halo)alkyl, hydroxyalkyl, or any of R5aR6a, R5bR6b, and R5cR6c together to form oxo, etc.; R7 is H, OH and derivs., CHO, acyl, NH2 and derivs., etc.; R8 is H, (halo)alkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, (un)substituted cycloalkyl, etc.; each R9 is independently OH and derivs., alkyl, hydroxyalkyl, (halo)alkyl, aryl and aralkyl; and their single stereoisomers, mixts. of stereoisomers, pharmaceutically acceptable salts, solvates, polymorphs, clathrates, ammonium ions, N-oxides, and prodrugs thereof, are claimed. Example compound II was prepared by alkylation of hexahydro-1H-1,4-diazepine with 1-(chloromethyl)-4-(benzyloxy)benzene. All the invention compds. were evaluated for their leukotriene A4 hydrolase inhibitory activity. The tested compds. exhibited IC50 values of less than 100 μM.

IT [illegible]

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diamine derivs. as inhibitors of leukotriene A4 hydrolase for treating inflammatory disorders)

RN 943765-37-5 CAPLUS

CN Benzoic acid, 4-[[(1S,4S)-5-[[4-[4-(2-thiazolyl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 943765-38-6 CAPLUS

CN Benzoic acid, 4-[[(1S,4S)-5-[[4-[4-(2-thiazolyl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 8 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:632256 CAPLUS Full-text

DN 147:226220

TI QSAR study of selective ligands for the thyroid hormone receptor β

AU Liu, Huanxiang; Gramatica, Paola

CS QSAR Research Unit in Environmental Chemistry and Ecotoxicology, Department of Structural and Functional Biology, University of Insubria, Varese, 21100, Italy

SO Bioorganic & Medicinal Chemistry (2007), 15(15), 5251-5261
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Ltd.

DT Journal

LA English

AB In this paper, an accurate and reliable QSAR model of 87 selective ligands for the thyroid hormone receptor β 1 (TRβ1) was developed, based on theor. mol. descriptors to predict the binding affinity of compds. with receptor. The structural characteristics of compds. were described wholly by a large amount of mol. structural descriptors calculated by DRAGON. Six most relevant structural descriptors to the studied activity were selected as the inputs of QSAR model by a robust optimization algorithm Genetic Algorithm. The built model was fully assessed by various validation methods, including internal and external validation, Y-randomization test, chemical applicability domain, and all the validations indicate that the QSAR model we proposed is robust and satisfactory. Thus, the built QSAR model can be used to fast and accurately predict the binding affinity of compds. (in the defined applicability domain) to TRβ1. At the same time, the model proposed could also identify and provide some insight into what structural features are related to the biol. activity of these compds. and provide some instruction for further designing the new selective ligands for TRβ1 with high activity.

IT 725239-54-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(QSAR of selective ligands for thyroid hormone receptor β)

RN 725239-54-3 CAPLUS

CN Benzeneacetic acid, 3,5-dichloro-4-[4-hydroxy-3-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 9 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:619459 CAPLUS Full-text
DN 147:52913
TI Fused pyrimidines as growth factor receptor tyrosine kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy
IN Ishikawa, Tomoyasu; Miwa, Kazuhiro; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 643pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007064045	A1	20070607	WO 2006-JP324499	20061201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2005-349858	A	20051202		
	JP 2006-60648	A	20060307		

OS MARPAT 147:52913
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyrrolo[3,2-d]pyrimidines represented by formula I and related derivs., which are inhibitors of growth factor receptor tyrosine kinase. In compds. I, R1 is H; R2 is carbonylamino-substituted C1-6 alkyl; R3 is H or C1-6 alkyl; R4 and R5 are independently halo or C1-6 alkyl; and X is H or halo; including salts and prodrugs thereof; with several compds. excluded. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, a related compound or a salt or prodrug thereof, as well as to the use of the compns. for the prophylaxis or treatment of cancer. Coupling of the dihydrochloride of amine II with 2-methyl-2-(methylsulfonyl)propanoic acid gave pyrrolopyrimidine III. The compds. of the invention are inhibitors of growth factor receptor tyrosine kinases, e.g.,

compound III expressed 98% inhibition of HER2 kinase at 1 μM and IC50 value below 100 nM in an assay for inhibition of breast cancer cell proliferation.

IT 940303-54-8P, 2-[2-[4-[[3-Chloro-4-[3-(1,3-thiazol-5-yl)phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethoxy]ethanol 940303-77-5P, 2-[2-[4-[[4-[3-(4-tert-Butyl-1,3-thiazol-2-yl)phenoxy]-3-chlorophenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethoxy]ethanol 940303-88-8P, 2-[2-[4-[[3-Chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethoxy]ethanol 940303-96-8P, N-[2-[4-[[3-Chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-2-(methylsulfonyl)acetamide 940305-09-9P, N-[2-[4-[[3-Chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-2-methyl-2-(methylsulfonyl)propanamide 940305-11-3P, N-[2-[4-[[3-Chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused pyrimidines as growth factor receptor tyrosine kinase inhibitors)

RN 940303-54-8 CAPLUS
CN Ethanol, 2-[2-[4-[[3-chloro-4-[3-(5-thiazolyl)phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethoxy]- (CA INDEX NAME)



RN 940303-77-5 CAPLUS
CN Ethanol, 2-[2-[4-[[3-chloro-4-[3-[4-(1,1-dimethylethyl)-2-thiazolyl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethoxy]- (CA INDEX NAME)



RN 940303-88-8 CAPLUS
CN Ethanol, 2-[2-[4-[[3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethoxy]- (CA INDEX NAME)



RN 940303-96-8 CAPLUS
CN Acetamide, N-[2-[4-[[3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-2-(methylsulfonyl)- (CA INDEX NAME)



RN 940305-09-9 CAPLUS
CN Propanamide, N-[2-[4-[[3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-2-methyl-2-(methylsulfonyl)- (CA INDEX NAME)



RN 940305-11-3 CAPLUS
CN Butanamide, N-[2-[4-[[3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methyl- (CA INDEX NAME)



IT 940303-53-9P, 5-[3-(2-Chloro-4-nitrophenoxy)phenyl]-1,3-thiazole 940303-84-4P, 4-tert-Butyl-2-[3-(2-chloro-4-nitrophenoxy)phenyl]-1,3-thiazole 940303-86-6P, 4-[3-(4-tert-Butyl-1,3-thiazol-2-yl)phenoxy]-3-chloroaniline 940303-53-9P, 2-[3-(2-Chloro-4-nitrophenoxy)phenyl]-4-(trifluoromethyl)-1,3-thiazole 940303-94-6P, 3-Chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]aniline 940303-97-9P, tert-Butyl N-[2-[4-[[3-chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]carbamate 940303-98-0P, 5-(2-Aminoethyl)-N-[3-chloro-4-[3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-4-amine dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; preparation of fused pyrimidines as growth factor receptor tyrosine kinase inhibitors)

RN 940303-56-0 CAPLUS
CN Thiazole, 5-[3-(2-chloro-4-nitrophenoxy)phenyl]- (CA INDEX NAME)



RN 940303-84-4 CAPLUS
CN Thiazole, 2-[3-(2-chloro-4-nitrophenoxy)phenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 940303-86-6 CAPLUS
CN Benzenamine, 3-chloro-4-[3-[4-(1,1-dimethylethyl)-2-thiazolyl]phenoxy]- (CA INDEX NAME)



RN 940303-93-5 CAPLUS
CN Thiazole, 2-[3-(2-chloro-4-nitrophenoxy)phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 940303-94-6 CAPLUS
CN Benzenamine, 3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]- (CA

INDEX NAME)



RN 940303-97-9 CAPLUS
CN Carbamic acid, N-[2-[4-[[3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 940303-98-0 CAPLUS
CN 5H-Pyrrolo[3,2-d]pyrimidine-5-ethanamine, 4-[[3-chloro-4-[3-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]phenyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 10 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:590026 CAPLUS Full-text
DN 147:226206
TI 2D QSAR studies on thyroid hormone receptor ligands
AU Valadares, Napoleao F.; Castilho, Marcelo S.; Polikarpov, Igor; Garratt, Richard C.
CS Departamento de Fisica e Informatica, Instituto de Fisica de Sao Carlos, Universidade de Sao Paulo, Sao Carlos-SP, 13560-970, Brazil
SO Bioorganic & Medicinal Chemistry (2007), 15(13), 4609-4617
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
AB 2D QSAR studies were carried out for a series of 55 ligands for the Thyroid receptors, TRα and TRβ. Significant cross-validated correlation coeffs. (q 2 = 0.751 (TRα) and 0.693 (TRβ)) were obtained. The models' predictive abilities were proved more valuable than the classical 2D-QSAR, and were further investigated by an external test set of 13 compds. The predicted values are in good agreement with exptl. values, suggesting that the models could be useful in the design of novel, more potent TR ligands. Contribution map anal. identified a number of positions that are promising for the development of receptor isoform specific ligands.
IT 725239-54-3
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(QSAR studies on thyroid hormone receptor ligands)
RN 725239-54-3 CAPLUS
CN Benzeneacetic acid, 3,5-dichloro-4-[4-hydroxy-3-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 11 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:431722 CAPLUS Full-text
DN 146:441828
TI Preparation of oxazolone oxazinone, or thiazolone compounds as PDGF receptor antagonists and pharmaceutical compositions containing them
IN Kumasawa, Hiroaki; Sadakane, Chiharu; Igarashi, Yasushi; Hattori, Tomohisa; Tsuchiya, Kazuaki; Yamaguchi, Sachie
PA Tsumura and Co., Japan
SO Jpn. Kokai Tokkyo Koho, 58pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI JP 2007099630	A	20070419	JP 2005-288169	20050930
PRAI JP 2005-288169		20050930		
OS MARPAT 146:441828				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Claimed are oxazolone compds. I [R1a = OR3a, OCOR4a, COR5a, OSO2R6a, NHSO2R7a, Ph, pyrazinyl, naphthyl, etc. (R3a-R7a = aryl, alkyl optionally substituted with alkoxy; these (hetero)aryl groups may be substituted with 1-3 alkenyl optionally having carbonyl group-containing substituent, alkyl, aryl, heterocyclyl, NO2, halo); R2a = alkenyl optionally having carbonyl group-containing substituent, thiazolidinylidene (Markush given), OCONR16aR17a, NHSO2R21a, COR22a, (R16a, R17a, R21a, R22a = alkyl), etc.] or their pharmaceutically-acceptable salts, oxazinone compds. II (R1b = any group given for R1a; R2b = any group given for R2a) or their pharmaceutically-acceptable salts, and thiazolone compds. III (R1c = any group given for R1a; R2c = any group given for R2a) or their pharmaceutically-acceptable salts. Also claimed are pharmaceutical compns. containing I, II, III, or their salts as PDGF inhibitors, therapeutic agents for nephritis, smooth muscle cell proliferation inhibitors, and therapeutic agents for restenosis. Thus, a mixture of tert-Bu 3-(3-formylphenyl)acrylate, N-(3-nitrobenzoyl)glycine, NaOAc, and Ac2O was stirred at 80° for 4 h to give 58% 5-oxo-1,3-oxazole compound, which was treated with CF3CO2H in CH2Cl2 at room temperature for 3 h to give 52% (E)-3-[3-[[2-(3-nitrophenyl)-5-oxo-1,3-oxazol-4(5H)- ylidene]methyl]phenyl]propenoic acid. Similarly-prepared (E)-3-[4-[[2-(2-indolyl)-5-oxo-1,3-oxazol-4(5H)-ylidene]methyl]phenyl]propenoic acid (IV) inhibited binding of PDGF-BB to PDGFβ receptor in a dose-dependent manner. IV also inhibited PDGF-BB-stimulated proliferation of normal human mesangial cells.
IT 934622-60-6P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolone, oxazinone, or thiazolone compds. as PDGF receptor
antagonists as drugs for nephritis and restenosis and as smooth muscle cell proliferation inhibitors)
RN 934623-60-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[4-oxo-2-(3-phenoxyphenyl)-5(4H)-thiazolylidene]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.



L31 ANSWER 12 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:332888 CAPLUS Full-text

DN 146:358712
TI Preparation of heterocyclic compounds containing biaryl moiety as LTA4H inhibitors
IN Sandanayaka, Vincent; Singh, Jasbir; Gurney, Mark; Mamat, Bjorn; Yu, Peng; Bedel, Louis; Zhao, Lei
PA Decode Chemistry, Inc., USA
SO U.S. Pat. Appl. Publ., 97pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007066820	A1	20070322	US 2006-426287	20060623
	US 2007078263	A1	20070405	US 2006-426284	20060623
	WO 2007040681	A1	20070412	WO 2006-US24392	20060623
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2007040682	A1	20070412	WO 2006-US24393	20060623
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-719016P P 20050921
OS MARPAT 146:358712
GI



I



II

AB Title compds. I [Ar = aryl (optionally substituted with halo, alkyl, acyl, etc.), heteroaryl with (optionally substituted halo, alkyl, acyl, etc.); X = direct bond, O, SO, etc.; HetAr = aryl or heteroaryl ring attached via a ring carbon to Q, further characterized in that Q and X cannot be on adjacent positions in said aryl or heteroaryl ring; Q = -O-, -NR1-, S(O)p; R1 = H, alkyl; p = 0-2; n = 1-5; HET = saturated nitrogenous heterocycle (optionally substituted with halo, hydroxyl, amino, etc.); taken together ZW is H; or Z = (CH2)1-10, in which one or two (CH2) may optionally be replaced by -O-, -NR1-, -SO-, etc.; W = acyl, hydroxyl, carboxyl, etc.; with the provisos that (a) when Q is -O-, HET is (S)-pyrrolidine, rac-pyrrolidine or piperidine, Ar is Ph or halo-substituted Ph, and HetAr is p-phenylene, then the Z-W combination is other than H, (b) when Q is -NR1-, HET is thiazolidine, Ar is Ph or substituted Ph and HetAr is m-phenylene, then the Z-W combination is other than H, (c) when Q is -O-, HET is azetidine, Ar is Ph, n is 1 and HetAr is a 2,5-substituted pyridine, then the Z-W combination is other than H.] were prepared For example, recation of (S)-2-[4-(4-chlorophenoxy)-phenoxymethyl]-piperidine hydochloride, e.g., prepared from (S)-piperidine-1,2-dicarboxylic acid 1-tert-Bu ester in 5 steps, with 3-(chloromethyl)-1,2,4-oxadiazole followed by treatment with HCl afforded compound II·HCl. In leukotriene A4 hydrolase (LAT4H) inhibition assays, compound II·HCl exhibited the IC50 value of <5 μM. Compds. I are claimed useful for the treatment of inflammation, asthma, etc.
IT 929916-92-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. containing biaryl moiety as LTA4H inhibitors for treatment of inflammation and asthma)
RN 929916-92-7 CAPLUS
CN Thiazole, 2-[4-[4-[(2R)-2-pyrrolidinylmethoxy]phenoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 929916-93-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. containing biaryl moiety as LTA4H inhibitors for treatment of inflammation and asthma)
RN 929916-93-8 CAPLUS
CN 1-Pyrrolidinebutanoic acid, 2-[[4-[4-(2-thiazolyl)phenoxy]phenoxy]methyl]-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 929918-55-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. containing biaryl moiety as LTA4H inhibitors for treatment of inflammation and asthma)
RN 929918-55-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[4-(2-thiazolyl)phenoxy]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



AN 2006:845146 CAPLUS Full-text
DN 145:271760
TI Preparation of thiazole amides, imidazole amides and related analogues as histamine H3 receptor modulators
IN Pringle, Wallace C.; Peterson, John M.; Xie, Linghong; Ge, Ping; Gao, Yang; Ochterski, Joseph W.; Lan, Jiong
PA Neurogen Corporation, USA
SO PCT Int. Appl., 329pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006089076	A2	20060824	WO 2006-US5562	20060216
	WO 2006089076	A3	20061221		
	WO 2006089076	A9	20070426		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1848428	A2	20071031	EP 2006-735288	20060216
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRAI US 2005-654558P P 20050218
US 2005-720500P P 20050926
WO 2006-US5562 W 20060216
OS MARPAT 145:271760
GI



I



II

AB The title compds. I [R1 = (un)substituted alkyl, alkenyl or cycloalkylalkyl; or R1 taken together with R2 or R4 can form (un)substituted 4-8 membered heterocycloalkyl; R2 = alkyl, alkenyl, cycloalkylalkyl; or R2 taken together with R1, R3 or R4 can form (un)substituted 4-8 membered heterocycloalkyl; R3 = H, alkyl, alkenyl, cycloalkylalkyl; or R3 taken together with R2 or R4 can form (un)substituted 4-8 membered heterocycloalkyl; R4 = H or taken together with R1, R2 or R3 can form (un)substituted 4-8 membered heterocycloalkyl; n = 1-3; X = CH2 or C(O); Y = thiazole, imidazole, etc.; Ar = (un)substituted Ph, naphthyl, biphenyl, 5-13 membered heteroaryl; with provisos] which may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals, were prepared Thus, reacting 2-bromo-4-methylthiazole-5-carboxylic acid with N-isopropylpiperazine afforded II. Over 1000 compds. I were prepared Most of them exhibit a Ki in the chimeric human H3 receptor GTP binding assay that is less than 1 μM. Compds. I may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compns. and methods for treating the mentioned above disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

IT 906466-72-6P 906466-73-7P 906466-90-8P
906466-91-9P 906467-09-2P 906467-21-8P
906467-34-3P 906467-35-4P 906467-36-5P
906467-64-9P 906467-65-0P 906467-66-1P
906467-85-4P 906474-83-7P 906475-10-3P
906475-11-4P 906475-32-1P 906475-33-0P
906475-48-7P 906475-49-8P 906475-59-0P
906475-71-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole amides, imidazole amides and related analogs as histamine H3 receptor modulators)

RN 906466-72-6 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-2-(4-phenoxyphenyl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 906466-73-7 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-2-(4-phenoxyphenyl)-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 906466-90-8 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 906466-91-9 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-N-[3-(2-methyl-1-piperidinyl)propyl]-2-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 906467-09-2 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-2-(4-phenoxyphenyl)-N-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)



RN 906467-21-8 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-N-(1-methyl-4-piperidinyl)-2-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 906467-34-3 CAPLUS

CN Piperazine, 1-(1-methylethyl)-4-[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906467-35-4 CAPLUS

CN Piperazine, 1-cyclopentyl-4-[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906467-36-5 CAPLUS

CN 1H-1,4-Diazepine, 1-butylhexahydro-4-[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906467-64-9 CAPLUS

CN Piperidine, 4-(hexahydro-1H-azepin-1-yl)-1-[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906467-65-0 CAPLUS

CN Piperidine, 1-[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 906467-66-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906467-85-4 CAPLUS
CN 5-Thiazolecarboxamide, N-[2-(diethylamino)ethyl]-N,4-dimethyl-2-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 906474-83-7 CAPLUS
CN 5-Thiazolecarboxamide, N-ethyl-N-[2-(ethylmethylamino)ethyl]-4-methyl-2-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 906475-10-3 CAPLUS
CN Piperazine, 1-(1-methylethyl)-4-[[4-methyl-2-(2-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906475-11-4 CAPLUS
CN Piperazine, 1-cyclopentyl-4-[[4-methyl-2-(2-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906475-32-9 CAPLUS
CN 4-Piperidinamine, N,N-diethyl-1-[[4-methyl-2-(2-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906475-33-0 CAPLUS
CN 3-Pyrrolidinamine, N,N-diethyl-1-[[4-methyl-2-(2-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906475-48-7 CAPLUS
CN Piperidine, 4-(hexahydro-1H-azepin-1-yl)-1-[[4-methyl-2-(2-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906475-49-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[4-methyl-2-(2-phenoxyphenyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 906475-59-0 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2-(2-phenoxyphenyl)- (CA INDEX NAME)



RN 906475-71-6 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-2-(2-phenoxyphenyl)-N-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)



L31 ANSWER 14 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:333420 CAPLUS Full-text
DN 144:369771
TI Preparation of bisaryl-sulfonamides as PPARγ or PPARδ modulators
IN Bergeron, Philippe; Farthing, Christopher N.; Jones, Stuart D.; Liebeschuetz, John W.; Lively, Sarah E.; Mcgee, Lawrence R.; Mckendry, Sharon; Sheppard, David; Young, Stephen C.
PA Amgen Inc., USA
SO PCT Int. Appl., 250 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006020830	A2	20060223	WO 2005-US28673	20050811
	WO 2006020830	A3	20070412		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2005272786	A1	20060223	AU 2005-272786	20050811
	CA 2576993	A1	20060223	CA 2005-2576993	20050811
	US 2006084802	A1	20060420	US 2005-203006	20050811
	EP 1786782	A2	20070523	EP 2005-790029	20050811
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-601578P	P	20040812		
	WO 2005-US28673	W	20050811		

OS MARPAT 144:369771

GI



I



II

AB The title compds. I [Ar = (un)substituted Ph, naphthyl, pyridyl; B = (un)substituted (hetero)aryl; L = O, SOk, CRaRb, C(O) (wherein Ra, Rb = H, CN, NO2, alkyl); W = CR3, N; X = CR4, N; Y = CR5, N; Z = CR6, N (wherein at least one of W, X, Y and Z = N and at least one of W, X, Y and Z is other than N); R1 = H, alkyl, heteroalkyl, arylalkyl; R2 = H, halo, CN, NO2, etc.; R3-R6 = H, OH, halo, CN, etc.; k = 0-2] that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ or PPARδ, were prepared E.g., a multi-step synthesis of II, starting from 4-nitrobenzenesulfonyl chloride and piperidine, was given. In particular, the compds. I modulate the function of PPARγ or PPARδ. IC50 values for selected compds. I in a PPARγ ligand binding

assay utilizing [3H]-BRL 49653 as the radioligand are provided. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

IT 882496-99-3P 882498-42-2P 882499-37-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bisaryl-sulfonamides as PPARγ or PPARδ modulators)

RN 882496-99-3 CAPLUS

CN Benzenesulfonamide, 2,4-dichloro-N-[3-(2-methyl-4-thiazolyl)-4-[4-(4-morpholinylsulfonyl)phenoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 882498-42-2 CAPLUS

CN 2-Thiazolecarboxylic acid, 4-[5-[[(2,4-dichlorophenyl)sulfonyl]amino]-2-[4-(4-morpholinylsulfonyl)phenoxy]phenyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 882499-37-8 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[3-(2-methyl-4-thiazolyl)-4-[4-(4-morpholinylsulfonyl)phenoxy]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L31 ANSWER 15 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1290025 CAPLUS Full-text

DN 144:36329

TI Thiazole compounds as PPAR modulators, their preparation, pharmaceutical compositions, and use in therapy

IN Epple, Robert; Cow, Christopher; Xie, Yongping; Wang, Xing; Russo, Ross; Azimioara, Mihai; Saez, Enrique

PA IRM LLC, Bermuda

SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116000	A1	20051208	WO 2005-US18167	20050524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005247931	A1	20051208	AU 2005-247931	20050524
	CA 2563818	A1	20051208	CA 2005-2563818	20050524
	EP 1748993	A1	20070207	EP 2005-754130	20050524
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1980906	A	20070613	CN 2005-80016538	20050524
	US 2007203155	A1	20070830	US 2006-597282	20061121
	KR 2007030791	A	20070316	KR 2006-724606	20061123
	IN 2006CN04307	A	20070615	IN 2006-CN4307	20061123
	NO 2006005984	A	20070205	NO 2006-5984	20061222
PRAI	US 2004-574137P	P	20040524		
	US 2005-648985P	P	20050131		
	WO 2005-US18167	W	20050524		

OS MARPAT 144:36329

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to thiazole compds. of formula I, which are modulators of peroxisome proliferator-activated receptors (PPAR), particularly PPARδ. In compds. I, p is 0-3; L is selected from -XOX-, -XS(O)mX-, and -XS(O)mXO-, where m is 0-2 and X is a bond or (un)substituted C1-4 alkylene; R1 is selected from halo, C1-6 alkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, (un)substituted C6-10 aryl, (un)substituted C5-10 heteroaryl, (un)substituted C3-12 cycloalkyl, and (un)substituted C3-8 heterocyclyl; R2 is -XOXCO2R5 or -XCO2R5, where X is as defined previously and R5 is H or C1-6 alkyl; and R3 and R4 are independently selected from R6 and R6Y, where R6 is (un)substituted C3-12 cycloalkyl, (un)substituted C3-8 heterocyclyl, (un)substituted C6-10 aryl, and (un)substituted C5-13 heteroaryl, and Y is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, -C(O)N(R5)-, and -OX-, where X and R5 are as defined previously, or R3 and R4, together with the atoms to which they are attached, form fused bi- or tricyclic C5-14 heteroaryl; including pharmaceutically acceptable salts, hydrates, solvates, isomers, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a therapeutically effective amount of compound I in combination with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. to treat or prevent diseases or disorders associated with PPAR activity. Cyclocondensation of 2-bromo-4'-methoxyacetophenone with thioacetamide followed by bromination, demethylation, and alkylation with iso-Pr iodide gave bromothiazole II, which was brominated and substituted with phenol III (preparation in 3 steps from 4-hydroxy-3-methylacetophenone given) to give thiazole IV. Compound IV underwent Suzuki coupling with 4-(trifluoromethoxy)phenylboronic acid and ester hydrolysis to give thiazole V. Most preferred compds. of the invention express an EC50 value for PPARδ of less than 100 nM. The compds. of the invention are at least 100-fold selective for PPARδ over PPARγ.

IT 870521-87-2P 870522-09-1P 870523-30-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazole compds. as PPAR modulators and their use for treatment and prevention of diseases associated with PPARδ activity)

RN 870521-87-2 CAPLUS
CN Acetic acid, [2-methyl-4-[[5-(4-phenoxyphenyl)-4-phenyl-2-thiazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870522-09-1 CAPLUS
CN Acetic acid, [4-[[4-(4-methoxyphenyl)-5-(4-phenoxyphenyl)-2-thiazolyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870523-30-1 CAPLUS
CN Acetic acid, [4-[[4,5-bis(4-phenoxyphenyl)-2-thiazolyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 16 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1289826 CAPLUS Full-text
DN 144:36328
TI Preparation of substituted thiazoleacetic acids as CRTH2 receptor ligands
IN Ulven, Trond; Frimurer, Thomas; Rist, Oeystein; Kostenis, Evi; Hoegberg, Thomas; Receveur, Jean-Marie; Grimstrup, Marie
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005116001	A1	20051208	WO 2005-EP5882	20050530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005247610	A1	20051208	AU 2005-247610	20050530
CA 2568742	A1	20051208	CA 2005-2568742	20050530
EP 1758874	A1	20070307	EP 2005-748037	20050530
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1980908	A	20070613	CN 2005-80022519	20050530
NO 2006006049	A	20070227	NO 2006-6049	20061228
KR 2007044404	A	20070427	KR 2006-727509	20061228
IN 2006CN04780	A	20070629	IN 2006-CN4780	20061228
PRAI GB 2004-12198	A	20040529		
GB 2004-14194	A	20040624		
GB 2004-24016	A	20041029		
WO 2005-EP5882	W	20050530		

OS MARPAT 144:36328
GI



AB Title compds. I [X1 = S, O, N=N, etc.; A = carboxy, carboxy bioisostere; Ar2-3 = Ph, 5-6 membered heteroaryl, etc.; B = Ar2-3, N-pyrrolidinyl, etc.; q = 0-1; L1-4 = (Alk1)m-Zn-(Alk2)p; m, n, p = 0-1; Alk1-2 = alkylene, alkenylene, etc.; Z = O, S, CO, SO2, etc.; Q1 = H, alkyl; Q2 = alkyl, alkoxy, OH, hydroxyalkyl, etc.] are prepared For instance, [2-benzhydryl-4-(4-chlorophenyl)thiazol-5-yl]acetic acid (II) is prepared from 3-bromo-4-(4-chlorophenyl)-4-oxobutyric acid and 2,2-diphenylthioacetamide in 77% yield. II has an IC50 < 0.5 μM for the CRTH2 receptor. I are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity.

IT 870861-81-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted thiazoleacetic acids as CRTH2 receptor ligands)

RN 870861-81-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-(diphenylmethyl)-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 17 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:732649 CAPLUS Full-text
DN 143:194251
TI Preparation of 2-(aminoacylamino)thiazole derivatives and their therapeutic applications
IN Baltzer, Sylvie; Van Dorsselaer, Viviane
PA Sanofi-Aventis, Fr.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005073226	A1	20050811	WO 2005-FR32	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2865206	A1	20050722	FR 2004-387	20040116
FR 2873370	A1	20060127	FR 2004-8115	20040722
FR 2873370	B1	20061020		
AU 2005209442	A1	20050811	AU 2005-209442	20050107
CA 2551142	A1	20050811	CA 2005-2551142	20050107
EP 1709041	A1	20061011	EP 2005-717380	20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1930155	A	20070314	CN 2005-80005095	20050107
BR 2005006880	A	20070626	BR 2005-6880	20050107
JP 2007517840	T	20070705	JP 2006-548342	20050107
IN 2006KN01876	A	20070511	IN 2006-KN1876	20060705
US 2006293365	A1	20061228	US 2006-456123	20060707
MX 2006PA08040	A	20061002	MX 2006-PA8040	20060713
NO 2006003675	A	20061016	NO 2006-3675	20060815
PRAI FR 2004-387	A	20040116		
FR 2004-8115	A	20040722		
WO 2005-FR32	W	20050107		

OS MARPAT 143:194251
GI



I

II

AB The invention relates to thiazolamine amino acid derivs. I [R1 is (un)substituted alkyl or Ph, cycloalkyl, thienyl, benzothienyl, pyridyl or furyl; R2, R2' are independently H, halo, OH, alkoxy, alkyl, cycloalkyl, alkanoyloxy; or CR2R2' is CO; R3 is H, hydroxy-, cycloalkyl- or alkoxyalkyl; one of R4 and R5 is substituted Ph, benzyl, pyridyl or pyridylmethyl and the other is a (thio)acyl or (thio)carbamoyl group], which are inhibitors of β-amyloid (β-A4) formation and can be used for the treatment of Alzheimer's disease and other disorders. Thus, compound II was prepared via coupling of Me 2-amino-5-[2-(4- fluorophenoxy)phenyl]thiazole-4-carboxylate (preparation given) with Boc-protected (S)-norvaline and 3,5-difluorophenylacetic acid.

IT [illegible]

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (aminoacylamino)thiazole derivs. as β-amyloid inhibitors and their therapeutic applications)

RN 859148-93-9 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(2S)-(3,5-difluorophenyl)hydroxyacetyl]amino]-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-94-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(3,5-difluorophenyl)acetyl]amino]-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-95-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 5-[2-(4-fluorophenoxy)phenyl]-2-[[(2S)-2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-1-oxopentyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-96-2 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(3,5-difluorophenyl)acetyl]amino]-1-oxopentyl]amino]-5-[2-(3-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-97-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 5-[2-(3-fluorophenoxy)phenyl]-2-[[(2S)-2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-1-oxopentyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-98-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(2S)-(3,5-difluorophenyl)hydroxyacetyl]amino]-1-oxopentyl]amino]-5-[2-(3-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861853-27-2 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-1-oxopentyl]amino]-5-[2-[4-(trifluoromethoxy)phenoxy]phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 861853-28-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(2S)-2-hydroxy-3-methyl-1-oxobutyl]amino]-1-oxopentyl]amino]-5-[2-[4-(trifluoromethoxy)phenoxy]phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 859149-02-3P 859149-03-4P 859149-04-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (aminoacylamino)thiazole derivs. as β-amyloid inhibitors and their therapeutic applications)

RN 859149-02-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-amino-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (CA INDEX NAME)



RN 859149-03-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-amino-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 859149-04-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 18 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:732628 CAPLUS Full-text
DN 143:194249
TI Preparation of acylaminothiazole derivatives as β-amyloid inhibitors
IN Baltzer, Sylvie; Pascal, Marc; Van Dorsselaer, Viviane
PA Sanofi-Aventis, Fr.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005073202	A1	20050811	WO 2005-FR29	20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2865207	A1	20050722	FR 2004-388	20040116
	FR 2873374	A1	20060127	FR 2004-8116	20040722
	FR 2873374	B1	20061020		
	EP 1709018	A1	20061011	EP 2005-717377	20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CN 1910165	A	20070207	CN 2005-80002588	20050107
	JP 2007520478	T	20070726	JP 2006-548340	20050107
	IN 2006KN01943	A	20070518	IN 2006-KN1943	20060711
	US 2006293366	A1	20061228	US 2006-457490	20060714
PRAI	FR 2004-388	A	20040116		
	FR 2004-8116	A	20040722		
	WO 2005-FR29	W	20050107		

OS MARPAT 143:194249
GI



I

II

AB The invention relates to thiazolamine amino acid derivs. I [R1 is (un)substituted alkyl or Ph, cycloalkyl, thienyl, benzothienyl, pyridyl or furyl; R2, R2' are independently H, halo, OH, alkoxy, alkyl, cycloalkyl, alkanoyloxy; or CR2R2' is CO; R3 is H, hydroxy-, alkoxy- or cycloalkylalkyl; R4, R5 are independently H, CF3, alkyl, CN, aminosulfonyl, heteroaryl, etc.], which are inhibitors of β-amyloid (β-A4) formation and can be used for the treatment of Alzheimer's disease and other disorders. Thus, compound II was prepared via coupling of 2-amino-5-(1-methylethyl)-4-(3-phenyl-1,2,4-oxadiazol-5-yl)thiazole (preparation given) with Boc-protected (S)-norvaline and α- hydroxyisovaleric acid. Four compds. of the invention showed EC50 values in the range 42-94 nM for inhibition of the production of β-A4.

IT 859840-99-6P 859841-00-2P 862096-42-2P
862096-43-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminothiazole derivs. as β-amyloid inhibitors)

RN 859840-99-6 CAPLUS
CN Pentanamide, 2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-N-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(2-phenoxyphenyl)-2-thiazolyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859841-00-2 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(2-phenoxyphenyl)-2-thiazolyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 862096-42-2 CAPLUS
CN Pentanamide, 2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-N-[4-(2-oxazolyl)-5-(2-phenoxyphenyl)-2-thiazolyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862096-43-3 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[[4-(2-oxazolyl)-5-(2-phenoxyphenyl)-2-thiazolyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 19 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:642342 CAPLUS Full-text
DN 144:331853
TI Synthesis and characterization of novel heterocyclic ring-based poly(arylene ether)s
AU Dubey, Rama; Alam, Sarfaraz; Mathur, G. N.
CS Defence Materials and Stores, Research and Development Establishment, Kanpur, 208013, India
SO Polyimides and Other High Temperature Polymers (2005), 3, 175-183
CODEN: POHTAH
PB VSP
DT Journal
LA English
AB Heterocyclic-ring-based poly(arylene ether)s (PAEs) are considered to be a unique class of high-temperature polymers which find use as structural resins for a variety of aerospace applications. Incorporation of heterocyclic units in the backbones of PAEs offers certain advantages over PAEs without heterocyclic units such as higher glass transition temperature (Tg), tensile strength and modulus. Heterocycles such as phenylquinoxalines, benzoxazoles, benzothiazoles, oxadiazoles, triazoles, imidazoles and benzimidazoles, etc., have been incorporated into the backbones of PAEs via the aromatic nucleophilic displacement reaction. The resulting polymers showed excellent thermal properties. In view of the excellent thermal properties of heterocyclic ring based poly(arylene ether)s, some novel heterocyclic ring structures, such as thioxopyrimidinedione, amidotriazine, amidothiazole, imidothiazole and thiadiazine, have been successfully introduced into the backbones of poly(arylene ether)s. It was observed that the Tg of synthesized polymers was in the range of 150-197 °C and most of the polymers showed no weight loss below 400 °C. The focus of this paper is, therefore, on structure-property relationships between the variety of heterocyclic rings introduced into the polymeric backbone and their effect on thermal properties of the resulting polymers.
IT [illegible]
RL: PRP (Properties)
(synthesis and characterization of novel heterocyclic ring-based poly(arylene ether)s)
RN 880797-55-7 CAPLUS
CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)carbonyl(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-2,4-thiazolediyl-1,4-phenyleneoxy[1,1'-biphenyl]-4,4'-diyloxy-1,4-phenylene-4,2-thiazolediyl] (9CI) (CA INDEX NAME)





RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 20 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:637811 CAPLUS Full-text
DN 143:153710
TI Preparation of 2-(aminoacylamino)thiazole derivatives and their therapeutic applications
IN Baltzer, Sylvie; Pascal, Marc; Van Dorsselaer, Viviane
PA Sanofi-Synthelabo S.A., Fr.
SO Fr. Demande, 55 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2865207	A1	20050722	FR 2004-388	20040116
	WO 2005073202	A1	20050811	WO 2005-FR29	20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1709018	A1	20061011	EP 2005-717377	20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

	CN 1910165	A	20070207	CN 2005-80002588	20050107
	JP 2007520478	T	20070726	JP 2006-548340	20050107
	IN 2006KN01943	A	20070518	IN 2006-KN1943	20060711
	US 2006293366	A1	20061228	US 2006-457490	20060714
PRAI	FR 2004-388	A	20040116		
	FR 2004-8116	A	20040722		
	WO 2005-FR29	W	20050107		
OS	MARPAT 143:153710				
GI					



AB The invention relates to thiazolamine amino acid derivs. I [R1 is (un)substituted alkyl or Ph, cycloalkyl, thienyl, benzothienyl, pyridyl or furyl; R2, R2' are independently H, halo, OH, alkoxy, alkyl, cycloalkyl, alkanoyloxy; or CR2R2' is CO; R3 is H, hydroxy- or alkoxyalkyl; R4, R5 are independently H, CF3, alkyl, CN, aminosulfonyl, heteroaryl, etc.], which are inhibitors of β-amyloid (β-A4) formation and can be used for the treatment of Alzheimer's disease and other disorders. Thus, compound II was prepared via coupling of 2-amino-5-(1-methylethyl)-4-(3-phenyl-1,2,4- oxadiazol-5-yl)thiazole (preparation given) with Boc-protected (S)-norvaline and α-hydroxyisovaleric acid. Four compds. of the invention showed EC50 values in the range 42-94 nM for inhibition of the production of β-A4.
IT 859840-99-6P 859841-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (aminoacylamino)thiazole derivs. as β-amyloid inhibitors and their therapeutic applications)
RN 859840-99-6 CAPLUS
CN Pentanamide, 2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-N-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(2-phenoxyphenyl)-2-thiazolyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859841-00-2 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(2-phenoxyphenyl)-2-thiazolyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 21 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:637810 CAPLUS Full-text
DN 143:133699
TI Preparation of 2-(aminoacylamino)thiazole derivatives and their therapeutic applications
IN Baltzer, Sylvie; Van Dorsselaer, Viviane
PA Sanofi-Synthelabo S.A., Fr.
SO Fr. Demande, 35 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2865206	A1	20050722	FR 2004-387	20040116
	AU 2005209442	A1	20050811	AU 2005-209442	20050107
	CA 2551142	A1	20050811	CA 2005-2551142	20050107
	WO 2005073226	A1	20050811	WO 2005-FR32	20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1709041	A1	20061011	EP 2005-717380		20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1930155	A	20070314	CN 2005-80005095		20050107
BR 2005006880	A	20070626	BR 2005-6880		20050107
JP 2007517840	T	20070705	JP 2006-548342		20050107
IN 2006KN01876	A	20070511	IN 2006-KN1876		20060705
US 2006293365	A1	20061228	US 2006-456123		20060707
MX 2006PA08040	A	20061002	MX 2006-PA8040		20060713
NO 2006003675	A	20061016	NO 2006-3675		20060815
PRAI FR 2004-387	A	20040116			
FR 2004-8115	A	20040722			
WO 2005-FR32	W	20050107			

OS MARPAT 143:133699

GI



I



II

AB The invention relates to thiazolamine amino acid derivs. I [R1 is - (un)substituted alkyl or Ph, cycloalkyl, thienyl, benzothienyl, pyridyl or furyl; R2, R2' are independently H, halo, OH, alkoxy, alkyl, cycloalkyl, alkanoyloxy; or CR2R2' is CO; R3 is H, hydroxy- or alkoxyalkyl; one of R4 and R5 is substituted Ph, benzyl, pyridyl or pyridylmethyl and the other is a (thio)acyl or (thio)carbamoyl group], which are inhibitors of β-amyloid (β-A4) formation and can be used for the treatment of Alzheimer's disease and other disorders. Thus, compound II was prepared via coupling of Me 2-amino-5-[2-(4-fluorophenoxy)phenyl]thiazole-4-carboxylate (preparation given) with Boc-protected (S)-norvaline and 3,5- difluorophenylacetic acid.

IT 859148-93-9P 859148-94-0P 859148-95-1P
859148-96-2P 859148-97-3P 859148-98-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of (aminoacylamino)thiazole derivs. as β-amyloid inhibitors and their therapeutic applications)

RN 859148-93-9 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(2S)-(3,5-difluorophenyl)hydroxyacetyl]amino]-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-94-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(3,5-difluorophenyl)acetyl]amino]-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-95-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 5-[2-(4-fluorophenoxy)phenyl]-2-[[(2S)-2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-1-oxopentyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-96-2 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(3,5-difluorophenyl)acetyl]amino]-1-oxopentyl]amino]-5-[2-(3-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-97-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 5-[2-(3-fluorophenoxy)phenyl]-2-[[(2S)-2-[[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]amino]-1-oxopentyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 859148-98-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(2S)-(3,5-difluorophenyl)hydroxyacetyl]amino]-1-oxopentyl]amino]-5-[2-(3-fluorophenoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859149-02-3P 859149-03-4P 859149-04-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (aminoacylamino)thiazole derivs. as β-amyloid inhibitors and their therapeutic applications)

RN 859149-02-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-amino-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (CA INDEX NAME)



RN 859149-03-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-amino-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 859149-04-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopentyl]amino]-5-[2-(4-fluorophenoxy)phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 22 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:431406 CAPLUS Full-text
DN 142:463752

TI Preparation of pyrimidine-2,4,6-trione metalloproteinase inhibitors
IN Noe, Mark C.
PA USA
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 32,837.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005107414	A1	20050519	US 2004-778990	20040213
	US 2002132822	A1	20020919	US 2001-32837	20011025
	US 6706723	B2	20040316		
PRAI	US 2000-243314P	P	20001026		
	US 2001-32837	A2	20011025		

OS MARPAT 142:463752
GI



I



II

AB The invention relates to a group of pyrimidine-2,4,6-triones I and similar compds., which are inhibitors of matrix metalloproteinases (MMP). In compds. I (claimed), R1 is H, (un)substituted C1-4 alkyl, (un)substituted C6-10 aryl, (un)substituted C3-8 cycloalkyl, (un)substituted C1-10 heteroaryl, or (un)substituted C1-10 heterocyclyl; X is a bond or O, and n is 1-10; and G is R2-(CH2)p-, where G is on any ring carbon atom meta or para to -O-, R2 is substituted acylamino or aminocarbonylamino, and p is 1-6. Thus, reacting 4-(4-[1,3,4]oxadiazol-2-ylphenoxy)phenol with 5-bromo-5-(2-ethoxyethyl)pyrimidine-2,4,6-trione (prepns. given) in the presence of 1,5,7-triazabicyclo[4.4.0]dec-5-ene bound to polystyrene crosslinked with 2% DVB in MeCN afforded II. The compds. I that were tested all have IC50 values of less than 100 μM in at least one of the assays against MMPs such MMP-1, MMP-9, MMP-13, etc. Some compds. showed selectivity towards MMP-13 (no data).
IT 420122-07-2P 420122-19-6P 420122-24-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrimidinetriones as metalloproteinase inhibitors)
RN 420122-07-2 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(2-methyl-4-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



RN 420122-19-6 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(4-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



RN 420122-24-3 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(2-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



L31 ANSWER 23 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:244459 CAPLUS Full-text
DN 142:456259
TI Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
AU Blagg, Julian A.; Noe, Mark C.; Wolf-Gouveia, Lilli A.; Reiter, Lawrence A.; Laird, Ellen R.; Chang, Shang-Poa P.; Danley, Dennis E.; Downs, James T.; Elliott, Nancy C.; Eskra, James D.; Griffiths, Richard J.; Hardink, Joel R.; Haugeto, Amber I.; Jones, Christopher S.; Liras, Jennifer L.; Lopresti-Morrow, Lori L.; Mitchell, Peter G.; Pandit, Jayvardhan; Robinson, Ralph P.; Subramanyam, Chakrapani; Vaughn-Bowser, Marcie L.;

Yocum, Sue A.
CS Pfizer Global Research and Development, Groton Laboratories, Groton, CT, 06340, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(7), 1807-1810
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:456259
GI



I

AB Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor (I) identified through file screening. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring resulted in a dramatic enhancement of MMP-13 potency. Protein crystallog. revealed that this moiety binds in the S1' pocket of the enzyme. Optimization of the C-4 substituent of the terminal aromatic ring led to incorporation of selectivity vs. MMP-14 (MT-1 MMP). Structure activity relationships of the biaryl ether substituent are presented as is pharmacokinetic data for a compound that meets our in vitro potency and selectivity goals.
IT 420122-19-6P 420122-24-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(pyrimidinetrione derivs. preparation and structure-related inhibition of MMP-13 and MMP-14)
RN 420122-19-6 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(4-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



RN 420122-24-3 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(2-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



IT 213315-40-3 864086-39-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyrimidinetrione derivs. preparation and structure-related inhibition of MMP-13 and MMP-14)
RN 213315-40-3 CAPLUS
CN Phenol, 4-[4-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



RN 864086-39-5 CAPLUS
CN Phenol, 4-[4-(4-thiazolyl)phenoxy]- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 24 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1156488 CAPLUS Full-text
DN 142:69226
TI Method for promoting impaired wound healing
IN Nilsson, Cecilia; Dreifeldt, Catrine
PA Biovitrum Ab, Swed.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2004112783	A1	20041229	WO 2004-SE959 20040616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI SE 2003-1885 A 20030625
OS MARPAT 142:69226
AB The invention relates to a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of such promotion an effective amount of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), said 11ss-HSD1 inhibitor having the formula (I) wherein T, A, and B are as defined in the specification. These compds. may also be used in the manufacture of a medicament for promoting wound healing.
IT 376349-81-4 376349-84-7 376349-87-0 376349-92-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for promoting impaired wound healing)
RN 376349-81-4 CAPLUS
CN Benzenesulfonamide, 2,3,4-trichloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 376349-84-7 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]-2,5-difluoro- (CA INDEX NAME)



RN 376349-87-0 CAPLUS
CN 2-Thiophenesulfonamide, 4-bromo-5-chloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 376349-92-7 CAPLUS
CN Benzenesulfonamide, 2,4,6-trichloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 25 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927006 CAPLUS Full-text
DN 141:395288
TI New [3,5-dihalo-4-(4-hydroxyphenoxy)phenyl]acetic acid derivatives useful as thyroid receptor ligands, and their preparation, pharmaceutical compositions, and methods of use
IN Ryono, Dennis E.; Hangeland, Jon J.; Friends, Todd J.; Dejneka, Tamara; Devasthale, Pratik; Caringal, Yolanda V.; Zhang, Minsheng; Doweyko, Arthur M. P.; Malm, Johan; Sanin, Andrei
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093799	A2	20041104	WO 2004-US11883	20040416
WO 2004093799	A3	20050224		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005004184	A1	20050106	US 2004-826100	20040415
PRAI US 2003-463774P	P	20030418		

OS MARPAT 141:395288
GI



I



II

AB Thyroid receptor ligands are provided which have the general formula I [wherein: R1 = (un)substituted CONR5R6, CH2NR5R6, NR5COR6, OR7, R8, 4-R9-4,5-dihydrooxazol-2-yl; R2, R3 = H, halo, C1-4 alkyl or C3-5 cycloalkyl, provided that at least 1 of R2 and R3 ≠ H; R4 = (CH2)nR13 or (CH2)nCONR16CR13R14R15; R5, R6 = H, (hetero)aryl, (cyclo)alkyl, or (hetero)aralkyl; R7 = (hetero)aryl, alkyl, or (hetero)aralkyl; R8 = (hetero)aryl or cycloalkyl; R9 = R7 or H; R10 = H, halo, cyano, or alkyl; R11, R12 = H, halo, alkoxy, OH, cyano, or alkyl; R13 = COOH and esters, phosphonic and phosphinic acid and esters, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates; R14, R15 = H, alkyl; or R14R15 = (CH2)2-5, forming 3- to 6-membered cycloalkyl rings; R16 = H or C1-4 alkyl; R17 and R18 = H, halo, or alkyl; n = 0-4; X = O, S, S(O)2, S(O), Se, CO, NH, or CH2]. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction, or which are dependent upon the expression of, a T3 regulated gene, wherein a compound I is administered therapeutically. Claims cover the above, as well as pharmaceutical compns. containing I, and methods of coadministration of I with other compds., particularly certain antidiabetic agents. Compds. I include selective agonists, partial agonists, antagonists, and partial antagonists of thyroid receptors (no data). Approx. 168 compds. were prepared For instance, Me (3,5-dibromo-4-hydroxyphenyl)acetate underwent O-arylation with (4-MeOC6H4)2I+ BF4-, and the resultant 4-methoxyphenyl ether derivative underwent a sequence of: (1) formylation in the 3-position, (2) O-demethylation, (3) oxidation of the aldehyde to an acid, (4) amidation of the acid, and (5) alkaline saponification of the ester, to give title compound II.
IT 725239-54-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [dihalo(hydroxyphenoxy)phenyl]acetic acid derivs. as thyroid receptor ligands)
RN 725239-54-3 CAPLUS
CN Benzeneacetic acid, 3,5-dichloro-4-[4-hydroxy-3-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



L31 ANSWER 26 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:465510 CAPLUS Full-text
DN 141:133551
TI Thyroid receptor ligands. Part 2: thyromimetics with improved selectivity for the thyroid hormone receptor beta
AU Hangeland, Jon J.; Doweyko, Arthur M.; Dejneka, Tamara; Friends, Todd J.; Devasthale, Pratik; Mellstrom, Karin; Sandberg, Johnny; Grynfarb, Marlena; Sack, John S.; Einspahr, Howard; Faernegardh, Mathias; Husman, Bolette; Ljunggren, Jan; Koehler, Konrad; Sheppard, Cheryl; Malm, Johan; Ryono, Denis E.
CS Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ, 08543, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3549-3553
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:133551
AB A set of thyromimetics having improved selectivity for TR-β1 were prepared by replacing the 3'-iso-Pr group of 2 and 3 with substituents having increased steric bulk. From this limited SAR study, the most potent and selective compds. identified were derived from 2 and contained a 3'-Ph moiety bearing small hydrophobic groups meta to the biphenyl link. X-ray crystal data of 15c complexed with TR-β1 LBD shows methionine 442 to be displaced by the bulky R3' Ph Et amide side chain. Movement of this amino acid side chain provides an expanded pocket for the bulky side chain while the ligand-receptor complex retains full agonist activity.
IT [illegible]
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(structure activity relationships of thyromimetics with selectivity for thyroid hormone receptor beta)
RN 725239-54-3 CAPLUS
CN Benzeneacetic acid, 3,5-dichloro-4-[4-hydroxy-3-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 27 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:285596 CAPLUS Full-text
DN 140:270844
TI Preparation of 4,4'-bipyridyl-2,2'-bisoxazoles and 4,4'-bipyridyl-2,2'-bisthiazoles as antitumor agents
IN Sanchez-Cantalejo, Yolanda Martin; Villa Hormaeche, Maria Jesus; Saez Pizarro, Beatriz; Soto Romero, Javier; Fernandez Brana, Miguel; Lacal Sanjuan, Juan Carlos
PA Consejo Superior de Investigaciones Cientificas, Spain; Universidad Europea de Madrid
SO Span., 11 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ES 2183734	A1	20030316	ES 2001-1818	20010802
PRAI ES 2001-1818		20010802		

OS MARPAT 140:270844
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I•2Y- [wherein X = O or S; Z = a bond or 1,2-ethylene, isopropylidene, p,p'-biphenylene, p-phenylene, m-phenylene, 2,6-pyridylene, p,p'-oxidiphenylene, p,p'-hexafluoroisopropylidenediphenyl ene; R = H, organic residues; when R' = alkyl or absent; Y = sulfate, methanesulfonate, hydrochloride, phosphate, nitrate, acetate, propionate, butyrate, palmitate, oxalate, malonate, maleate, fumarate, citrate, benzoate or absent] were prepared as antiproliferative agents for treating human tumors. For example, II was prepared by cyclization of III with trifluoroanhydride in the presence of Py/toluene for 12 h at room temperature. II inhibited proliferation of HT29 cells with an IC50 value of 0.75 μM. THus, I are useful as antitumor agents.
IT [illegible]
RL: SPN (Synthetic preparation); PREP (Preparation)
(antitumor agent; preparation of bisoxazoles and bisthiazoles as antitumor agents)
RN 662144-97-0 CAPLUS
CN Pyridinium, 4,4'-[oxybis[4,1-phenylene[5-(trifluoromethyl)-2,4-thiazolediyl]]]bis[1-methyl-, diiodide (9CI) (CA INDEX NAME)



IT 637324-44-8
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of bisoxazoles and bisthiazoles as antitumor agents)
RN 637324-44-8 CAPLUS
CN Pyridine, 4,4'-[oxybis[4,1-phenylene[5-(trifluoromethyl)-2,4-thiazolediyl]]]bis- (9CI) (CA INDEX NAME)



L31 ANSWER 28 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:162697 CAPLUS Full-text
DN 140:199318
TI Preparation of 4-4'-bipyridyl-2-2'-bisoxazoles and 4-4'-bipyridyl-2-2'-bisthiazoles as antitumor agents
IN Martin Sanchez-Cantalejo, Yolanda; Villa Hormaeche, Maria Jesus; Saez Pizarro, Beatriz; Soto Romero, Javier; Fernandez Brana, Miguel; Lacal Sanjuan, Juan Carlos
PA Consejo Superior de Investigaciones Cientificas, Spain; Universidad Europea de Madrid
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004016622	A1	20040226	WO 2003-ES424	20030814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2200706	B1	20050601	ES 2002-1938	20020816
AU 2003260515	A1	20040303	AU 2003-260515	20030814
PRAI ES 2002-1938	A	20020816		
WO 2003-ES424	W	20030814		

OS MARPAT 140:199318
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I•2Y- [wherein X = O or S; Z = direct bond, or 1,2-ethylidene, isopropylidene, p,p'-biphenyl, p-phenylene, m-phenylene, 2,6-pyridylene, p,p'-oxydiphenylene, p,p'-hexafluoroisopropylidenphenylene;

R = H, or common organic substituents; R' = none or alkyl; Y = sulfate, methanesulfonate, hydrochloride, phosphate, nitrate, acetate, propionate, butyrate, palmitate, oxalate, malonate, maleate, fumarate, citrate, benzoate or absent when R = COOH] were prepared as antiproliferative agents against malignant cells such as HT-29. The invention also relates to the industrial production of I and their pharmaceutical compns. for use in treatment human tumors. For example, II was prepared, in 80% yield, by cyclization of III with acetic anhydride in the presence of SnCl4/TEA for 4 h at reflux. I showed antiproliferative activity against the HT29 cell lines with IC50 ranging between 0.2 - 5.7 μM, except for one compound Thus, I and their formulations are useful for treating neoplasm.
IT [illegible]
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation of 4-4'-bipyridyl-2-2'-bisoxazoles and 4-4'-bipyridyl-2-2'-bisthiazoles as antitumor agents)
RN 662144-97-0 CAPLUS
CN Pyridinium, 4,4'-[oxybis[4,1-phenylene[5-(trifluoromethyl)-2,4-thiazolediyl]]]bis[1-methyl-, diiodide (9CI) (CA INDEX NAME)



IT 637324-44-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-4'-bipyridyl-2-2'-bisoxazoles and 4-4'-bipyridyl-2-2'-bisthiazoles as antitumor agents)
RN 637324-44-8 CAPLUS
CN Pyridine, 4,4'-[oxybis[4,1-phenylene[5-(trifluoromethyl)-2,4-thiazolediyl]]]bis- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 29 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:151244 CAPLUS Full-text
DN 140:368073
TI Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast

cancer cell proliferation
AU Gorczynski, Michael J.; Leal, Rachel M.; Mooberry, Susan L.; Bushweller, John H.; Brown, Milton L.
CS Department of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA
SO Bioorganic & Medicinal Chemistry (2004), 12(5), 1029-1036
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 140:368073
AB Several substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles were synthesized and evaluated for cytotoxic activity against estrogen-pos., estrogen-neg., and adriamycin-resistant human breast cancer cell lines. 4-[4'-(3,4-Dichlorophenoxy)-phenyl]-thiazol-2-yl ammonium iodide demonstrated potent activity against both estrogen-pos. and neg. breast cancer cell lines with low micromolar (μM) GI50 values. In addition, we have identified several 2-aminothiazoles that demonstrated selective potency for the adriamycin-resistant and estrogen-neg. breast cancer cell lines. The results suggest that these 2-aminothiazoles represent lead compds. for evaluation in animal models of breast cancer.
IT 684255-32-1P 684255-33-2P 684255-34-3P
684255-35-4P 684255-36-5P 684255-37-6P
684255-38-7P 684255-39-8P 684255-40-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity relationship studies of substituted 4-aryloxy- and 4-arylsulfanyl-Ph-2-aminothiazoles as inhibitors of human breast cancer cell proliferation)
RN 684255-32-1 CAPLUS
CN 2-Thiazolamine, 4-[4-(4-chlorophenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-33-2 CAPLUS
CN 2-Thiazolamine, 4-[4-(3-chlorophenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-34-3 CAPLUS
CN 2-Thiazolamine, 4-[4-(2-chlorophenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-35-4 CAPLUS
CN 2-Thiazolamine, 4-[4-(3,4-dichlorophenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-36-5 CAPLUS
CN 2-Thiazolamine, 4-[4-(4-methoxyphenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-37-6 CAPLUS
CN 2-Thiazolamine, 4-[4-(4-methylphenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-38-7 CAPLUS
CN 2-Thiazolamine, 4-[4-([1,1'-biphenyl]-4-yloxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-39-8 CAPLUS
CN 2-Thiazolamine, 4-[4-(4-phenoxyphenoxy)phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 684255-40-1 CAPLUS
CN Benzoic acid, 3-[4-(2-amino-4-thiazolyl)phenoxy]-, ethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

IT 684255-31-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and structure-activity relationship studies of substituted 4-aryloxy- and 4-arylsulfanyl-Ph-2-aminothiazoles as inhibitors of human breast cancer cell proliferation)
RN 684255-31-0 CAPLUS
CN 2-Thiazolamine, 4-(4-phenoxyphenyl)-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 30 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:59992 CAPLUS Full-text
DN 140:128678
TI Preparation of acylaminothiazoles as inhibitors of formation of β amyloid and their therapeutic applications
IN Baltzer, Sylvie; Schoentjes, Bruno; Van Dorsselaer, Viviane
PA Sanofi-Synthelabo, Fr.
SO Fr. Demande, 85 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2842523	A1	20040123	FR 2002-9061	20020717
	WO 2004009565	A2	20040129	WO 2003-FR2194	20030711
	WO 2004009565	A3	20040408		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003269018	A1	20040209	AU 2003-269018	20030711
	EP 1525193	A2	20050427	EP 2003-750801	20030711
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005538086	T	20051215	JP 2004-522233	20030711
	US 2005182104	A1	20050818	US 2005-35803	20050114
	US 7291636	B2	20071106		
PRAI	FR 2002-9061	A	20020717		
	WO 2003-FR2194	W	20030711		

OS MARPAT 140:128678

GI



I

II

AB Acylaminothiazoles (shown as I; variables defined below; e.g. II), methods for their preparation, intermediates, pharmaceutical compns. and therapeutic applications are claimed. Compds. I are claimed effective by inhibition of formation of β amyloid peptide (β-A4; IC50 < 500 nM in general but no specific values stated) against disorders such as senile dementia, Alzheimer's disease, Down syndrome, Parkinson's disease, amyloid angiopathy and cerebrovascular disorders (no data). For I: R1 = (un)substituted C1-6 alkyl, C3-7 cycloalkyl, thienyl, benzothiophenyl, pyridinyl, furanyl or (un)substituted phenyl; R2 and R2' = H, halo, hydroxy, C1-3 alkoxy, C1-3 alkyl, C3-7 cycloalkyl, O-C(O)-C1-6 alkyl, or R2 and R2' = oxo; R3 = H or (un)substituted C1-6 alkyl; R4 and R5 = H, (un)substituted C1-7 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, naphthyl or -C(X)R6; at least one of R4 or R5 = -C(X)R6; X = O or S; R6 = C1-6 alkoxy, OH or -NR7R8; R7 and R8 = H, (un)substituted C1-6 alkyl, (un)substituted C3-7 cycloalkyl, C1-6 alkoxy or (un)substituted phenyl; or R7 and R8, with the N to which they are bound, form a ring = aziridine, azetidine, pyrrolidine, piperidine or morpholine; addnl. details are given in the claims. Twenty-five example prepns. of I and characterization data for .apprx.185 examples of I are included. For example, II was prepared in 5 steps starting from Me 2-amino-5-(1-methylethyl)thiazole-4-carboxylate and involving intermediates 2-[(tert-butoxycarbonyl)amino]-5-(1-methylethyl)thiazole-4- carboxylic acid, N,N-dimethyl-2-[(tert-butoxycarbonyl)amino]-5-(1- methylethyl)thiazole-4-carboxamide, N,N-dimethyl-2-amino-5-(1- methylethyl)thiazole-4-carboxamide and N,N-dimethyl-2-((2S)-2-aminopentanoylamino)-5-(1-methylethyl)thiazole-4-carboxamide.

IT [illegible], Methyl 2-[[(2S)-2-[[2-(3,5-difluorophenyl)acetyl]amino]pentanoyl]amino]-5-(3-phenoxyphenyl)thiazole-4-carboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylaminothiazoles as inhibitors of formation of β amyloid and their therapeutic applications)

RN 649738-99-8 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(2S)-2-[[(3,5-difluorophenyl)acetyl]amino]-1-oxopentyl]amino]-5-(3-phenoxyphenyl)-, methyl ester (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 31 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:1006767 CAPLUS Full-text
DN 140:42032
TI Preparation of 2-chromenones as inhibitors of VEGF production in mammalian cells, as well as of the angiogenesis, and useful as antiproliferative agents for treatment of cancer
IN Menta, Ernesto; Da Re, Giovanni; Grugni, Mario
PA Novuspharma S.p.A., Italy
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003105842	A1	20031224	WO 2003-EP6191	20030612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003245935	A1	20031231	AU 2003-245935	20030612
	US 2006122387	A1	20060608	US 2005-517805	20051205
PRAI	US 2002-387917P	P	20020613		
	WO 2003-EP6191	W	20030612		

OS MARPAT 140:42032
GI



I



II

AB Title compds. I [wherein A = aromatic or nonarom. 4- to 7-membered heterocycle, optionally substituted on the carbon atoms; R1, R2, R3, R4 = independently H, alkyl optionally interrupted by one or more heteroatoms, OH and derivs., haloalkoxy, phenoxy, aralkoxy, acyloxy, monoalkyl/bisalkyl/amino, halo, NO2, CN, CF3, CO2H and derivs., alkyl/amino/alkylamino/sulfonyl, mercapto, alkylthio, alkylsulfinyl, or R1CCR2, R2CCR3, R3CCR4 = hetero/aryl ring, -C(:O)(CH2)nNR6R7, CH2NR6R7; R6, R7 = independently H, alkyl or R6R7N = pyrrolidino, piperidino, piperazino or morpholino ring; n = 0, 2, 3, 4; R5 = H, ar/alkyl; their pharmaceutical acceptable salts, solvates, amides, esters, N-oxides, chemical protected forms and prodrugs] were prepared as inhibitors of vascular endothelial growth factor (VEGF), and useful as angiogenesis inhibitors in vivo or in vitro and as antiproliferative agents. For example, II was prepared, in 93% yield, by cyclization of (4-phenylthiazol-2-yl)acetonitrile (preparation given) with 4-(N,N-diethylamino)salicylaldehyde. In a VEGF-Luciferase assay, II showed an IC50 < 10 μM for the inhibition of the activation of the VEGF promoter in hepatoma 3B (Hep3B) cell line. Thus, I and their pharmaceutical compns. are useful for treating cancer.

IT [illegible], 3-[4-(4'-Phenoxyphenyl)thiazol-2-yl]-7-hydroxychromen-2-one 303126-21-8P, 3-[4-(4'-Phenoxyphenyl)thiazol-2-yl]-6-(n-hexyl)-7-hydroxychromen-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor of VEGF production; preparation of 2-chromenones as inhibitors of VEGF production in mammalian cells)

RN 303067-53-0 CAPLUS

CN 2H-1-Benzopyran-2-one, 7-hydroxy-3-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



RN 303126-21-8 CAPLUS

CN 2H-1-Benzopyran-2-one, 6-hexyl-7-hydroxy-3-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



IT 298194-30-6P, [4-(4'-Phenoxyphenyl)thiazol-2-yl]acetonitrile
313231-80-0P 637040-54-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-chromenones as inhibitors of VEGF production in
mammalian cells)

RN 298194-30-6 CAPLUS

CN 2-Thiazoleacetonitrile, 4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 313231-80-0 CAPLUS

CN 2H-1-Benzopyran-7-ol, 6-hexyl-2-imino-3-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



RN 637040-54-1 CAPLUS

CN 2H-1-Benzopyran-7-ol, 2-imino-3-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 32 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:830736 CAPLUS Full-text
DN 140:59551
TI A new convergent synthesis of 4,4'-bispyridyl-5,5'-disubstituted-2,2-bisoxazoles and -bisthiazoles
AU Martin-Cantalejo, Yolanda; Saez, Beatriz; Soto, Javier; Villa, Maria Jesus; Brana, Miguel F.
CS Departamento de Quimica y Materiales, Escuela Superior Politecnica, Universidad Europea de Madrid, Madrid, 28670, Spain
SO Synthesis (2003), (14), 2211-2215
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 140:59551
GI



AB A convergent strategy for the synthesis of 4,4'-bispyridyl-5,5'-disubstituted-2,2'-bisoxazoles and -bisthiazoles, e.g., I (X = O, S), from diamides, e.g., II, has been achieved.
IT 637324-44-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of bispyridyl bisoxazoles and bisthiazoles from diamides)
RN 637324-44-8 CAPLUS
CN Pyridine, 4,4'-[oxybis[4,1-phenylene[5-(trifluoromethyl)-2,4-thiazolediyl]]]bis- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 33 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:5930 CAPLUS Full-text
DN 138:73261
TI Preparation of heterocyclyliminophenyl compounds as agricultural and horticultural fungicides and insecticides
IN Niki, Toshio; Mizukoshi, Takashi; Takahashi, Hiroaki; Satow, Jun; Ogura, Tomoyuki; Yamagishi, Kazuhiro; Suzuki, Hiroyuki; Hayasaka, Fumio
PA Nissan Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 508 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000659	A1	20030103	WO 2002-JP6424	20020626
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004002250	A	20040108	JP 2002-184667	20020625
	AU 2002318545	A1	20030108	AU 2002-318545	20020626
PRAI	JP 2001-192285	A	20010626		
	JP 2001-193428	A	20010626		
	JP 2001-385120	A	20011218		
	JP 2001-386846	A	20011220		
	JP 2002-90213	A	20020328		
	WO 2002-JP6424	W	20020626		

OS MARPAT 138:73261
GI



AB The title compds. I [A is an optionally substituted heterocycle; X is hydrogen or the like; and G is CH2COOMe, N(Me)COOMe, or the like; n = 0 - 4] are prepared Compds. of this invention at 500 ppm gave ≥ 70% control of Pyricularia oryzae.
IT 347873-88-5P 347874-12-8P 347874-13-9P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyliminophenyl compds. as agricultural and horticultural fungicides and insecticides)
RN 347873-88-5 CAPLUS
CN Benzeneacetic acid, 2-[[3-methyl-4-(4-phenoxyphenyl)-2(3H)-thiazolylidene]amino]-, methyl ester (CA INDEX NAME)



RN 347874-12-8 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[[3-methyl-4-(4-phenoxyphenyl)-2(3H)-thiazolylidene]amino]-, methyl ester, (αE)-(CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 347874-13-9 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[[3-methyl-4-(4-phenoxyphenyl)-2(3H)-thiazolylidene]amino]-, methyl ester, (αZ)-(CA INDEX NAME)

Double bond geometry as described by E or Z.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 34 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:925264 CAPLUS Full-text
DN 138:11431
TI 5-HT1a antagonist or an α2-adrenergic antagonist in combination with an serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea
IN Howard, Harry Ralph, Jr.
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1262197	A2	20021204	EP 2002-253589	20020522
	EP 1262197	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002183306	A1	20021205	US 2002-75849	20020213
	CA 2387699	A1	20021130	CA 2002-2387699	20020528
	BR 2002001974	A	20030422	BR 2002-1974	20020528
	JP 2003026602	A	20030129	JP 2002-155222	20020529
	MX 2002PA05380	A	20021209	MX 2002-PA5380	20020530
PRAI	US 2001-294322P	P	20010530		

OS MARPAT 138:11431
AB The invention provides a method of treating sleep disorders, including sleep apnea, in a mammal, including a human, by administering to the mammal a 5-HT1a antagonist or an α2-adrenergic antagonist in combination with an serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in efficacy. Also provided are pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5-HT1a antagonist or an α2-adrenergic antagonist, and an SRI antidepressant agent.
IT 444888-70-4 444889-73-7 444889-79-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT1a antagonist or α2-adrenergic antagonist in combination with serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea)
RN 444888-70-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-methyl-4-thiazolyl)- (CA INDEX NAME)



RN 444888-73-7 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(2,5-dimethyl-4-thiazolyl)-N-methyl- (CA INDEX NAME)



RN 444888-79-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(2,4-dimethyl-5-thiazolyl)-N-methyl- (CA INDEX NAME)



L31 ANSWER 35 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:925263 CAPLUS Full-text
DN 138:336
TI Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
IN Howard, Harry Ralph, Jr.
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1262196	A2	20021204	EP 2002-253105	20020502
	EP 1262196	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2002370975	A	20021224	JP 2002-132804	20020508
	AU 200240686	A	20021205	AU 2002-40686	20020516
	CA 2386740	A1	20021123	CA 2002-2386740	20020517
	ZA 2002004019	A	20031121	ZA 2002-4019	20020521
	US 2003130322	A1	20030710	US 2002-153379	20020522
	HU 2002001722	A2	20030728	HU 2002-1722	20020522
	CN 1386503	A	20021225	CN 2002-120350	20020523
	US 2004162316	A1	20040819	US 2004-783196	20040220
PRAI	US 2001-293088P	P	20010523		
	US 2002-153379	A1	20020522		

OS MARPAT 138:336
GI



I

AB The present invention relates to a method of treating alcoholism or alc. dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist. An example monoamine reuptake inhibitor is I.
IT 334980-60-8 476310-78-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alc. dependence)
RN 334980-60-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-thiazolyl)- (CA INDEX NAME)



RN 476310-78-8 CAPLUS
CN Benzeneethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-thiazolyl)- (CA INDEX NAME)



L31 ANSWER 36 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:907188 CAPLUS Full-text
DN 138:1673

TI Inhibitors of histone deacetylase and their therapeutic use
IN Curtin, Michael L.; Dai, Yujia; Davidsen, Steven K.; Frey, Robin R.; Guo, Yan; Heyman, Howard R.; Holms, James H.; Ji, Zhiqin; Michaelides, Michael R.; Vasudevan, Anil; Wada, Carol K.
PA USA
SO U.S. Pat. Appl. Publ., 49 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002177594	A1	20021128	US 2001-45747	20011026
PRAI	US 2001-275770P	P	20010314		
	US 2001-308435P	P	20010726		

OS MARPAT 138:1673
AB Compds. having the formula (R4L2)nL1CR1R2R3 (n = 1,2; L1 = alkenylene, alkylene, alkynylene, cycloalkylene, heteroalkylene, alkylene-CONR5- alkylene, alkylene-O-alkylene; L2 = bond, C2-alkenylene, O, S, SO2, OC(:O)NR5, NR6C:O, C(:O)NR6, SO2NR6, NR6SO2, C(:N)O, NR6C(:O)NR6, C(:O)NR6NR6C:O; R1 = alkanoyl, alkoxycarbonyl, aminocarbonyl, carboxy, haloalkyl, heterocycle; R2,R3 = OH or R2,R3 together = oxo; R4 = alkoxyalkyl, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycle, (heterocycle)alkyl; R5,R6 = hydrogen, alkyl, aryl, arylalkyl; R4,R6 and N to which they are attached = heterocycle) or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compds., compns. containing the compds., and treatment of diseases using the compds. are disclosed. Thus, more than 200 histone deacetylase inhibitors (no data) were synthesized.
IT 436151-99-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of histone deacetylase and their therapeutic use)
RN 436151-99-4 CAPLUS
CN Nonanediamide, N1-methyl-2-oxo-N9-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 37 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:904325 CAPLUS Full-text
DN 137:380038
TI Combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety
IN Howard, Harry Ralph, Jr.
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	EP 1260221	A2	20021127	EP 2002-253135	20020503
	EP 1260221	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2386287	A1	20021123	CA 2002-2386287	20020514
	AU 200240681	A	20021205	AU 2002-40681	20020516
	JP 2002370976	A	20021224	JP 2002-141515	20020516
	ZA 2002004018	A	20031121	ZA 2002-4018	20020521
	HU 2002001720	A2	20030728	HU 2002-1720	20020522
	CN 1386504	A	20021225	CN 2002-120351	20020523
PRAI	US 2001-293063P	P	20010523		

OS MARPAT 137:380038
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.
IT 334980-60-8 334980-65-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoamine reuptake inhibitor; combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety)
RN 334980-60-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-thiazolyl)- (CA INDEX NAME)



RN 334980-65-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-(2-thiazolyl)- (CA INDEX NAME)



L31 ANSWER 38 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:674788 CAPLUS Full-text
DN 137:195595

TI Atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis
IN Howard, Harry R., Jr.
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002123490	A1	20020905	US 2001-10651	20011206
EP 1238676	A1	20020911	EP 2002-251153	20020220
EP 1238676	B1	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 267021	T	20040615	AT 2002-251153	20020220
PT 1238676	T	20040831	PT 2002-251153	20020220
ES 2217239	T3	20041101	ES 2002-251153	20020220
CA 2373596	A1	20020901	CA 2002-2373596	20020227
JP 2002308801	A	20021023	JP 2002-50579	20020227
PRAI US 2001-272619P	P	20010301		

OS MARPAT 137:195595
AB The invention provides a method for treating depression, obsessive compulsive disorder, and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also provides pharmaceutical compns. containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and a serotonin reuptake inhibitor.
IT 444888-70-4 444888-73-7 444888-79-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis)
RN 444888-70-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-methyl-4-thiazolyl)- (CA INDEX NAME)



RN 444888-73-7 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(2,5-dimethyl-4-thiazolyl)-N-methyl- (CA INDEX NAME)



RN 444888-79-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(2,4-dimethyl-5-thiazolyl)-N-methyl- (CA INDEX NAME)



L31 ANSWER 39 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:595509 CAPLUS Full-text
DN 137:135106
TI Combination of a 5-HT3 receptor antagonist with a serotonin reuptake inhibitor for the treatment of depression
IN Howard, Harry R.
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002107244	A1	20020808	US 2001-2303	20011102
EP 1230921	A1	20020814	EP 2002-250541	20020128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002275097	A	20020925	JP 2002-20186	20020129
CA 2369789	A1	20020802	CA 2002-2369789	20020131
BR 2002000246	A	20021029	BR 2002-246	20020131
MX 2002PA01198	A	20020918	MX 2002-PA1198	20020201
US 2004029972	A1	20040212	US 2003-633847	20030804
PRAI US 2001-266340P	P	20010202		
US 2001-2303	B1	20011102		

OS MARPAT 137:135106
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor

antagonist in combination with a serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in sexual function and/or reduction in gastro-intestinal side effects. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant. The ratio of the 5-HT3 receptor antagonist and the SRI antidepressant agent is between 0.001 to 1 and 1000 to 1, and especially between 0.01 to 1 and 100 to 1 (no data).
IT 444888-70-4 444888-73-7 444888-79-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of 5-HT3 receptor antagonist with serotonin reuptake inhibitor for treatment of depression)
RN 444888-70-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-methyl-4-thiazolyl)- (CA INDEX NAME)



RN 444888-73-7 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(2,5-dimethyl-4-thiazolyl)-N-methyl- (CA INDEX NAME)



RN 444888-79-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(2,4-dimethyl-5-thiazolyl)-N-methyl- (CA INDEX NAME)



L31 ANSWER 40 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:481424 CAPLUS Full-text
DN 137:194996
TI Synthesis of Potent Leukotriene A4 Hydrolase Inhibitors. Identification of 3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid
AU Penning, Thomas D.; Russell, Mark A.; Chen, Barbara B.; Chen, Helen Y.; Liang, Chi-Dean; Mahoney, Matthew W.; Malecha, James W.; Miyashiro, Julie M.; Yu, Stella S.; Askonas, Leslie J.; Gierse, James K.; Harding, Elizabeth I.; Highkin, Maureen K.; Kachur, James F.; Kim, Suzanne H.; Villani-Price, Doreen; Pyla, E. Yvonne; Ghoreishi-Haack, Nayereh S.; Smith, Walter G.
CS Department of Medicinal Chemistry and Departments of Inflammatory Diseases Research and Molecular Pharmacology, Pharmacia Corporation, Skokie, IL, 60077, USA
SO Journal of Medicinal Chemistry (2002), 45(16), 3482-3490
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:194996
AB Leukotriene B4 (LTB4) is a potent, proinflammatory mediator involved in the pathogenesis of a number of diseases including inflammatory bowel disease, psoriasis, rheumatoid arthritis, and asthma. The enzyme LTA4 hydrolase represents an attractive target for pharmacol. intervention in these disease states, since the action of this enzyme is the rate-limiting step in the production of LTB4. Our previous efforts focused on the exploration of a series of analogs related to screening hit SC-22716 (1-[2-(4-phenylphenoxy)ethyl]pyrrolidine) and resulted in the identification of potent, orally active inhibitors. Addnl. structure-activity relation studies around this structural class resulted in the identification of a series of α-, β-, and γ-amino acid analogs that are potent inhibitors of the LTA4 hydrolase enzyme and demonstrated good oral activity in a mouse ex vivo whole blood LTB4 production assay. The efforts leading to the identification of clin. candidate SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid) are described.
IT 213315-24-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure activity relationships of aminopropanoic acid derivs. as leukotriene A4 hydrolase inhibitors)
RN 213315-24-3 CAPLUS
CN β-Alanine, N-methyl-N-[3-[4-[4-(2-thiazolyl)phenoxy]phenoxy]propyl]- (CA INDEX NAME)



IT 213315-16-0P 213315-40-3P 213315-41-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and structure activity relationships of aminopropanoic acid derivs. as leukotriene A4 hydrolase inhibitors)
RN 213315-39-0 CAPLUS
CN Thiazole, 2-[4-(4-methoxyphenoxy)phenyl]- (CA INDEX NAME)



RN 213315-40-3 CAPLUS
CN Phenol, 4-[4-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



RN 213315-41-4 CAPLUS
CN Propanenitrile, 3-[methyl[3-[4-[4-(2-thiazolyl)phenoxy]phenoxy]propyl]amino]- (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 41 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:449627 CAPLUS Full-text
DN 137:33319
TI Preparation of N-aryl, N-arylalkyl, and N-heterocyclylnonanamide and -octanamide derivatives and related compounds as inhibitors of histone deacetylase
IN Curtin, Michael L.; Dai, Yujia; Davidsen, Steven K.; Frey, Robin R.; Guo, Yan; Heyman, Howard R.; Holms, James H.; Ji, Zhiqin; Michaelides, Michael R.; Vasudevan, Anil; Wada, Carol K.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046129	A2	20020613	WO 2001-US50931	20011026
	WO 2002046129	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2002103192	A1	20020801	US 2001-808389	20010314
	AU 2002043402	A5	20020618	AU 2002-43402	20011026
PRAI	US 2000-697387	A	20001026		
	US 2001-808389	A	20010314		
	WO 2001-US50931	W	20011026		

OS MARPAT 137:33319
AB Compds. having the formula (R4-L2)nL1-CR1R2R3 or therapeutically acceptable salts thereof [wherein n = 1, 2; L1 = alkenylene, alkylene, alkynylene, cycloalkylene, heteroalkylene, (alkylene)-C(O)N(R5)- (alkylene), (alkylene)-O-(alkylene) (wherein each group is drawn with its left-hand end being the end which attaches to L2, and its right-hand end being the end which attaches to the carbon substituted with R1, R2, and R3); L2 = , C2 alkenylene, O, S, SO2, OC(O)NR5, N(R6)C(O), C(O)N(R6), SO2N(R6), N(R6)SO2, C:N-O, N(R6)C(O)N(R6), and C(O)N(R6)N(R6)C(O) (wherein each group is drawn with its left-hand end being the end which attaches to R4, and its right-hand end being the end which attaches to L1); R1 is selected from the group consisting of alkanoyl, alkoxycarbonyl, CONH2, CO2H, haloalkyl, heterocyclyl (wherein the heterocycle is selected from the group consisting of oxazolyl, dihydrooxazolyl, oxadiazolyl, and tetrazolyl); R2 = R3 = HO; or R2 and R3 together are oxo; R4 = alkoxyalkyl, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclylalkyl; R5, R6 = H, alkyl, aryl, arylalkyl; or R5 and R6, together with the nitrogen atom to which they are attached, form a heterocycle selected from the group consisting of (un)substituted morpholinyl, piperazinyl, piperidinyl, and thiomorpholinyl], which are histone deacetylase (HDAC) inhibitors (no data), are prepared These compds. are used for the treatment of diseases, possibly e.g. several human cancers associated with malfunction in histone deacetylases. Thus, a mixture of 9,9,9-trifluoro-8-oxononanoic acid (50 mg, 0.22 mmol), HOBt (30 mg, 0.22 mmol), carbodiimide PS resin (720 mg), and 4-phenyl-1,3-thiazol-2- amine (0.27 mmol) in DMF (5 mL) at room temperature was agitated in a Quest 210 parallel synthesizer for 18 h, treated with trisamine PS resin (220 mg), and agitated for 2 h. The solution was decanted, the resin was rinsed with dichloromethane, and the combined solns. were concentrated, followed by purification using preparative HPLC with a gradient system of 0 to 95 % over 10 min of MeCN (containing 0.1% CF3CO2H) in water to give 9,9,9-trifluoro-8-oxo-N-(4- phenyl-1,3-thiazol-2-yl)nonanamide.
IT 436151-99-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl, N-arylalkyl, and N-heterocyclylnonanamide and -octanamide derivs. and related compds. as inhibitors of histone deacetylase)
RN 436151-99-4 CAPLUS
CN Nonanediamide, N1-methyl-2-oxo-N9-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



IT [illegible], 4-(4-Phenoxyphenyl)-2-amino-1,3-thiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-aryl, N-arylalkyl, and N-heterocyclylnonanamide and -octanamide derivs. and related compds. as inhibitors of histone deacetylase)
RN 105512-82-1 CAPLUS
CN 2-Thiazolamine, 4-(4-phenoxyphenyl)- (CA INDEX NAME)



L31 ANSWER 42 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:332169 CAPLUS Full-text
DN 136:355245
TI Preparation of pyrimidine-2,4,6-trione metalloproteinase inhibitors
IN Noe, Mark Carl; Reiter, Lawrence Alan; Wythes, Martin James
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034726	A2	20020502	WO 2001-IB1953	20011017
	WO 2002034726	A3	20021017		
	WO 2002034726	A9	20030306		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2425280	A1	20020502	CA 2001-2425280	20011017
	AU 200210800	A	20020506	AU 2002-10800	20011017
	BR 2001014917	A	20030701	BR 2001-14917	20011017
	EP 1332136	A2	20030806	EP 2001-978707	20011017
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300195	A	20031015	EE 2003-195	20011017
	HU 2003002337	A2	20031028	HU 2003-2337	20011017
	JP 2004512327	T	20040422	JP 2002-537717	20011017

	NZ 524774	A	20040924	NZ 2001-524774	20011017
	CN 1714084	A	20051228	CN 2001-818094	20011017
	IN 2003MN00308	A	20050211	IN 2003-MN308	20030317
	ZA 2003002192	A	20040505	ZA 2003-2192	20030319
	BG 107651	A	20031231	BG 2003-107651	20030320
	NO 2003001852	A	20030623	NO 2003-1852	20030424
	MX 2003PA03734	A	20030728	MX 2003-PA3734	20030425
	HR 2003000331	A1	20030630	HR 2003-331	20030428
PRAI	US 2000-243314P	P	20001026		
	WO 2001-IB1953	W	20011017		

OS MARPAT 136:355245
GI



I



II

AB The title compds. (I; A = (un)substituted aryl, heteroaryl; B = (un)substituted aryl, cycloalkyl, heteroaryl, etc.; X = O, CO, S, etc.; Y = a bond, O, S, etc.; R1 = H, (CH2)2OEt, (un)substituted cycloalkyl, etc.; G is a substituent on any ring carbon atom of B capable of forming an addnl. bond and is oriented at a position other than α to the point of attachment of the B ring to Y; G = CHO, CO2H, NH2, etc.], useful in treating inflammation, cancer and other disorders, were prepared Thus, reacting 4-(4-[1,3,4]oxadiazol-2-ylphenoxy)phenol with 5-bromo-5-(2-ethoxyethyl)pyrimidine-2,4,6-trione (prepns. given)in the presence of 1,5,7-triazabicyclo[4.4.0]dec-5-ene bound to polystyrene crosslinked with 2% DVB in MeCN afforded II. The compds. I that were tested all have IC50's of less than 100 μM in at least one of the assays against MMPs such MMP-1, MMP-9, MMP-13, etc.
IT 420122-07-2P 420122-19-6P 420122-24-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine-2,4,6-trione metalloproteinase inhibitors)
RN 420122-07-2 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(2-methyl-4-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



RN 420122-19-6 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(4-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



RN 420122-24-3 CAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-ethoxyethyl)-5-[4-[4-(2-thiazolyl)phenoxy]phenoxy]- (CA INDEX NAME)



L31 ANSWER 43 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:923794 CAPLUS Full-text
DN 136:37598
TI Preparation of thiazolylpyrrolidones, -furanones, and -thiazolones as pesticides and herbicides.
IN Fischer, Reiner; Bretschneider, Thomas; Trautwein, Axel; Ullmann, Astrid; Drewes, Mark Wilhelm; Erdelen, Christoph; Dahmen, Peter; Feucht, Dieter; Pontzen, Rolf
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001096333	A1	20011220	WO 2001-EP6174	20010531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,			
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,			
	UZ, VN, YU, ZA, ZW			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
DE 10029077	A1	20011220	DE 2000-10029077	20000613
CA 2411111	A1	20021210	CA 2001-2411111	20010531
EP 1296979	A1	20030402	EP 2001-953967	20010531
EP 1296979	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011625	A	20030520	BR 2001-11625	20010531
JP 2004503552	T	20040205	JP 2002-510475	20010531
CN 1683370	A	20051019	CN 2005-10075402	20010531
AT 315037	T	20060215	AT 2001-953967	20010531
ES 2254453	T3	20060616	ES 2001-1953967	20010531
IN 2002MN01715	A	20050204	IN 2002-MN1715	20021202
US 2004009877	A1	20040115	US 2002-297873	20021210
US 6767864	B2	20040727		
MX 2002PA12400	A	20040503	MX 2002-PA12400	20021213
US 2004220243	A1	20041104	US 2004-850679	20040521
US 7141533	B2	20061128		
PRAI DE 2000-10029077	A	20000613		
CN 2001-811147	A3	20010531		
WO 2001-EP6174	W	20010531		
US 2002-297873	A3	20021210		

OS MARPAT 136:37598
GI



AB Title compds. [I; W = ND, O, S; Q = (substituted) thiazolyl, oxazolyl, pyrazolyl; A = H, (substituted) alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, heterocyclyl, aryl, aralkyl, heteroaryl; B = H, alkyl, alkoxyalkyl; AB = atoms to form an (unsatd.) (substituted) ring; D = H, (substituted) alkyl, alkenyl, alkynyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, heterocyclyl, aryl, aralkyl, heteroarylalkyl, heteroaryl; AD = atoms to form a (substituted) (heterocyclic) ring; G = H, acyl], were prepared Thus, Me 4-methyl-1-aminocyclohexane-1-carboxylate hydrochloride, 4-[2-(4-chlorophenyl)-5-methyl]thiazolylacetic acid, Et3N, and POCl3 were refluxed 30 min. to give 73% amide, which was stirred 1 h with KOCMe3 in DMF at 0° to 20° to give 83% title compound (II). Several I at 250 g/ha postemergent gave 100% control of Avena fatua, Echinochloa, etc.
IT 380647-93-8P 380647-96-1P 380648-00-0P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolylpyrrolidones, -furanones, and -thiazolones as pesticides and herbicides)
RN 380647-93-8 CAPLUS
CN 2H-Pyrrol-2-one, 1,5-dihydro-4-hydroxy-5,5-dimethyl-3-[5-methyl-2-(4-phenoxyphenyl)-4-thiazolyl]- (CA INDEX NAME)



RN 380647-96-1 CAPLUS
CN 1-Azaspiro[4.5]dec-3-en-2-one, 4-hydroxy-8-methoxy-3-[5-methyl-2-(4-phenoxyphenyl)-4-thiazolyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 380648-00-0 CAPLUS
CN 1-Azaspiro[4.5]dec-3-en-2-one, 4-hydroxy-8-methoxy-3-[5-methyl-2-(4-phenoxyphenyl)-4-thiazolyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 380648-45-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolylpyrrolidones, -furanones, and -thiazolones as pesticides and herbicides)
RN 380648-45-3 CAPLUS
CN Cyclohexanecarboxylic acid, 4-methoxy-1-[[[4-methyl-2-(4-phenoxyphenyl)-5-thiazolyl]acetyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 44 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:868438 CAPLUS Full-text
DN 136:5981
TI Preparation of N-thiazol-2-ylbenzenesulfonamides as 11-β-hydroxysteroid dehydrogenase type 1 inhibitors for treatment of diabetes and related diseases
IN Kurz, Guido; Nilsson, Marianne
PA Biovitrum AB, Swed.
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001090092	A1	20011129	WO 2001-SE1158	20010522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408783	A1	20011129	CA 2001-2408783	20010522
EP 1283832	A1	20030219	EP 2001-934782	20010522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003534338	T	20031118	JP 2001-586280	20010522
NZ 522591	A	20040924	NZ 2001-522591	20010522
ZA 2002009359	A	20040218	ZA 2002-9359	20021118
ZA 2002009360	A	20040218	ZA 2002-9360	20021118
ZA 2002009362	A	20040218	ZA 2002-9362	20021118
ZA 2002009364	A	20040218	ZA 2002-9364	20021118
NO 2002005585	A	20021223	NO 2002-5585	20021121
NO 323831	B1	20070709		
IN 2002CN02040	A	20050225	IN 2002-CN2040	20021211
US 2003166689	A1	20030904	US 2003-296552	20030401
US 7132436	B2	20061107		
PRAI SE 2000-1899	A	20000522		

WO 2001-SE1158 W 20010522
OS MARPAT 136:5981
GI



I

II

AB Title compds. I [wherein T = substituted Ph or thienyl substituted with 1 or more Br or Cl; A = (un)substituted (hetero)aryl; B = H or alkoxycarbonyl; or A and B together with the C atoms to which they are attached form a 6-membered ring; and pharmaceutically acceptable salts, hydrates, and solvates thereof] were prepared as 11-β-hydroxysteroid dehydrogenase type 1 (11-β-HSD1) inhibitors. For example, 7-methoxy-4,5-dihydronaphtho[1,2-d][1,3]thiazol-2-amine•HBr was coupled with 5-propylbenzenesulfonyl chloride in the presence of TEA and DMAP in DMF and CH2Cl2 to give II, which inhibited 11-β-HSD1 with Ki of 14 nM. I are useful for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, depression, virus diseases, and inflammatory disorders (no data).

IT 376349-81-4P, 2,3,4-Trichloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-1,3-thiazol-2-yl]benzenesulfonamide 376349-84-7P, 4-Bromo-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-1,3-thiazol-2-yl]-2,5-difluorobenzenesulfonamide 376349-87-0P, 4-Bromo-5-chloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-1,3-thiazol-2-yl]-2-thiophenesulfonamide 376349-92-7P, 2,4,6-Trichloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-1,3-thiazol-2-yl]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-thiazolylbenzenesulfonamides by coupling thiazolamines with benzenesulfonyl chlorides as 11-β-hydroxysteroid dehydrogenase type 1 inhibitors for treatment of diabetes and related diseases)

RN 376349-81-4 CAPLUS
CN Benzenesulfonamide, 2,3,4-trichloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 376349-84-7 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]-2,5-difluoro- (CA INDEX NAME)



RN 376349-87-0 CAPLUS
CN 2-Thiophenesulfonamide, 4-bromo-5-chloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 376349-92-7 CAPLUS
CN Benzenesulfonamide, 2,4,6-trichloro-N-[4-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



IT 338756-39-1, 4-[2-Chloro-4-(4-chlorophenoxy)phenyl]-1,3-thiazol-2-amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-thiazolylbenzenesulfonamides by coupling thiazolamines with benzenesulfonyl chlorides as 11-β-hydroxysteroid dehydrogenase type 1 inhibitors for treatment of diabetes and related diseases)

RN 338756-39-1 CAPLUS
CN 2-Thiazolamine, 4-[2-chloro-4-(4-chlorophenoxy)phenyl]- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 45 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:489370 CAPLUS Full-text
DN 135:76866
TI Preparation of heterocyclic imino compounds as fungicides and insecticides for agricultural and horticultural use
IN Niki, Toshio; Mizukoshi, Takashi; Takahashi, Hiroaki; Satow, Jun; Ogura, Tomoyuki; Yamagishi, Kazuhiro; Suzuki, Hiroyuki; Hayasaka, Fumio
PA Nissan Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047888	A1	20010705	WO 2000-JP9411	20001228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001022305	A5	20010709	AU 2001-22305	20001228
	EP 1243580	A1	20020925	EP 2000-985987	20001228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003212116	A1	20031113	US 2002-168968	20020625
PRAI	JP 1999-374040	A	19991228		
	JP 2000-239624	A	20000808		
	JP 2000-334442	A	20001101		
	WO 2000-JP9411	W	20001228		

OS MARPAT 135:76866
GI



I



II

AB The title compds. I [G is a group of general formula BCOZ or the like; A is a 3- to 13-membered, mono-, di- or tricyclic ring which is composed of 3 to 13 atoms arbitrarily selected from among carbon, oxygen, sulfur and nitrogen, contains at least one heteroatom selected from among oxygen, sulfur and nitrogen, and may optionally have substituent(s), with the proviso that when A is a quinolone ring, the nitrogen atom of the ring is present at the α-position to the imino linkage; Z is OR1 or the like; B is CH2 or the like; n = 0 - 4; X is halogeno or the like; and R1 is hydrogen, C1-6 alkyl, C1-6haloalkyl, or the like] are prepared The title compound II at 500 ppm gave ≥ 70% control of Pyricularia oryzae, Erysiphe graminis, Puccinia recondita, Leptosphaera nodorum, and Pseudoperonospora cubensis. II at 500 ppm gave ≥ 70% control of leafhoppers.

IT 347871-85-5P 347874-12-8P 347874-13-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic imino compds. as fungicides and insecticides for agricultural and horticultural use)

RN 347873-88-5 CAPLUS
CN Benzeneacetic acid, 2-[[3-methyl-4-(4-phenoxyphenyl)-2(3H)-thiazolylidene]amino]-, methyl ester (CA INDEX NAME)



RN 347874-12-8 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[[3-methyl-4-(4-phenoxyphenyl)-2(3H)-thiazolylidene]amino]-, methyl ester, (αE)- (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 347874-13-9 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[[3-methyl-4-(4-phenoxyphenyl)-2(3H)-thiazolylidene]amino]-, methyl ester, (αZ)-(CA INDEX NAME)

Double bond geometry as described by E or Z.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 46 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:283913 CAPLUS Full-text
DN 134:310974
TI Preparation of biaryl ether derivatives as monoamine reuptake inhibitors
IN Howard, Harry Ralph, Jr.; Adam, Mavis Diane
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027068	A1	20010419	WO 2000-IB1373	20000927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2387517	A1	20010419	CA 2000-2387517	20000927
	CA 2387517	C	20051115		
	BR 2000014733	A	20020611	BR 2000-14733	20000927
	EP 1220831	A1	20020710	EP 2000-960916	20000927

	EP 1220831	B1	20050608	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	TR 200201004	T2	20021121	TR 2002-1004 20000927
	HU 2002003448	A2	20030228	HU 2002-3448 20000927
	JP 2003511434	T	20030325	JP 2001-530089 20000927
	EE 200200191	A	20030616	EE 2002-191 20000927
	AU 769430	B2	20040129	AU 2000-73070 20000927
	NZ 517696	A	20041224	NZ 2000-517696 20000927
	AT 297374	T	20050615	AT 2000-960916 20000927
	PT 1220831	T	20050930	PT 2000-960916 20000927
	ES 2240155	T3	20051016	ES 2000-960916 20000927
	US 6410736	B1	20020625	US 2000-692335 20001019
	IN 2002MN00303	A	20050318	IN 2002-MN303 20020311
	NO 2002001659	A	20020408	NO 2002-1659 20020408
	BG 106603	A	20021229	BG 2002-106603 20020410
	ZA 2002002804	A	20030410	ZA 2002-2804 20020410
	HR 2002000324	A1	20030831	HR 2002-324 20020412
	MX 2002PA03793	A	20020930	MX 2002-PA3793 20020415
	US 2003055038	A1	20030320	US 2002-153308 20020522
	US 6596741	B2	20030722	
	HK 1047577	A1	20050916	HK 2002-109177 20021218
PRAI	US 1999-159276P	P	19991013	
	US 1999-167761P	P	19991129	
	WO 2000-IB1373	W	20000927	
	US 2000-692335	A3	20001019	

OS MARPAT 134:310974
GI



AB The title compds. [I; rings A and B can be replaced by naphthyl group; n, m = 1-3; R1, R2 = H, alkyl, alkenyl, etc.; NR1R2 = 4-8 membered saturated (un)substituted ring containing 1-2 heteroatoms, including N atom to which R1 and R2 are attached; R3, R4 = H, alkyl optionally substituted with 1-3 F atoms; CR3R4 = 4-8 membered saturated (un)substituted carbocyclic ring; NR2CR3 = 4-8 membered saturated (un)substituted ring containing 1-2 heteroatoms, including N atom to which R2 is attached; X = (un)substituted Ph, heteroaryl, heterocyclyl; Y = H, halo, alkyl optionally substituted with 1-3 F atoms, etc.; Z = H, halo, alkoxy, etc.] and their pharmaceutically acceptable salts which exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders, were prepared E.g., a 3-step synthesis of I [R1 = Me; R2-R4 = H; X = 5-Ph; Z = H; Y = 3,4-Cl2] was given. All exemplified compds. I showed IC50 of ≤ 250 nM for serotonin reuptake inhibition, and IC50 of ≤ 1000 nM for dopamine and for norepinephrine reuptake inhibition.
IT 334980-60-3P 334980-65-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl ether derivs. as monoamine reuptake inhibitors)
RN 334980-60-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(2-thiazolyl)- (CA INDEX NAME)





RN 334980-65-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-(2-thiazolyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 47 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:706981 CAPLUS Full-text
DN 133:281779
TI Preparation of aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as sodium channels blockers
IN Hogenkamp, Derk J.; Upasani, Ravindra; Nguyen, Phong
PA Cocensys, Inc., USA
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000057877	A1	20001005	WO 2000-US7944	20000324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				

	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2368631	A1	20001005	CA 2000-2368631 20000324
	EP 1173169	A1	20020123	EP 2000-919636 20000324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 2000009322	A	20020430	BR 2000-9322 20000324
	TR 200102790	T2	20020621	TR 2001-2790 20000324
	US 6414011	B1	20020702	US 2000-533864 20000324
	DE 20080291	U1	20020801	DE 2000-20080291 20000324
	TW 502019	B	20020911	TW 2000-89105616 20000324
	JP 2002540155	T	20021126	JP 2000-607628 20000324
	NZ 514756	A	20040430	NZ 2000-514756 20000324
	AU 782353	B2	20050721	AU 2000-40291 20000324
	NO 2001004659	A	20011101	NO 2001-4659 20010925
	MX 2001PA09655	A	20030624	MX 2001-PA9655 20010925
	IN 2001KN01078	A	20050311	IN 2001-KN1078 20011015
	ZA 2001008807	A	20021025	ZA 2001-8807 20011025
	US 2003069292	A1	20030410	US 2002-134697 20020430
	US 6737418	B2	20040518	
	NZ 529690	A	20031219	NZ 2003-529690 20031121
PRAI	US 1999-126553P	P	19990326	
	US 2000-533864	A3	20000324	
	WO 2000-US7944	W	20000324	

OS MARPAT 133:281779
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Het = II-IV, etc.; R1 = H, alkyl, cycloalkyl, etc.; R2, R3 = H, alkyl, cycloalkyl, etc.; R5-R13 = H, halo, haloalkyl, etc.; X = O, S, CH2, NH, etc.] and their pharmaceutically acceptable salts which act as sodium channel blockers, and are useful as anticonvulsants, were prepared E.g. a 3-step synthesis of V which showed ED50 of 4.2 mg/kg (p.o.) against MES, was given.
IT 299206-72-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as sodium channels blockers)
RN 299206-72-7 CAPLUS
CN 2-Thiazolecarboxamide, 4-[3-fluoro-4-(4-fluorophenoxy)phenyl]- (CA INDEX NAME)



IT 299206-50-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as sodium channels blockers)

RN 299206-98-7 CAPLUS
CN 2-Thiazolecarboxylic acid, 4-[3-fluoro-4-(4-fluorophenoxy)phenyl]-, ethyl ester (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 48 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:170582 CAPLUS Full-text
DN 130:237794
TI Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases
AU Yu, Xiang Y.; Hill, Jason M.; Yu, Guixue; Wang, Weiheng; Kluge, Arthur F.; Wendler, Phil; Gallant, Paul
CS Department of Medicinal Chemistry, Cubist Pharmaceuticals, Inc., Cambridge, MA, 02139, USA
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(3), 375-380
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB A series of novel aminoacyl adenylate mimics has been prepared and evaluated for their inhibitory activity against aminoacyl-tRNA synthetases. Several of these thiazole derivs. displayed potent and selective enzyme activity against both Gram-pos. and Gram-neg. bacteria.
IT 221315-49-7P 221315-51-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and structure-activity relationships of amino acid thiazole nucleosides as inhibitors of aminoacyl-tRNA synthetases)
RN 221315-49-7 CAPLUS
CN D-Ribitol, 1,4-anhydro-1-C-[4-(4-phenoxyphenyl)-2-thiazolyl]-, 5-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]sulfamate], (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221315-51-1 CAPLUS
CN D-Ribitol, 1,4-anhydro-1-C-[4-(4-phenoxyphenyl)-2-thiazolyl]-, 5-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]sulfamate], (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 49 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:745044 CAPLUS Full-text
DN 130:3842
TI Preparation of guanidinothiazoles as bactericides
IN Baasner, Bernd; Matzke, Michael; Militzer, Hans-christian; Schaller, Klaus; Labischinski, Harald; Endermann, Rainer; Werling, Hans-otto
PA Bayer A.-G., Germany
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9850373	A1	19981112	WO 1998-EP2378	19980422
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19719053	A1	19981112	DE 1997-19719053	19970506
AU 9876465	A	19981127	AU 1998-76465	19980422
PRAI DE 1997-19719053	A	19970506		
WO 1998-EP2378	W	19980422		

OS MARPAT 130:3842
GI



I

AB R1OZ1Z2N:C(NR2R3)NR4R5 [R1 = (un)substituted Ph; R2-R5 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, etc.; Z1 = (un)substituted phenylene; Z2 = thiazole-4,2-diyl] were prepared as bactericides (no data). Thus, H2NCSN:C(NH2)NHZNEt2 (Z = 1,4-cyclohexylene) was cyclocondensed with 2,4-Me2C6H3OC6H4(COCH2Br)-2 to give title compound I.
IT 215798-24-6P 215798-25-7P 215798-27-9P
215798-28-0P 215798-29-1P 215798-30-4P
215798-31-5P 215798-32-6P 215798-33-7P
215798-34-8P 215798-36-0P 215798-37-1P
215798-39-3P 215798-39-2P 215798-40-6P
215798-42-8P 215798-43-9P 215798-44-0P
215798-45-1P 215798-46-2P 215798-47-3P
215798-49-5P 215798-50-8P 215798-51-9P
215798-53-1P 215798-56-4P 215798-58-6P
215798-61-1P 215798-63-2P 215798-65-5P
215798-67-7P 215798-69-9P 215798-72-4P
215798-74-6P 215798-76-8P 215798-78-0P
215798-81-5P 215798-83-7P 215798-86-0P
215798-88-2P 215798-91-7P 215798-93-9P
215798-95-1P 215798-98-4P 215799-00-1P
215799-02-7P 215799-04-5P 215799-06-7P
215799-08-9P 215799-10-2P 215799-13-6P
215799-15-8P 215799-17-0P 215799-19-2P
215799-20-5P 215799-25-0P 215799-27-2P
215799-29-4P 215799-32-9P 215799-34-1P
215799-36-3P 215799-38-5P 215799-41-0P
215799-43-2P 215799-45-4P 215799-47-6P
215799-50-1P 215799-52-3P 215799-54-5P
215799-56-7P 215799-60-2P 215799-62-5P
215799-64-7P 215799-66-9P 215799-68-1P
215799-70-5P 215799-72-9P 215799-75-0P
215799-77-2P 215799-80-7P 215799-83-0P
215799-85-2P 215799-87-4P 215799-90-9P
215799-92-1P 215799-94-3P 215799-96-5P
215799-98-7P 215800-00-3P 215800-02-5P
215800-04-7P 215800-07-0P 215800-10-4P
215800-12-6P 215800-14-8P 215800-17-1P
215800-19-3P 215800-21-9P 215800-23-0P
215800-25-2P 215800-27-4P 215800-30-9P
215800-32-1P 215800-34-3P 215800-37-6P
215800-39-8P 215800-42-3P 215800-45-6P
215800-47-8P 215800-49-0P 215800-52-3P
215800-54-5P 215800-56-7P 215800-59-0P
215800-61-4P 215800-63-6P 215800-65-8P
215800-67-0P 215800-69-2P 215800-72-7P
215800-74-9P 215800-76-1P 215800-78-3P
215800-80-7P 215800-82-9P 215800-84-1P
215800-86-3P 215800-88-5P 215800-90-9P
215800-92-1P 215800-94-3P 215800-96-5P
215800-98-7P 215801-00-4P 215801-02-8P
215801-04-0P 215801-06-2P 215801-09-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of guanidinothiazoles as bactericides)
RN 215798-24-6 CAPLUS
CN Guanidine, N-[4-(diethylamino)cyclohexyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-25-7 CAPLUS
CN Guanidine, N-[2-(4,5-dihydro-1H-1,2,3-triazol-1-yl)-1-methylethyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-27-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 215798-28-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-methyl-N''-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)



RN 215798-29-1 CAPLUS

CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[4-(4-morpholinyl)butyl]- (CA INDEX NAME)



RN 215798-30-4 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 215798-31-5 CAPLUS
CN Guanidine, N-cyclododecyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-32-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 215798-33-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-methyl-N''-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 215798-34-8 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 215798-36-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[(2R)-2-methyl-3-(1-piperidinyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-37-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[2-methyl-3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 215798-38-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[2-methyl-3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 215798-39-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[3-methyl-2-(2-thienyl)butyl]- (CA INDEX NAME)



RN 215798-40-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(2-fluoro-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 215798-42-8 CAPLUS
CN Guanidine, N,N'-dicyclohexyl-N''-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-43-9 CAPLUS
CN Guanidine, N,N'-dicyclopropyl-N''-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-44-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-diethyl- (9CI) (CA INDEX NAME)



RN 215798-45-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-methyl- (9CI) (CA INDEX NAME)



RN 215798-46-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-diphenyl- (CA INDEX NAME)



RN 215798-47-3 CAPLUS
CN Guanidine, N-[4-[2-(4-chloro-2-methylphenoxy)phenyl]-2-thiazolyl]-N',N''-dimethyl- (CA INDEX NAME)



RN 215798-49-5 CAPLUS
CN Guanidine, N-[4-[2-(4-chloro-2-methylphenoxy)phenyl]-2-thiazolyl]-N',N''-diethyl- (CA INDEX NAME)



RN 215798-50-8 CAPLUS
CN Guanidine, N-[4-[2-(4-chloro-2-methylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-methyl- (CA INDEX NAME)



RN 215798-51-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 215798-53-1 CAPLUS
CN Guanidine, N,N'-dimethyl-N''-[4-[2-[2-methyl-4-[(trifluoromethyl)thio]phenoxy]phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215798-56-4 CAPLUS
CN Guanidine, N,N'-diethyl-N''-[4-[2-[2-methyl-4-[(trifluoromethyl)thio]phenoxy]phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-59-7 CAPLUS
CN Guanidine, N-ethyl-N'-methyl-N''-[4-[2-[2-methyl-4-[(trifluoromethyl)thio]phenoxy]phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215798-61-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(3,3,3-trifluoropropyl)- (CA INDEX NAME)



RN 215798-63-3 CAPLUS
CN Guanidine, N,N'-dicyclopentyl-N''-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-65-5 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis[2-(trifluoromethyl)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 215798-67-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis[3-(trifluoromethyl)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 215798-69-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3,3,3-trifluoropropyl)- (CA INDEX NAME)



RN 215798-72-4 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 215798-74-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215798-76-8 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)



RN 215798-78-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-di-1-pyrrolidinyl- (9CI) (CA INDEX NAME)



RN 215798-81-5 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(2-thienylmethyl)- (CA INDEX NAME)



RN 215798-83-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis[2-methyl-1-(2-thienyl)propyl]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



RN 215798-86-0 CAPLUS
CN Guanidine, N,N'-dicyclododecyl-N''-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-89-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 215798-91-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 215798-93-9 CAPLUS
CN Guanidine, N-cyclopentyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215798-95-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 215798-98-4 CAPLUS
CN Cyclohexanecarboxamide, 4,4'-[[[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]carbonimidoyl]diimino]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



RN 215799-00-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-methyl-N''-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 215799-02-3 CAPLUS
CN Guanidine, N-cyclododecyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N''-ethyl- (9CI) (CA INDEX NAME)



RN 215799-04-5 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]amino](ethylamino)methylene]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 215799-06-7 CAPLUS
CN Guanidine, N-cyclododecyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N''-methyl- (9CI) (CA INDEX NAME)



RN 215799-08-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 215799-10-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-[1-methyl-2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215799-13-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(methoxymethyl)-N''-methyl- (9CI) (CA INDEX NAME)



RN 215799-15-8 CAPLUS
CN Guanidine, N-cyclopentyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N''-ethyl- (9CI) (CA INDEX NAME)



RN 215799-17-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-methyl-N''-[1-methyl-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215799-19-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-methyl-N''-2-propynyl- (9CI) (CA INDEX NAME)



RN 215799-23-8 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-2-propynyl- (9CI) (CA INDEX NAME)



RN 215799-25-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 215799-27-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-ethyl-N''-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 215799-29-4 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 215799-32-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-methylpropyl)- (CA INDEX NAME)



RN 215799-34-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 215799-36-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 215799-38-5 CAPLUS
CN Guanidine, N-[3-(diethylamino)propyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-41-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-thienylmethyl)- (CA INDEX NAME)



RN 215799-43-2 CAPLUS
CN Guanidine, N-[2-(diethylamino)ethyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-45-4 CAPLUS
CN Guanidine, N-[3-(dimethylamino)propyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-47-6 CAPLUS
CN Guanidine, N-(1-bicyclo[2.2.1]hept-2-ylethyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-50-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis[2-fluoro-1,1-bis(fluoromethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215799-52-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis[1-methyl-2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215799-54-5 CAPLUS
CN Guanidine, N,N'-bis(2,2-difluoro-1-methylcyclopropyl)-N''-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-56-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N',N''-bis[1-methyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 215799-60-3 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]amino](methylamino)methylene]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 215799-62-5 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-furanylmethyl)-N''-methyl- (9CI) (CA INDEX NAME)



RN 215799-64-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-methyl-N''-[1-methyl-2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215799-66-9 CAPLUS
CN Guanidine, N,N'-dicyclopentyl-N''-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-, mononydrobromide (9CI) (CA INDEX NAME)



RN 215799-68-1 CAPLUS
CN Guanidine, [4-[2-(4-chloro-2-methylphenoxy)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215799-70-5 CAPLUS
CN Guanidine, [4-[2-[2-methyl-4-[(trifluoromethyl)thio]phenoxy]phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215799-73-8 CAPLUS
CN Guanidine, N-[4-[2-(4-chloro-2-methylphenoxy)phenyl]-2-thiazolyl]-N'-[1-methyl-2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 215799-75-0 CAPLUS
CN Guanidine, N-[1-methyl-2-(1-piperidinyl)ethyl]-N'-[4-[2-[2-methyl-4-[(trifluoromethyl)thio]phenoxy]phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215799-77-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[(octahydro-4,7-methano-1H-inden-5-yl)methyl]- (CA INDEX NAME)



RN 215799-80-7 CAPLUS
CN Guanidine, N-(2,2-dimethoxyethyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-83-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-methylbutyl)- (9CI) (CA INDEX NAME)



RN 215799-85-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(1,1-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 215799-87-4 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)- (CA INDEX NAME)



RN 215799-90-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3,3,5-trimethylcyclohexyl)- (CA INDEX NAME)



RN 215799-92-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 215799-94-3 CAPLUS
CN Guanidine, N-cyclobutyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215799-96-5 CAPLUS

CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[3-(4-morpholinyl)butyl]- (CA INDEX NAME)



RN 215799-98-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[3-(2-methylpropoxy)propyl]- (CA INDEX NAME)



RN 215800-00-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(1-methylhexyl)- (9CI) (CA INDEX NAME)



RN 215800-02-5 CAPLUS
CN Guanidine, N-bicyclo[2.2.1]hept-2-yl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-04-7 CAPLUS
CN Guanidine, N-(2,2-dimethoxy-1-methylethyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-07-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-2-propenyl- (9CI) (CA INDEX NAME)



RN 215800-10-5 CAPLUS
CN Guanidine, N-(2,6-diethylcyclohexyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-12-7 CAPLUS
CN Guanidine, N-[3-(cyclohexylethylamino)propyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-14-9 CAPLUS
CN Guanidine, N-(decahydro-2-naphthalenyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-17-2 CAPLUS
CN Guanidine, N-[3-(diethylamino)butyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-19-4 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[3-[(3-methylpentyl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 215800-21-8 CAPLUS
CN Guanidine, N-(decahydro-1,4:5,8-dimethanonaphthalen-2-yl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215800-23-0 CAPLUS
CN Guanidine, N-[1,1'-bicyclohexyl]-2-yl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-27-4 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3-ethoxy-1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 215800-29-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3-methoxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 215800-31-0 CAPLUS
CN Cysteine, N-[[[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]amino]iminomethyl]-S-methyl- (CA INDEX NAME)



RN 215800-33-2 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3-ethoxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 215800-36-5 CAPLUS
CN Guanidine, N-2-azabicyclo[2.2.2]oct-2-yl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-38-7 CAPLUS
CN Guanidine, N-(1,3-dimethylbutyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-40-1 CAPLUS

CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 215800-42-3 CAPLUS
CN Guanidine, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-45-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 215800-47-8 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-ethyl-6-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 215800-49-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(2-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 215800-52-5 CAPLUS
CN Guanidine, N-[4-(diethylamino)-1-methylbutyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-54-7 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[(tetrahydro-2H-pyran-3-yl)methyl]- (CA INDEX NAME)



RN 215800-56-9 CAPLUS
CN Guanidine, N-[4-[2-(4-chloro-2-methylphenoxy)phenyl]-2-thiazolyl]-N'-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 215800-58-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[1-methyl-2-(3-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215800-61-6 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[1-methyl-2-(4-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 215800-63-8 CAPLUS
CN Guanidine, N-(2,3-dimethylcyclohexyl)-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-65-0 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)



RN 215800-67-2 CAPLUS
CN Guanidine, N-cyclooctyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME).



RN 215800-69-4 CAPLUS
CN Guanidine, N-[4-(1,1-dimethylethyl)cyclohexyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-72-9 CAPLUS
CN Guanidine, N-cycloheptyl-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-74-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[3-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 215800-76-3 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(4-ethoxycyclohexyl)- (9CI) (CA INDEX NAME)



RN 215800-78-5 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[2-(4-morpholinyl)-1-(4-morpholinylmethyl)ethyl]- (CA INDEX NAME)



RN 215800-80-9 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[1-(1-piperidinylmethyl)propyl]- (CA INDEX NAME)



RN 215800-82-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-tricyclo[2.2.1.02,6]hept-3-yl- (9CI) (CA INDEX NAME)



RN 215800-84-3 CAPLUS
CN Guanidine, N-[2-(3-azabicyclo[3.2.2]non-3-yl)-1-methylethyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215800-86-5 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 215800-88-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]amino]iminomethyl]amino]-, ethyl ester (CA INDEX NAME)



RN 215800-90-1 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[2-(3,4-dimethyl-1-piperidinyl)-1-methylethyl]- (CA INDEX NAME)



RN 215800-92-3 CAPLUS
CN Guanidine, N-[4-[2-[2-methyl-4-[(trifluoromethyl)thio]phenoxy]phenyl]-2-thiazolyl]-N'-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 215800-94-5 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 215800-96-7 CAPLUS
CN Guanidine, [4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 215800-98-9 CAPLUS
CN 1-Piperazinecarboximidamide, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-4-methyl- (CA INDEX NAME)



RN 215801-00-6 CAPLUS
CN 1-Piperidinecarboximidamide, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-4-(hydroxymethyl)- (CA INDEX NAME)



RN 215801-02-8 CAPLUS
CN Guanidine, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-N'-[3-(1H-pyrrol-1-yl)propyl]- (CA INDEX NAME)



RN 215801-04-0 CAPLUS
CN 2(1H)-Isoquinolinecarboximidamide, N-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]-3,4-dihydro- (CA INDEX NAME)



RN 215801-06-2 CAPLUS
CN Guanidine, N-[2-(dimethylamino)ethyl]-N'-[4-[2-(2,4-dimethylphenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



RN 215801-09-5 CAPLUS
CN Guanidine, [4-[2-(4-cyclohexylphenoxy)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 50 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:621200 CAPLUS Full-text
DN 129:245139
TI Preparation of LTA4 hydrolase inhibitors
IN Chen, Barbara B.; Chen, Helen; Russell, Mark A.; Miyashiro, Julie M.; Malecha, James W.; Penning, Thomas D.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9840364	A1	19980917	WO 1998-US3926 19980306
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5925654	A	19990720	US 1997-815696 19970312
	CA 2282349	A1	19980917	CA 1998-2282349 19980306
	AU 9866731	A	19980929	AU 1998-66731 19980306
	EP 970060	A1	20000112	EP 1998-908786 19980306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	JP 2001515490	T	20010918	JP 1998-539603 19980306
	US 6265433	B1	20010724	US 1999-312394 19990514
PRAI	US 1997-815696	A	19970312	
	WO 1998-US3926	W	19980306	
OS	MARPAT 129:245139			
GI				



I



II

AB The title compds. I [A = Ph, etc.; B = O, etc.; n = 2 - 4; R1 = H, alkyl; R2 = (CH2)mR3; m = 1 - 3; R3 = CO2R4; R4 = H, alkyl, etc.; further details on R1 and R2 are given] are prepared I are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as psoriasis, ulcerative colitis, inflammatory bowel disease and asthma. Oxazole derivative II showed IC50 of 0.43 μM in a recombinant human LTA4 hydrolase inhibition assay.

IT 213315-24-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of LTA4 hydrolase inhibitors)

RN 213315-24-3 CAPLUS
CN β-Alanine, N-methyl-N-[3-[4-[4-(2-thiazolyl)phenoxy]phenoxy]propyl]- (CA INDEX NAME)



IT 213315-39-0P 213315-40-3P 213315-41-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of LTA4 hydrolase inhibitors)

RN 213315-39-0 CAPLUS
CN Thiazole, 2-[4-(4-methoxyphenoxy)phenyl]- (CA INDEX NAME)



RN 213315-40-3 CAPLUS
CN Phenol, 4-[4-(2-thiazolyl)phenoxy]- (CA INDEX NAME)



RN 213315-41-4 CAPLUS
CN Propanenitrile, 3-[methyl[3-[4-[4-(2-thiazolyl)phenoxy]phenoxy]propyl]amino]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 51 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:572653 CAPLUS Full-text
DN 129:290086
TI Synthesis of 4,4'-disubstituted 2,2'-dithiazolyls
AU Silin, A. V.; Gorobets, N. Yu.; Ismail, Omar M. S.; Nikitchenko, V. M.
CS Ukraine
SO Visnik Kharkivs'kogo Universitetu (1997), 395, 264-273
CODEN: VKSGA3; ISSN: 0453-8048
PB Kharkivs'kii Derzhavnii Universitet
DT Journal
LA Russian

AB Sym. 4,4'-disubstituted 2,2'-dithiazoles and 4-substituted 2-thiocarbamidothiazoles have been synthesized by condensation of 3-(bromoacetyl)coumarins and aromatic α-halo ketones with dithiooxamide. The optimal conditions for obtaining 2- thiocarbamidothiazoles have been found. Nonsym. 4,4'-disubstituted 2,2'-dithiazoles have been obtained from 2-thiocarbamidothiazoles. More than fifty new compds. are obtained.

IT 4072-66-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 4072-66-6 CAPLUS

CN 2,2'-Bithiazole, 4,4'-bis(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 52 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:424227 CAPLUS Full-text

DN 129:95491

TI Preparation of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivatives as Na+/H+ exchanger inhibitors

IN Okazaki, Toshio; Kikuchi, Kazumi; Sugasawa, Keizo; Kaku, Hidetaka; Takanashi, Masahiro

PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Merck Patent G.m.b.H.

SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9827061	A1	19980625	WO 1997-JP4605	19971215
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1997DE03414	A	20050311	IN 1997-DE3414	19971127
ZA 9711102	A	19980813	ZA 1997-11102	19971210
AU 9854119	A	19980715	AU 1998-54119	19971215
PRAI JP 1996-335638	A	19961216		
WO 1997-JP4605	W	19971215		

OS MARPAT 129:95491

GI



AB N-[(Substituted five-membered heteroaryl)carbonyl]guanidine derivs. represented by general formula (I) or pharmacol. acceptable salts thereof [wherein the five-membered heteroaryl ring represents Q or Q1 (wherein X1 represents oxygen, sulfur, or NR3; and X2 represents nitrogen or CR4); R1 represents optionally substituted aryl or optionally substituted five- or six-membered monocyclic heteroaryl; R2 represents hydrogen, halogeno, optionally halogen-substituted lower alkyl, lower alkoxy, lower alkylthio, or optionally protected amino, provided that when the R1-substituted five-membered heteroaryl ring is Q2, R2 is neither hydrogen nor ethoxy; and R3 and R4 each represents hydrogen or optionally halogen-substituted lower alkyl] are prepared They are useful as a drug, especially an Na+/H+ exchanger inhibitor, for the prevention, treatment, or diagnosis of various diseases in which an Na+/H+ exchanger participates, such as hypertension, arrhythmia, angina pectoris, myocardial infarct, organ damages caused by ischemia or ischemic reperfusion, cell proliferative diseases (e.g. arteriosclerosis and cancer), and disorders caused by high blood sugar (e.g. complications of diabetes). Thus, imidazole was treated with NaH in DMF at room temperature for 30 min and then stirred with Et 2-[3-(2-bromoethoxy)phenyl]-4-methylthiazole-5-carboxylate at 70° for 3 h followed by heating with guanidine hydrochloride in the presence of NaH at 80° for 3 h to give the title compound, [(imidazolylmethoxy)phenyl]thiazolecarbonylguanidine derivative (II). The tile compds. I in vitro inhibited Na+/H+ exchanger with Ki of from 10-6 to 10-8.

IT 209537-51-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

RN 209537-51-9 CAPLUS

CN 5-Thiazolecarboxamide, N-(aminoiminomethyl)-2-[4-[4-[(dimethylamino)methyl]phenoxy]phenyl]-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 209539-06-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

RN 209539-06-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[4-[(dimethylamino)methyl]phenoxy]phenyl]-4-methyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 53 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:268474 CAPLUS Full-text

DN 128:321451

TI Preparation of alkenecarboxylic acid derivatives as pesticides

IN Muller, Urs

PA Novartis A.-G., Switz.; Muller, Urs

SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9817631	A2	19980430	WO 1997-EP5857	19971023
WO 9817631	A3	19980618		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, SZ, BE, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868116	A	19980515	AU 1998-68116	19971023
PRAI CH 1996-2599	A	19961023		

WO 1997-EP5857 W 19971023

OS MARPAT 128:321451

GI



AB The title compds. [I; R1 = H, C1-5 alkyl, C3-6 alkenyl, etc.; R2 = C1-5 alkyl, C1-3 alkoxy-C1-5 alkyl, C3-6 alkenyl, etc.; R3, R4 = H, C1-5 alkyl, C1-3 alkoxy-C1-5 alkyl; A = ketimino, aldimino; X = O, NH, NR9 (wherein R9 = H, C1-5 alkyl)] and their possible isomers and mixts. of isomers, having plant-protecting properties and are suitable for the protection of plants against infestation by phytopathogenic microorganisms, were prepared Thus, treatment of 3-(3-chlorobenzyloxy)acetophenone oxime with NaH in DMF followed by the addition of 4-chloro-3-methoxypent-2-enecarboxylic acid Me ester in DMF and KI afforded the title compound [E]-II. Compds. I showed a good action against, e.g., Phytophthora infestans on tomatoes.

IT 206653-21-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkenecarboxylic acid derivs. as pesticides)

RN 206653-21-6 CAPLUS

CN Ethanone, 1-[2-(4-phenoxyphenyl)-4-thiazolyl]-, oxime (CA INDEX NAME)



L31 ANSWER 54 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:265450 CAPLUS Full-text

DN 126:277465

TI Preparation and formulation of guanidinothiazole derivatives as Maillard reaction inhibitors and antioxidants

IN Matsui, Toshiaki; Tatsumi, Tadashi; Oonada, Shuichi

PA Ono Pharmaceutical Co, Japan

SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09059258	A	19970304	JP 1995-225989	19950811
PRAI JP 1995-225989		19950811		

OS MARPAT 126:277465
GI For diagram(s), see printed CA Issue.
AB The title compds. I [Z = S, etc.; R1 = H, alkyl, etc.; A = bond, alkylene, etc.; ring D is benzoquinone with substituents (generic structure given), etc.] are prepared. The title compound II.HCl in vitro showed IC50 of 0.82 μM against lipid peroxidn.
IT [illegible]
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of guanidinothiazole derivs. as Maillard reaction inhibitors and antioxidants)
RN 188611-67-8 CAPLUS
CN Guanidine, [4-(4-phenoxyphenyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L31 ANSWER 55 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:209653 CAPLUS Full-text
DN 124:261036
TI Preparation of 5-imino-2-imidazolines as agrochemical fungicides
IN Hutt, Jean; Lacroix, Guy; Perez, Joseph; Veyrat, Christine
PA Rhone Poulenc Agrochimie, Fr.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9534541	A1	19951221	WO 1995-FR748	19950608
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2721022	A1	19951215	FR 1994-7344	19940610
FR 2721022	B1	19960719		
AU 9527425	A	19960105	AU 1995-27425	19950608

ZA 9504784	A	19960208	ZA 1995-4784	19950609
PRAI FR 1994-7344	A	19940610		
WO 1995-FR748	W	19950608		

OS CASREACT 124:261036; MARPAT 124:261036
GI



AB Title compds. [I; R1,R2 = H, (halo)alkyl, (hetero)aryl, etc.; R3 = (un)substituted alkyl; R4 = (hetero)aryl, (un)substituted alkyl; R5 = H, alkyl, acyl, etc.; R6 = H, OH, alkoxy, NH2, etc.; Z = O or S] were prepared. Thus, MeCHR2NCS [R2 = 4-(PhCH2CH2)C6H4] (preparation given) was cyclocondensed with CS2 and the product cyclocondensed with PhNHNH2 to give imidazolidinedithione II [R2 = 4-(PhCH2CH2)C6H4]. II (R2 = Ph) was iminated with NH3 and the product S-alkylated by MeI to give title compound III which gave 75-100% control of Puccinia recondita on wheat at 1g/L.
IT 175073-65-4P 175073-70-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-imino-2-imidazolines as agrochem. fungicides)
RN 175073-68-4 CAPLUS
CN 2,5-Thiazolidinedithione, 4-methyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 175073-70-8 CAPLUS
CN 2,5-Thiazolidinedithione, 4-[4-(4-fluorophenoxy)phenyl]-4-methyl- (CA INDEX NAME)



L31 ANSWER 56 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:134490 CAPLUS Full-text
DN 120:134490

TI Bone resorption-inhibiting condensed thiadiazoles
IN Sohda, Takashi; Terashita, Zen-ichi; Momose, Yu; Fujisawa, Yukio; Mizoguchi, Junji
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 562599	A1	19930929	EP 1993-104939	19930325
EP 562599	B1	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5550138	A	19960827	US 1993-39579	19930323
CA 2092390	A1	19930926	CA 1993-2092390	19930324
JP 06298771	A	19941025	JP 1993-65507	19930324
JP 3232350	B2	20011126		
AT 223419	T	20020915	AT 1993-104939	19930325
PRAI JP 1992-67615	A	19920325		
JP 1993-30872	A	19930219		

OS MARPAT 120:134490
GI For diagram(s), see printed CA Issue.
AB The title compds. I [A = substituted pyridine ring, (un)substituted thiazole ring; R = (un)substituted heterocyclic group, (un)substituted hydrocarbon group], which exhibit excellent endothelin receptor antagonist activity, potent cathepsin B-inhibiting action, and potent bone resorption inhibitory action, are prepared and I-containing formulations presented. Thus, thiazolothiadiazole II (m.p. 165-166°) was prepared in 60% yield and demonstrated 50% inhibitory concentration against cathepsin B of 1.1 × 10-6 M.
IT 152363-34-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of condensed thiadiazole bone resorption inhibitors)
RN 152363-34-3 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[([5-methyl-4-(4-phenoxyphenyl)-2-thiazolyl]amino]thioxomethyl]- (CA INDEX NAME)



L31 ANSWER 57 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:191769 CAPLUS Full-text
DN 118:191769
TI Preparation of 1-thiazolylaminocarbonyl-4-arylpiperazines and analogs as bronchodilators
IN De Cillis, Gianpiero; Long, Giorgio; D'Alo, Simonetta; Rozzi, Antonella; Gallico, Licia
PA Boehringer Mannheim Italia S.p.A., Italy
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 519449	A1	19921223	EP 1992-110267	19920617
R: PT				
WO 9300342	A1	19930107	WO 1992-EP1377	19920617
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9220000	A	19930125	AU 1992-20000	19920617
EP 589985	A1	19940406	EP 1992-912406	19920617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 07502014	T	19950302	JP 1992-501313	19920617
ZA 9204478	A	19930331	ZA 1992-4478	19920618
PRAI IT 1991-MI1714	A	19910621		
IT 1992-MI786	A	19920401		
WO 1992-EP1377	A	19920617		

OS MARPAT 118:191769
GI



AB Title compds. [I; R1 = (substituted) Ph, pyridyl, etc.; X = O, S; Z = CH2, O, S, NR; R = alkyl, Ph, heterocyclyl, etc.] were prepared. Thus, 2,3-(AcO)2C6H3COCH2Br (preparation given) was cyclocondensed with H2NCSNH2 and the product condensed carbonyldiimidazole and N-[3,6-bis(diethylamino)-2-pyridyl]piperazine to give title compound II. I gave 4-6 h protection against PAF-induced hyperactivity in guinea-pigs at 2-50 μg/kg (route of administration not given).
IT 146871-56-9P 146871-64-9P 146871-65-0P
146894-70-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as bronchodilator)
RN 146871-56-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3,6-bis(diethylamino)-2-pyridinyl]-N-[4-[4-[(methylsulfonyl)amino]-3-phenoxyphenyl]-2-thiazolyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 146871-64-9 CAPLUS
CN 1-Piperazinecarbothioamide, N-[4-[4-[(methylsulfonyl)amino]-3-phenoxyphenyl]-2-thiazolyl]-4-(phenylmethyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 146871-65-0 CAPLUS
CN 1-Piperazinecarbothioamide, 4-methyl-N-[4-[4-[(methylsulfonyl)amino]-3-phenoxyphenyl]-2-thiazolyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 146884-70-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-[4-[(methylsulfonyl)amino]-3-phenoxyphenyl]-2-thiazolyl]-4-(phenylmethyl)- (CA INDEX NAME)



L31 ANSWER 58 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:124134 CAPLUS Full-text
DN 118:124134
TI Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2'-phenoxymethanesulfonanilide derivatives
AU Tsuji, Kiyoshi; Nakamura, Katsuya; Konishi, Nobukiyo; Okumura, Hiroyuki; Matsuo, Masaaki
CS New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan
SO Chemical & Pharmaceutical Bulletin (1992), 40(9), 2399-409
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
GI



AB Various 2'-phenoxymethanesulfonanilide derivs. I (R1 = H, NO2, CF3, CONH2, SEt, cyano, etc., R2 = H, COMe, Me) and II (R3-R5 = H, 2-F, 2,3-Cl2, 2-Br, 2-OMe, 2-SMe, etc.) were synthesized and evaluated for antiinflammatory and analgesic activities. Thus, 3-(2,4-difluorophenoxy)-4- nitrobenzonitrile reacted with Fe/NH4Cl/EtOH and MeSO2Cl/pyridine to give I (R1 = cyano, R2 = H). Some compds. bearing an electron-attracting substituent at the 4'-position strongly inhibited adjuvant-induced arthritis in rats and acetic acid-induced writhing syndrome in mice without causing gastro-intestinal irritation. Among them, 4'-cyano-(FK867) and 4'-acetyl-(FK3311) 2'-(2,4-difluorophenoxy)methanesulfonanilides were selected as the candidates for further development.
IT 116686-60-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, analgesic, and antiinflammatory activity of)
RN 116686-60-3 CAPLUS
CN Acetamide, N-[4-[3-(2,4-difluorophenoxy)-4-[(methylsulfonyl)amino]phenyl]-2-thiazolyl]- (CA INDEX NAME)



IT 116686-59-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, N-acetylation, analgesic, and antiinflammatory activity of)
RN 116686-59-0 CAPLUS
CN Methanesulfonamide, N-[4-(2-amino-4-thiazolyl)-2-(2,4-difluorophenoxy)phenyl]- (CA INDEX NAME)



L31 ANSWER 59 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:38917 CAPLUS Full-text
DN 118:38917
TI Preparation of 2-sulfonamido-4,5-diphenylthiazole derivatives
IN Yoshikawa, Yoshinari; Saito, Hideji; Oochi, Yutaka; Ochi, Yutaka
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04173782	A	19920622	JP 1990-302853	19901108
PRAI JP 1990-302853		19901108		

OS MARPAT 118:38917
GI



AB The title compds. [I; R1 = haloalkyl; R2-R5 = H, halo, (halo)alkyl, alkoxy, alkylthio, alkylsulfonyl, NO2, Ph, PhO] and their pharmaceutically compatible salts, useful as antiinflammatory agents, are prepared A mixture of p-ClC6H4COCH2Ph 4.61, thiourea 3.04, and iodine 5.08 g was heated with stirring at 110-120°, 10% NH4OH was added, and the mixture was extracted with CH2Cl2 to give 3.12 g aminothiazole derivative II (R = H), which (2.0 g) was stirred with 2.26 g CF3SO3H and Et3N in CH2Cl2 under cooling to give 1.12 g

sulfonamide II (R = CF3SO2) (III). III showed 56.1% inhibition of carrageenan-induced inflammation at 50 mg/kg orally in rats, vs. 36.9% with ibuprofen.
IT 144984-48-5P 144984-60-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)
RN 144984-48-5 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-(4-phenoxyphenyl)-5-phenyl-2-thiazolyl]- (CA INDEX NAME)



RN 144984-60-1 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[5-(4-nitrophenyl)-4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 60 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:38915 CAPLUS Full-text
DN 118:38915
TI Preparation of 2-arylthiazole derivatives as pharmaceutical compositions
IN Kondo, Shiro; Fukushima, Hisashi; Hasegawa, Masaichi; Tsuchimoto, Masahiro; Nagata, Ikuo; Osada, Yoshio; Komoriya, Keiji; Yamaguchi, Hisao
PA Teijin Ltd., Japan
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9209279	A1	19920611	WO 1991-JP1670	19911129
W: AU, CA, HU, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, NL, SE				
CA 2073981	A1	19920531	CA 1991-2073981	19911129
CA 2073981	C	20020108		
AU 9189522	A	19920625	AU 1991-89522	19911129
AU 645867	B2	19940127		

	EP 513379	A1	19921119	EP 1991-920699	19911129
	EP 513379	B1	19960911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	HU 63838	A2	19931028	HU 1992-2265	19911129
	HU 218942	B	20010129		
	AT 142494	T	19960915	AT 1991-920699	19911129
	ES 2092580	T3	19961201	ES 1991-920699	19911129
	JP 2725886	B2	19980311	JP 1991-500083	19911129
	SG 86971	A1	20020319	SG 1996-3299	19911129
	US 5614520	A	19970325	US 1995-380214	19950130
PRAI	JP 1990-330147	A	19901130		
	JP 1991-216586	A	19910802		
	WO 1991-JP1670	A	19911129		
	US 1992-917037	B1	19920730		

OS MARPAT 118:38915

GI



AB The title compds. [I; Ar = (un)substituted pyridyl, thienyl, furyl, naphthyl, (un)substituted Ph; X = H, alkyl, CO2H, alkoxycarbonyl, CONH2, alkylaminocarbonyl; Y = H, alkyl, OH, alkoxy, CO2H, alkoxycarbonyl, CONH2, mono- or dialkylaminocarbonyl], useful for treatment of gout, hyperuricemia and interleukin 1 production-related diseases, are prepared. Thus, 390 mg 3-isopropoxythiobenzamide and 360 mg ClCH2COCH2CO2Et were refluxed in EtOH for 5 h to give an ester as an oil which was saponified in 1N aqueous NaOH in EtOH to give 65% I [Ar = 3-iso-PrOC6H4, X = CO2H, Y = Me]. I [Ar = 3,4-cyano(iso-BuO)C6H3, X = CO2H, Y = Me] at 1 mg/kg p.o. lowered 95% serum uric acid in mice. I also inhibited xanthine oxidase, production of interleukin 1, and collagen-induced inflammation. Tablets containing I [Ar = 3,4-O2N(iso-PrO)C6H3, X = CO2H, Y = Me] were prepared

IT 144061-00-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for arylthiazole derivative drug)

RN 144061-00-7 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-(4-fluorophenoxy)phenyl]-4-methyl- (CA INDEX NAME)



L31 ANSWER 61 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:59362 CAPLUS Full-text

DN 116:59362

TI Preparation of 2-aryl-5-alkyl-4-thiazolidinones as cyclooxygenase and 5-lipoxygenase inhibitors

IN Walsh, David A.; Uwaydah, Ibrahim M.

PA A. H. Robins Co., Inc., USA

SO U.S., 30 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5061720	A	19911029	US 1989-406579	19890913
PRAI	US 1989-406579		19890913		

OS MARPAT 116:59362

GI



AB Title compds. I [R = H, C1-8 alkyl; R1 = C1-8 alkyl, A; X = (CH2)nA, O(CH2)nA, CO(CH2)nA, CHOH(CH2)nA, etc.; n = 0-3; A = (substituted) Ph, pyridyl; W = O; r = 0-2; Q = (Y1)m(O)m(B)m(O)m(Y2)m(CO2)m; B = pyridylene, (substituted) phenylene; Y1, Y2 = (alkyl) alkylene; Z = OR3, NR4R5; R3 = H, C1-8 alkyl, cation; R4, R5 = H, C1-8 alkyl; m = 0, 1; H takes the place of CO2 when m = 0] were prepared as cyclooxygenase and 5-lipoxygenase inhibitors useful as topical antiinflammatory agents. Thus, 3-phenoxybenzaldehyde, MeCH(SH)CO2H, and Ph(CH2)4NH2 were refluxed overnight in benzene using a Dean-Stark trap to give title compound II as a 2:3 mixture of cis:trans isomers. The isomeric mixture had IC50 of 1.4 μM and <20 μM against cyclooxygenase and 5-lipoxygenase, resp. The mixture was active against UV-induced erythema in guinea pigs. Topical formulations of I were prepared

IT 138619-65-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cyclooxygenase and lipoxygenase inhibitor)

RN 138619-65-5 CAPLUS

CN 4-Thiazolidinone, 5-butyl-2-(3-phenoxyphenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L31 ANSWER 62 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:680002 CAPLUS Full-text

DN 115:280002

TI Preparation of oxazolecarboxamides or thiazolecarboxamides as herbicides

IN Ditrich, Klaus; Maywald, Volker; Hamprecht, Gerhard; Harreus, Albrecht; Wuerzer, Bruno; Westphalen, Karl Otto

PA BASF A.-G., Germany

SO Eur. Pat. Appl., 98 pp.
CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 419944	A2	19910403	EP 1990-117567	19900912
	EP 419944	A3	19910717		
	EP 419944	B1	19950315		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	DE 3932052	A1	19910404	DE 1989-3932052	19890926
	CA 2026131	A1	19910327	CA 1990-2026131	19900925
	HU 56084	A2	19910729	HU 1990-6212	19900925
	HU 207058	B	19930301		
	BR 9004803	A	19910910	BR 1990-4803	19900925
	JP 03145478	A	19910620	JP 1990-254369	19900926
	US 5244867	A	19930914	US 1991-830326	19911226
	US 5256633	A	19931026	US 1992-870386	19920417
	US 5284821	A	19940208	US 1992-919457	19920727
PRAI	DE 1989-3932052	A	19890926		
	US 1990-587853	B1	19900925		
	US 1991-830326	A3	19911226		

OS CASREACT 115:280002; MARPAT 115:280002

AB Certain oxazolecarboxamides and thiazolecarboxamides and herbicides containing them are claimed. A mixture of N-tert-butyl-2-methoxy-4-thiazolecarboxamide (8.00 g) and 150 mL THF was treated with 1.5M BuLi (65 mL) and carboxylated (solid CO2) to give 85% 4-(tert-butylaminocarbonyl)-2-methoxy- 5-thiazolecarboxylic acid. The latter had herbicidal activity against Cassia tora, Chenopodium album, Chrysanthemum coronarium, and others and was compatible with wheat.

IT 135297-67-5P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)

RN 135297-67-5 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[(1,1-dimethylethyl)amino]carbonyl]-2-(4-phenoxyphenyl)- (CA INDEX NAME)



L31 ANSWER 63 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:559127 CAPLUS Full-text

DN 115:159127

TI Preparation of 2-substituted phenyl-2-oxazoline or thiazoline derivatives as acaricides and insecticides

IN Miyamoto, Satoshi; Suzuki, Junji; Kikuchi, Yasuo; Toda, Kazuya; Itoh, Yoshiaki; Ikeda, Tatsufumi; Ishida, Tatsuya; Hariya, Yasuaki; Tsukidate, Yokichi; Morikawa, Chiharu

PA Yashima Chemical Industrial Co., Ltd., Japan

SO Eur. Pat. Appl., 139 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 432661	A2	19910619	EP 1990-123555	19901207
	EP 432661	A3	19920304		
	EP 432661	B1	19960306		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 03232867	A	19911016	JP 1990-329851	19901130
	JP 07062006	B	19950705		
	AU 9067820	A	19910613	AU 1990-67820	19901206
	AU 634608	B2	19930225		
	CA 2031766	A1	19910610	CA 1990-2031766	19901207
	CA 2031766	C	20010109		
	BR 9006233	A	19910924	BR 1990-6233	19901207
	HU 57751	A2	19911230	HU 1990-8127	19901207
	HU 206691	B	19921228		
	RU 2029766	C1	19950227	RU 1990-4894033	19901207
	AT 135001	T	19960315	AT 1990-123555	19901207
	ES 2085317	T3	19960601	ES 1990-123555	19901207
	CN 1054422	A	19910911	CN 1990-110420	19901208
	CN 1040939	B	19981202		
	KR 156577	B1	19981116	KR 1990-20177	19901208
	US 5141948	A	19920825	US 1990-625918	19901210
PRAI	JP 1989-320420	A	19891209		

OS CASREACT 115:159127; MARPAT 115:159127

GI



AB Title compds. I [R1,R2 = H, halo, alkyl, alkoxy, O2N, haloalkyl, haloalkoxy, R1 = R2 ≠ H; R3 = H, halo, alkyl, alkoxy; R4 = alkyl or alkoxy having 7 or more C, alkylthio, alkoxyalkyl, alkoxyalkoxy, alkenyloxy having 3 or more C, alkynyloxy, trialkylsilyl, (substituted) cycloalkyl; A = bond, alkylene; Z = O, S] were prepared To a mixture of 2-amino-2-(4-n-decyloxyphenyl)ethanol, Et3N and THF, 2,6-F2C6H3COCl in THF was added over 30 min to give after work-up 2-(2,6-difluorophenyl)-4-(4-n- decyloxyphenyl)-2-oxazoline (II). In an ovicidal test, II at 100 ppm showed 100% control against two-spotted spider mite and Kanzawa spider mite. Addition 393 compds. were prepared I were also tested against nymphs of Myzus persicae, nymphs of cotton aphid, nymphs of

Nephotettix cincticeps, larvae of diamondback moth, and larvae of Culex pipiens.

IT 136406-64-9P 136406-67-2P 136406-73-0P
136406-96-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as acaricide and insecticide)

RN 136406-64-9 CAPLUS
CN Thiazole, 2-(2,6-difluorophenyl)-4,5-dihydro-4-[4-(4-methylphenoxy)phenyl]- (CA INDEX NAME)



RN 136406-67-2 CAPLUS
CN Thiazole, 2-(2,6-diethylphenyl)-4,5-dihydro-4-[3-methyl-4-(4-methylphenoxy)phenyl]- (CA INDEX NAME)



RN 136406-73-0 CAPLUS
CN Thiazole, 2-(2-chloro-6-fluorophenyl)-4-[4-[4-(1,1-dimethylethyl)phenoxy]phenyl]-4,5-dihydro- (CA INDEX NAME)



RN 136406-96-7 CAPLUS
CN Thiazole, 4-[4-(4-bromophenoxy)phenyl]-2-(2-chloro-6-fluorophenyl)-4,5-dihydro- (CA INDEX NAME)



L31 ANSWER 64 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:42777 CAPLUS Full-text
DN 114:42777
TI Preparation of thiazolinones and thiazolinethiones as antifungals
IN Kojima, Shigeru; Tanaka, Katsunori; Nakada, Akira; Hashimoto, Akira
PA Nippon Soda Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02145577	A	19900605	JP 1988-298961	19881126
PRAI	JP 1988-298961		19881126		

OS MARPAT 114:42777
GI



AB The title compds. [I; R1 = (substituted) aryl, etc.; R2 = alkyl, alkenyl, (substituted) aryl, etc.; R3 = H, halo, alkyl, etc.; Z = O, S] were prepared Refluxing QCOCH2Br [Q = 2,4-Cl2C6H3] with EtNHC(S)OEt in xylene 2 h gave I [R1 = Q, R2 = H, R3 = Et, Z = O], which at 200 ppm killed 98% Botryis cinerea without damage to kidney beans.

IT 121477-98-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antifungal)

RN 131477-98-0 CAPLUS
CN 2(3H)-Thiazolone, 3-ethyl-4-[4-[4-(trifluoromethyl)phenoxy]phenyl]- (CA INDEX NAME)



L31 ANSWER 65 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:532169 CAPLUS Full-text
DN 113:132169
TI Preparation of heterocyclylcarbazates as advanced glycosidation end product formation inhibitors
IN Sohda, Takashi; Ikeda, Hitoshi; Momose, Yu
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 359112	A2	19900321	EP 1989-116469	19890906
	EP 359112	A3	19900829		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 02167264	A	19900627	JP 1989-173369	19890704
	JP 2817219	B2	19981030		
	US 5240950	A	19930831	US 1989-403288	19890907
PRAI	JP 1988-225198	A	19880908		
	JP 1989-173369	A	19890704		

OS MARPAT 113:132169

AB R1N:CHNHNHCO2R2 [I; R1 = heterocyclyl; R2 = alkyl, (substituted) aryl, phenylalkyl] and their pharmaceutically acceptable salts, which inhibit the formation of advanced glycosylation end products (AGE) and are therefore useful for treatment of diseases caused by AGE, are prepared 4-(4-Cyclohexylphenyl)-2-[(ethoxymethylene)amino]thiazole (preparation given) was condensed with H2NNHCO2Et in EtOH to give I [R1 = 4-(4- cyclohexylphenyl-2-thiazolyl, R2 = Et] (II). In an in vitro experiment according to the procedure of M. Brownlee et al. (1986), II decreased by 34% the glycosidation of bovine serum albumin by D-glucose.

IT 129577-23-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as advanced glycosylation end product formation inhibitor)

RN 129577-23-7 CAPLUS
CN Hydrazinecarboxylic acid, [[[4-[4-(4-chlorophenoxy)phenyl]-2-thiazolyl]amino]methylene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L31 ANSWER 66 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:178337 CAPLUS Full-text
DN 112:178337
TI Preparation of alkanesulfonanilide derivatives as analgesics and inflammation inhibitors
IN Matsuo, Masaaki; Tsuji, Kiyoshi; Konishi, Nobukiyo
PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO U.S., 28 pp. Cont.-in-part of U.S. Ser. No. 132,334.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4866091	A	19890912	US 1988-202017	19880602
	ZA 8709706	A	19880831	ZA 1987-9706	19871228
	SU 1799378	A3	19930228	SU 1987-4203921	19871230
	ZA 8803534	A	19890125	ZA 1988-3534	19880518
PRAI	GB 1986-31083	A	19861231		
	GB 1987-12647	A	19870529		
	GB 1987-24903	A	19871023		
	US 1987-132334	A2	19871214		

OS MARPAT 112:178337
GI



AB Title compds. I [R1, R2, R8 = H, cyano, halo, alkyl, haloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxy; R3 = alkyl; R4 = acyl, cyano, HO2C, hydroxyalkyl, HS, alkylthio, alkylsulfinyl, alkylsulfonyl, Q, R7N:CR6, alkanoylalkenyl, (un)substituted 5-membered unsat. heterocyclyl, PhS; R6 = H, H2N, alkyl; R7 = OH, alkoxy, carboxyalkoxy, alkoxycarbonylalkoxy, H2NCONH, H2NCSNH; R5 = H, halo, alkyl, alkanoyl] and pharmaceutically acceptable salts thereof were prepared. I are also useful for treating pyretic diseases, rheumatism, and arthritis. 4'-Amino-3'-(2,4- difluorophenoxy)acetophenone (preparation given) and MeSO2Cl in pyridine were stirred overnight at room temperature to give I (R1 = R5 = H; R2 = 2-F; R3 = Me; R4 = 4-Ac; R8 = 4-F). Similarly prepared was I (R1 = R5 = H; R2 = 2-F; R3 = Me; R4 = 4-cyano; R8 = 4-F) (II). The analgesic activity was demonstrated with II showing an oral ED50 at 2.4 mg/kg in the HOAc-induced writhing test in mice (cf. 1.6 mg/kg for indomethacin).

IT 116686-59-0P 116686-60-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as analgesic and antiinflammatory)

RN 116686-59-0 CAPLUS
CN Methanesulfonamide, N-[4-(2-amino-4-thiazolyl)-2-(2,4-difluorophenoxy)phenyl]- (CA INDEX NAME)



RN 116686-60-3 CAPLUS
CN Acetamide, N-[4-[3-(2,4-difluorophenoxy)-4-[(methylsulfonyl)amino]phenyl]-2-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 67 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:192810 CAPLUS Full-text
DN 110:192810
TI Preparation of thiazoline derivatives as acaricides and insecticides
IN Nagasaki, Fumihiko; Yamada, Tomio; Takahashi, Eiko; Kitagawa, Yukio; Hatano, Renpei
PA Nippon Soda Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63250371	A	19881018	JP 1987-82455	19870403
JP 07116168	B	19951213		
PRAI JP 1987-82455		19870403		

OS MARPAT 110:192810
GI



AB Title compds. I [R1, R2 = (Ph-substituted) alkyl, cycloalkyl, Q wherein R5 = alkyl, alkylamino, R6 = H, alkyl, alkylamino, R7 = (halo- or haloalkyl-substituted) Ph or pyridyl; X = O, S; at least one of R1 and R2 = Q; R3, R4 = H, halo, (halo-substituted) alkyl or Ph] are prepared by cyclocondensation of R1NHC(:S)NHR2 with R3CHX1CR4R8R9 (X1 = halo; R8, R9 = alkoxy or R1R2 = O). A solution of ClCH2COMe and 2,6,4- Me2(PhO)C6H2NHC(:S)NHCMe3 in EtCOMe was refluxed to give I [R1 = Me3C; R2 = 2,6,4-Me2(PhO)C6H2; R3 = H; R4 = Me], which at 125 ppm showed 100% control of imagoes of Tetranycus urticae, vs. 0% for a known I [R1 = p-(p-ClC6H4O)C6H4; R2 = R4 = Me; R3 = H]. An emulsion was

formulated containing I 10, alkyl phenyl polyoxyethylene 5, DMF 50, and xylene 35 parts.
IT 120258-84-6P 120259-01-0P 120259-02-1P
120259-05-4P 120259-06-5P 120259-07-6P
120259-08-7P 120259-09-8P 120259-10-1P
120259-11-2P 120259-12-3P 120259-13-4P
120259-14-5P 120259-15-6P 120259-16-7P
120259-17-8P 120259-18-9P 120259-19-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide and acaricide)
RN 120258-84-6 CAPLUS
CN Benzenamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4-methyl-2(3H)-thiazolylidene]-2,6-bis(1-methylethyl)-4-phenoxy- (CA INDEX NAME)



RN 120259-01-0 CAPLUS
CN 2-Propanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-02-1 CAPLUS
CN Benzenemethanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-2(3H)-thiazolylidene]-α,α-dimethyl- (CA INDEX NAME)



RN 120259-05-4 CAPLUS
CN 2-Propanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4-methyl-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-06-5 CAPLUS
CN Benzenemethanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4-methyl-2(3H)-thiazolylidene]-α,α-dimethyl- (CA INDEX NAME)



RN 120259-07-6 CAPLUS
CN Benzenamine, 2-[2-[(1,1-dimethylethyl)imino]-4-methyl-3(2H)-thiazolyl]-N,N-dimethyl-5-phenoxy- (CA INDEX NAME)



RN 120259-08-7 CAPLUS
CN 2-Propanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4-(chloromethyl)-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-09-8 CAPLUS
CN 2-Propanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4-phenyl-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-10-1 CAPLUS
CN 2-Propanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4,5-dimethyl-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-11-2 CAPLUS
CN Cyclohexanamine, N-[3-[2,6-bis(1-methylethyl)-4-phenoxyphenyl]-4-methyl-2(3H)-thiazolylidene]- (CA INDEX NAME)



RN 120259-12-3 CAPLUS
CN 2-Propanamine, N-[3-(2,6-dimethyl-4-phenoxyphenyl)-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-13-4 CAPLUS
CN 2-Propanamine, N-[3-(2,6-dimethyl-4-phenoxyphenyl)-4-methyl-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-14-5 CAPLUS
CN 2-Propanamine, 2-methyl-N-[3-[2-methyl-6-(1-methylethyl)-4-phenoxyphenyl]-2(3H)-thiazolylidene]- (CA INDEX NAME)



RN 120259-15-6 CAPLUS
CN 2-Propanamine, 2-methyl-N-[4-methyl-3-[2-methyl-6-(1-methylethyl)-4-phenoxyphenyl]-2(3H)-thiazolylidene]- (CA INDEX NAME)



RN 120259-16-7 CAPLUS
CN 2-Propanamine, N-[3-[2-ethyl-6-(1-methylethyl)-4-phenoxyphenyl]-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-17-8 CAPLUS
CN 2-Propanamine, N-[3-[2-ethyl-6-(1-methylethyl)-4-phenoxyphenyl]-4-methyl-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-18-9 CAPLUS
CN 2-Propanamine, N-[3-[4-(4-chlorophenoxy)-2,6-dimethylphenyl]-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



RN 120259-19-0 CAPLUS
CN 2-Propanamine, N-[3-[4-(4-chlorophenoxy)-2,6-dimethylphenyl]-4-methyl-2(3H)-thiazolylidene]-2-methyl- (CA INDEX NAME)



L31 ANSWER 68 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:76170 CAPLUS Full-text
DN 110:76170
TI Synthesis and characterization of phenyl-pendant aromatic polythiazoles from bis-α-bromophenylacetyl compounds and dithioamides
AU Inoue, Kazuto; Ueda, Mitsuru; Imai, Yoshio
CS Dep. Ind. Chem., Fukushima Tech. Coll., Iwaki, 970, Japan
SO Journal of Polymer Science, Part A: Polymer Chemistry (1988), 26(11), 2899-905
CODEN: JPACEC; ISSN: 0887-624X
DT Journal
LA English
AB Novel phenyl-pendant aromatic polythiazoles having inherent viscosities of 0.3-1.3 dL/g were synthesized by the solution polycondensation of bus[4-(α-bromophenylacetyl)phenyl] ether with aromatic dithioamides or dithiooxamide in DMF at 60°. The polythiazole having m-phenylene linkage was readily soluble in CHCl3 and m-cresol, and a transparent flexible film could be cast from the CHCl3 solution Glass transition temps. of these polythiazoles were in the range of 210-250°. They started to decompose at about 500° in air with 10% weight loss being recorded at around 570°C.

IT 104570-37-8P 104570-38-9P 118771-86-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and characterization of heat-resistant)
RN 104570-37-8 CAPLUS
CN Poly[(5-phenyl-4,2-thiazolediyl)-1,3-phenylene(5-phenyl-2,4-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 104570-38-9 CAPLUS
CN Poly[(5-phenyl-4,2-thiazolediyl)-1,4-phenylene(5-phenyl-2,4-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 118771-86-1 CAPLUS
CN Poly[(5,5'-diphenyl[2,2'-bithiazole]-4,4'-diyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



IT 119034-28-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as model compound for aromatic polythiazoles containing pendant Ph groups)
RN 119034-28-5 CAPLUS
CN Thiazole, 4,4'-(oxydi-4,1-phenylene)bis[2,5-diphenyl- (9CI) (CA INDEX NAME)



L31 ANSWER 69 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:549069 CAPLUS Full-text
DN 109:149069
TI Phenoxy-substituted alkanesulfonanilide derivatives useful as analgesics, antiinflammatories, and antipyretics, and processess for their preparation
IN Matsuo, Masaaki; Tsuji, Kiyoshi; Konishi, Nobukiyo
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 273369	A2	19880706	EP 1987-119063	19871222
	EP 273369	A3	19891018		
	EP 273369	B1	19920304		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 73131	T	19920315	AT 1987-119063	19871222
	ES 2033292	T3	19930316	ES 1987-119063	19871222
	FI 8705719	A	19880701	FI 1987-5719	19871228
	JP 63190869	A	19880808	JP 1987-335647	19871228
	JP 05019543	B	19930317		
	ZA 8709706	A	19880831	ZA 1987-9706	19871228
	DK 8706935	A	19880701	DK 1987-6935	19871230
	NO 8705488	A	19880701	NO 1987-5488	19871230
	NO 168299	B	19911028		
	NO 168299	C	19920205		
	AU 8783152	A	19880707	AU 1987-83152	19871230
	AU 600782	B2	19900823		
	HU 45971	A2	19880928	HU 1987-6136	19871230
	HU 200322	B	19900528		
	SU 1799378	A3	19930228	SU 1987-4203921	19871230
	CN 87108295	A	19880713	CN 1987-108295	19871231
	ZA 8803534	A	19890125	ZA 1988-3534	19880518
PRAI	GB 1986-31083	A	19861231		
	GB 1987-12647	A	19870529		
	GB 1987-24903	A	19871023		
	EP 1987-119063	A	19871222		

OS MARPAT 109:149069
GI



AB Title derivs. I (R1, R2, R8 = H, cyano, halo, alkyl, haloalkyl, alkythio, -sulfinyl, -sulfonyl, alkoxy; R3 = alkyl, mono- or dialkylamino; R4 = acyl, cyano, CO2H, hydroxyalkyl, SH, alkylthio, -sulfinyl, -sulfonyl, 2-oxodioxolan-3-ylidenemethyl, CR6:NR7, (un)substituted 5-membered unsatd. heterocyclyl; SPh; R5 = H, halo, alkoxy, carboxyalkoxy, alkoxycarbonylalkoxy, ureido, thiouredo] are prepared for use as analgesics, antiinflammatories, and antipyretics. 4-Amino-3-(2,4- difluorophenoxy)acetophenone was prepared in 4 steps and sulfonylated by MeSO2Cl in pyridine to give acetyl(difluorophenoxy)methanesulfonanilide II. In the adjuvant arthritis test in rats, II at 1.0 mg/kg/day orally inhibited secondary (uninjected) paw lesion by 50%, vs. only 24.7% by ibuprofen at 10.0 mg/kg.
IT 116686-59-0P 116686-60-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as analgesic, antipyretic and antiinflammatory)
RN 116686-59-0 CAPLUS
CN Methanesulfonamide, N-[4-(2-amino-4-thiazolyl)-2-(2,4-difluorophenoxy)phenyl]- (CA INDEX NAME)



RN 116686-60-3 CAPLUS
CN Acetamide, N-[4-[3-(2,4-difluorophenoxy)-4-[(methylsulfonyl)amino]phenyl]-2-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 70 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:195821 CAPLUS Full-text

DN 108:195821
TI Bis(thiazolinethione) derivative nondiffusing photographic additives
IN Heilmann, Steven M.; Krepski, Larry R.; Rasmussen, Jerald K.; Katritzky, Alan R.; Tarr, Richard D.
PA Minnesota Mining and Manufacturing Co., USA
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 239369	A1	19870930	EP 1987-302545	19870324
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AU 8769818	A	19871001	AU 1987-69818	19870309
	AU 586914	B2	19890727		
	JP 62246558	A	19871027	JP 1987-67723	19870320
	US 4946962	A	19900807	US 1989-356000	19890523
PRAI	US 1986-843078	A	19860324		

GI



AB Bis(thiazolinethione) derivs. represented by the formula I or II [R1 = H, C1-4 alkyl, C5-12 aryl; R2 = H, C1-20 alkyl, C5-12 aryl; Z1 = (branched) C2-20 alkylene that can be interrupted by ≥1 non-adjacent O, S or NR3 (R3 = H, lower alkyl), C5-12 arylene, C5-12 arene group; Z2 = C-C bond, (branched) C1-20 alkylene that can be interrupted by ≥1 non-adjacent O or S, C5-12 arylene, C6-20 arene, C6H4Z3C6H4; Z3 = (branched) C1-4 alkylene, O, S, SO2, CO, CR24, NR4 (R4 = H, lower alkyl)] are synthesized and used as nondiffusing photog. additives, such as antifoggants for image background reduction, sensitizers to increase the photosensitivity of Ag halide emulsions, and toners to enhance the black tone of images provided by Ag halide emulsions.
IT 112544-54-4
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. material containing, as nondiffusing additive)
RN 112544-54-4 CAPLUS
CN 2(3H)-Thiazolethione, 4,4'-(oxydi-4,1-phenylene)bis[3-methyl- (9CI) (CA INDEX NAME)



L31 ANSWER 71 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:56712 CAPLUS Full-text
DN 108:56712
TI Synthesis and characterization of poly([3H]-thiazole-2-thione)s
AU Katritzky, Alan R.; Tarr, Richard D.; Heilmann, Steven M.; Rasmussen, Jerald K.; Krepski, Larry R.
CS Dep. Chem., Univ. Florida, Gainesville, FL, 32611, USA
SO Journal of Polymer Science, Part A: Polymer Chemistry (1987), 25(12), 3205-14
CODEN: JPACEC; ISSN: 0887-624X
DT Journal
LA English
AB The reaction of dithiocarbamate salts with α-haloketones was extended to (i) dithiocarbamate salts with bis(α-haloketones), (ii) bis(dithiocarbamate salts) with α-haloketones, and (iii) bis(dithiocarbamate salts) with bis(α-haloketones). Both (i) and (ii) gave bis([3H]-thiazole-2-thiones) in high yields, and (iii) gave the corresponding polymers which were described and characterized.
IT 109674-35-3P 109674-36-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and characterization of)
RN 109674-35-3 CAPLUS
CN Poly[(2-thioxo-4,3(2H)-thiazolediyl)-1,2-ethanediyl(2-thioxo-3,4(2H)-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 109674-36-4 CAPLUS
CN Poly[(2-thioxo-4,3(2H)-thiazolediyl)-1,6-hexanediyl(2-thioxo-3,4(2H)-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



IT 112544-54-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 112544-54-4 CAPLUS
CN 2(3H)-Thiazolethione, 4,4'-(oxydi-4,1-phenylene)bis[3-methyl- (9CI) (CA INDEX NAME)



L31 ANSWER 72 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:491901 CAPLUS Full-text
DN 107:91901
TI Fungicidal thiazolines
IN Naumann, Holger; Dehne, Heinz; Fieseler, Christine; Goetzschel, Kurt; Pallas, Manfred; Schoenfelder, Dietmar; Mueller, Wolfgang; Kochmann, Werner; Naumann, Kurt; Steinke, Walter
PA VEB Chemiekombinat Bitterfeld, Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 241844	A1	19870107	DD 1985-281998	19851023
PRAI DD 1985-281998		19851023		

GI



AB Thiazolines I [R = cyclohexyl, (un)substituted Ph; R1 = H, Cl] and I-HCl are fungicides. I (R = Ph, R1 = H) (0.1%) totally controlled P. infestans on tomato.
IT 109902-42-3
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(fungicide)
RN 109902-42-3 CAPLUS
CN 2(3H)-Thiazolimine, 3-[4-(2,4-dichlorophenoxy)phenyl]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L31 ANSWER 73 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:478488 CAPLUS Full-text
DN 107:78488
TI Thiazolinethione-containing polymer
IN Katritzky, Alan R.; Heilmann, Steven M.; Krepski, Larry R.; Rasmussen, Jerald K.; Tarr, Richard D.
PA Minnesota Mining and Manufacturing Co., USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4659801	A	19870421	US 1985-807351	19851210
CA 1256241	A1	19890620	CA 1986-523638	19861124
EP 225804	A1	19870616	EP 1986-309583	19861209
EP 225804	B1	19900131		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 62187730	A	19870817	JP 1986-293343	19861209
PRAI US 1985-807351	A	19851210		

GI

AB Polymers containing units I (R = H, alkyl, etc.), useful as non-migrating components in photosensitive materials, are prepared by copolymg. a bis(dithiocarbamate) salt with a bis(α-halo ketone) with cyclization to form the thiazolinethione rings. CS2 was added to H2N(CH2)6NH2 in aqueous KOH to prepare KS2CNH(CH2)6NHCS2K which was copolymd. with 4,4'-bis(bromoacetyl)biphenyl (prepared from biphenyl and BrCH2COBr), and the copolymer was cyclized in the presence of HCl to give a polymer containing units I (R = H).
IT 109674-35-3P 109674-36-4P
RL: PREP (Preparation)
(preparation of, for non-migrating photog. component)
RN 109674-35-3 CAPLUS
CN Poly[(2-thioxo-4,3(2H)-thiazolediyl)-1,2-ethanediyl(2-thioxo-3,4(2H)-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 109674-36-4 CAPLUS
CN Poly[(2-thioxo-4,3(2H)-thiazolediyl)-1,6-hexanediyl(2-thioxo-3,4(2H)-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



IT 109674-38-6P
RL: PREP (Preparation)
(preparation of, for non-migrating photog. components)
RN 109674-38-6 CAPLUS
CN Poly[(2-thioxo-4,3(2H)-thiazolediyl)-1,3-propanediyl(2-thioxo-3,4(2H)-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



L31 ANSWER 74 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:49724 CAPLUS Full-text
DN 106:49724
TI Studies on hypolipidemic agents. III. ω-(4-Phenoxybenzoyl)alkanoic acid derivatives
AU Tomisawa, Kazuyuki; Kameo, Kazuya; Matsunaga, Tohru; Saito, Shiuji; Hosoda, Kazuaki; Asami, Yumiko; Sota, Kaoru
CS Res. Cent., Taisho Pharm. Co., Ltd., Saitama, 330, Japan
SO Chemical & Pharmaceutical Bulletin (1986), 34(2), 701-12
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 106:49724
AB 2-(Acetylthio)-3-(4-substituted phenoxybenzoyl)propionic acids and ω-(4-phenoxybenzoyl)alkanoic acids were prepared, and tested for hypolipemic activity in rats. 2-(Acetylthio)-3-(4- phenoxybenzoyl)propionic acid derivs. had the most potent hypolipemic activities, and halogen substitution on the phenoxy group increased the activity. Thus, the Friedel-Crafts acylation of 4-FC6H4OPh with maleic anhydride gave 4-FC6H4OC6H4COCH:CHCO2H, which added AcSH to give 4-FC6H4OC6H4COCH2CH(SAc)CO2H (I). I had greater hypolipemic activity than clofibrate.
IT 105769-31-1P 105769-32-2P 105769-33-3P
105769-34-4P 105769-35-5P 105769-36-6P
105769-37-7P 105769-38-8P 105769-39-9P
105769-40-2P 105769-41-3P 106132-59-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipemic activity of)
RN 105769-31-1 CAPLUS
CN 5-Thiazoleacetic acid, 2-methyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 105769-32-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-methyl-4-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 105769-33-3 CAPLUS
CN 5-Thiazoleacetic acid, 4-[4-(4-chlorophenoxy)phenyl]-2-methyl- (CA INDEX NAME)



RN 105769-34-4 CAPLUS
CN 5-Thiazolepropanoic acid, 2-methyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 105769-35-5 CAPLUS
CN 5-Thiazolepropanoic acid, 4-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 105769-36-6 CAPLUS
CN 5-Thiazolepropanoic acid, 4-[4-(4-chlorophenoxy)phenyl]-2-methyl- (CA INDEX NAME)



RN 105769-37-7 CAPLUS
CN 5-Thiazolepropanoic acid, 4-[4-(4-chlorophenoxy)phenyl]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 105769-38-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 105769-39-9 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-[4-(4-chlorophenoxy)phenyl]-, ethyl ester (CA INDEX NAME)



RN 105769-40-2 CAPLUS
CN 5-Thiazolepropanoic acid, 2-amino-4-(4-phenoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 105769-41-3 CAPLUS
CN 5-Thiazolepropanoic acid, 2-amino-4-[4-(4-chlorophenoxy)phenyl]-, ethyl ester (CA INDEX NAME)



RN 106132-59-6 CAPLUS
CN 5-Thiazoleacetic acid, 4-[4-(4-chlorophenoxy)phenyl]-2-methyl-, ethyl ester (CA INDEX NAME)



L31 ANSWER 75 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:621003 CAPLUS Full-text
DN 105:221003
TI Thiazolylamide herbicides

IN Lange, Arno; Wuerzer, Bruno; Meyer, Norbert
PA BASF A.-G., Fed. Rep. Ger.
SO Ger. Offen., 25 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3503773	A1	19860807	DE 1985-3503773	19850205
	US 4769062	A	19880906	US 1986-820232	19860121
	CA 1269987	A1	19900605	CA 1986-500542	19860128
	BR 8600374	A	19861014	BR 1986-374	19860130
	EP 192998	A2	19860903	EP 1986-101342	19860203
	EP 192998	A3	19860910		
	EP 192998	B1	19900124		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	HU 42463	A2	19870728	HU 1986-481	19860204
PRAI	DE 1985-3503773	A	19850205		

OS CASREACT 105:221003; MARPAT 105:221003
GI



I

AB The title compds. I (R1 = H, alkyl; R2 = alkyl, alkenyl, alkynyl, cycloalkyl; R3 = H, alkyl, halo; X = halo, alkoxy, haloalkoxy, alkyl, haloalkyl, cycloalkyl, alkylthio, NO2, CN, substituted Ph of PhO; n = 1-4) are prepared as herbicides. Thus, 8.23 g 4-(4-difluoromethoxyphenyl)thiazol e-2-ylamine (preparation given) and 3.46 g EtCOCl was heated at 50° for 2 h to give 7 g I (X = 4-F2CHO; R1 = R3 = H; R2 = Et) (II). Postemergence II applied at 0.5 kg/ha, controlled weeds in soybean, wheat and other crops.
IT 105512-82-1P 105512-84-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amidation by, of carboxylic acids)
RN 105512-82-1 CAPLUS
CN 2-Thiazolamine, 4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 105512-84-3 CAPLUS
CN 2-Thiazolamine, 4-(3-chloro-4-phenoxyphenyl)- (CA INDEX NAME)



IT 105527-98-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 105527-98-8 CAPLUS
CN Propanamide, N-[4-[3-chloro-4-(4-chlorophenoxy)phenyl]-2-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 76 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:553741 CAPLUS Full-text
DN 105:153741
TI Polythiazoles
IN Imai, Yoshio; Inoue, Kazuto; Ueda, Mitsuru
PA Japan Synthetic Rubber Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61097330	A	19860515	JP 1984-216366	19841017
PRAI	JP 1984-216366		19841017		

GI



AB Soluble, heat-resistant polythiazoles are prepared from the haloketones {PhCH(X)CO-p-C6H4]2O and bisthioamides. Thus, heating 1.5 mmol each {PhCH(Br)CO-p-C6H4]2O and dithioisophthalamide in 10 mL DMF at 60° for 3 days give the polythiazole I with intrinsic viscosity 1.14 dL/g (MeSO3H, 30°) which was soluble in MeSO3H, CHCl3, and cresol. A cast film lost 10% weight at 570° in air.
IT 104570-37-8 104570-38-9
RL: USES (Uses)
(heat-resistant, manufacture of soluble)
RN 104570-37-8 CAPLUS
CN Poly[(5-phenyl-4,2-thiazolediyl)-1,3-phenylene(5-phenyl-2,4-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 104570-38-9 CAPLUS
CN Poly[(5-phenyl-4,2-thiazolediyl)-1,4-phenylene(5-phenyl-2,4-thiazolediyl)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



L31 ANSWER 77 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:515053 CAPLUS Full-text
DN 105:115053
TI 2-Aminothiazole derivatives having acid secretion inhibiting activity
IN Baglioni, Alessandro
PA Medosan Industrie Biochimiche Riunite S.p.A., Italy
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 177463	A2	19860409	EP 1985-830248	19851002
	EP 177463	A3	19870527		
	EP 177463	B1	19901212		
	R: AT, BE, CH, DE, FR, GB, LI, NL, SE				
	US 4652575	A	19870324	US 1985-775245	19850912
	AT 59039	T	19901215	AT 1985-830248	19851002
	JP 61091186	A	19860509	JP 1985-221727	19851004

	JP 02062554	B	19901226		
	US 4705873	A	19871110	US 1987-3258	19870114
PRAI	IT 1984-48956	A	19841005		
	EP 1985-830248	A	19851002		

OS MARPAT 105:115053
GI



AB 2-Aminothiazole derivs. I [R = alkyl, naphthyl, adamantyl, Ph2CHO, (un)substituted Ph], which inhibit gastric secretion by antagonizing histamine H2 receptors, were prepared For example, 2-[[[5- [(dimethylamino)methyl]-2-furanyl]methyl]thio]ethanamine underwent addition reaction with BzNCS, followed by debenzoylation and cyclocondensation with BrCH2COPh to give I (R = Ph).
IT 104059-06-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as ulcer inhibitor)
RN 104059-06-5 CAPLUS
CN 2-Thiazolamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-4-(4-phenoxyphenyl)- (CA INDEX NAME)



L31 ANSWER 78 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:68849 CAPLUS Full-text
DN 104:68849
TI Thiazolylureas and their use in combatting unwanted vegetation
IN Lange, Arno; Parge, Adolf; Wuerzer, Bruno
PA BASF A.-G., Fed. Rep. Ger.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3413755	A1	19851024	DE 1984-3413755	19840412
	EP 161442	A2	19851121	EP 1985-103772	19850328
	EP 161442	A3	19861105		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	BR 8501705	A	19851210	BR 1985-1705	19850411
	ZA 8502680	A	19851224	ZA 1985-2680	19850411

	HU 37769	A2	19860228	HU 1985-1347	19850411
	HU 194546	B	19880229		
PRAI	DE 1984-3413755	A	19840412		

OS CASREACT 104:68849; MARPAT 104:68849
GI



AB The thiazolylureas I (R = H, halo, alkyl, alkoxy, CN, etc.; R1 and R3 = H, alkyl; R2 = alkyl, alkoxy, alkenyl, etc.; n = 0, 1, 2, 3), useful as herbicides, were prepared by 3 methods. 4-MeOC6H4COMe (30 g) was cyclized with 33.5 g thiourea and 56 g iodine in 5 h at 100° to give 37.8 g 4-(4-methoxyphenyl)-2-aminothiazole which (6.2 g) reacted with 2.9 g MeNCO in PhMe containing 2 drops Bu2Sn(OAc)2 in 12 h at 50° to give 5.5 g I (Rn = 4-MeO, R1 = Me, R2 = R3 = H). I (Rn = 4-CF3, R1 = Me, R2 = OMe, R3 = H) (3 kg/ha), applied postemergence in greenhouse expts., controlled many broadleaf and grass weeds.
IT 100283-82-8P 100283-86-1P 100284-05-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 100283-83-8 CAPLUS
CN Urea, N-[4-[4-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl]-2-thiazolyl]-N'-methyl- (CA INDEX NAME)



RN 100283-86-1 CAPLUS
CN Urea, N'-[4-[4-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl]-2-thiazolyl]-N-methoxy-N-methyl- (CA INDEX NAME)



RN 100284-05-7 CAPLUS

CN Urea, N-methoxy-N-methyl-N'-[4-(4-phenoxyphenyl)-2-thiazolyl]- (CA INDEX NAME)



L31 ANSWER 79 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1984:483697 CAPLUS Full-text
DN 101:83697
TI Studies on the antiinflammatory activity and ulcerogenic adverse effect of thiazole derivatives, especially 2-amino-thiazoleacetic acid derivatives
AU Nagatomi, H.; Ando, K.
CS Gen. Res. Cent., Funai Pharm. Ind. Ltd., Hirakata, Japan
SO Arzneimittel-Forschung (1984), 34(5), 599-603
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English
GI



AB Fifty-four thiazole-5-acetic acid derivs. (I; R1 = Ph, chlorophenyl, benzyl, phenylamino, benzoylamino, or NH2; R2 = various aryl) and 34 2-aminothiazole derivs. (II; R2 = Ph, chlorophenyl, or ethylphenyl; R3 = carboxymethyl or α-methylcarboxymethyl; R4 = H, Me, or Et; R5 = Et, trifluoromethyl, or various aryl) were tested for antiinflammatory activity in the rat carrageenan edema test. The 2 most active compds. were 4-(4-chlorophenyl)-2-(phenylamino)thiazole-5-acetic acid (III) [49779-95-5] and 4-(4-chlorophenyl)-2-(diethylamino)thiazole-5-acetic acid (IV) [49780-02-1]. In further antiinflammatory tests, both III and IV inhibited the heat-induced denaturation of albumin and erythrocyte lysis and inhibited chymotrypsin and trypsin activities; both were more active than the refs. drugs. Both III and IV had low ulcerogenic activity in rats; III, especially, caused almost no gastric damage, even at high doses.
IT [illegible]
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inflammation inhibition by, ulcerogenic side effect in relation to)
RN 91233-81-7 CAPLUS

CN 5-Thiazoleacetic acid, 4-(4-phenoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 91233-88-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-(2-chlorophenyl)-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 91233-97-5 CAPLUS
CN 5-Thiazoleacetic acid, 4-(4-phenoxyphenyl)-2-(phenylmethyl)- (CA INDEX NAME)



RN 91234-20-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 91254-37-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-(benzoylamino)-4-(4-phenoxyphenyl)- (CA INDEX NAME)



L31 ANSWER 80 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:438404 CAPLUS Full-text
DN 99:38404
OREF 99:6033a,6036a
TI N-(4-Substituted-thiazolyl)oxamic acid derivatives, new series of potent, orally active antiallergy agents
AU Hargrave, Karl D.; Hess, Friedrich K.; Oliver, James T.
CS Res. Dev., Boehringer Ingelheim Ltd., Ridgefield, CT, 06877, USA
SO Journal of Medicinal Chemistry (1983), 26(8), 1158-63
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 99:38404
GI



AB A series of N-(4-substituted-thiazolyl)oxamic acid derivs. were prepared by treatment of the appropriate acetophenone with thiourea and iodine or by

reaction of the chloroacetylbenzene with thiourea to give the corresponding aminothiazoles; subsequent condensation with EtO2CCOCl gave the thiazolyloxamidates. Many of the analogs showed a 50% inhibition at <2 mg/kg orally or <0.4 mg/kg i.v. and were significantly more potent than disodium cromoglycate. Hydrolysis of the oxamates generally resulted in enhanced activities, while substitution of the Ph ring with a variety of substituents (e.g., 4-F, 4-OEt, and 4-NHAc) did not significantly enhance the activity of the unsubstituted Ph derivative The ethanolamine salt of I has been selected for further pharmacol. evaluation.
IT 85849-61-2P 85849-63-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiallergic activity of)
RN 85849-61-2 CAPLUS
CN Acetic acid, oxo[[4-(4-phenoxyphenyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 85849-63-4 CAPLUS
CN Acetic acid, oxo[[4-(4-phenoxyphenyl)-2-thiazolyl]amino]-, compd. with 2-aminoethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 85849-62-3
CMF C17 H12 N2 O4 S



CM 2

CRN 141-43-5
CMF C2 H7 N O

L31 ANSWER 81 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1983:160624 CAPLUS Full-text
DN 98:160624
OREF 98:24378h,24379a
TI Studies on antidiabetic agents. III. 5-Arylthiazolidine-2,4-diones as potent aldose reductase inhibitors
AU Sohda, Takashi; Mizuno, Katsutoshi; Imamiya, Eiko; Tawada, Hiroyuki; Meguro, Kanji; Kawamatsu, Yutaka; Yamamoto, Yujiro
CS Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
SO Chemical & Pharmaceutical Bulletin (1982), 30(10), 3601-16
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
GI



I

AB Thiazolidine-2,4-dione derivs. (86 compds. having one or two substituent(s) such as Ph, heteroaryl and alkyl group(s) at the 5-position were synthesized by several methods and evaluated as aldose reductase inhibitors. Thus o-EtC6H4CHBrCO2Me was cyclized with H2NCSNH2 to give its thiazolidine I (X = NH), which was hydrolyzed to give I (X = O). Inhibition by the active compds. of the swelling of the lens in a rat-lens-culture assay was also measured. Among these compds., a series of 5-(3,4-dialkoxyphenyl)thiazolidine-2,4-diones showed pronounced activities in both assays. Structure-activity relationships are discussed and a new approach to the synthesis of 5-arylthiazolidine-2,4-diones is described.
IT 85258-86-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and aldose reductase inhibition by)
RN 85258-86-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[4-(4-chlorophenoxy)phenyl]- (CA INDEX NAME)



L31 ANSWER 82 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:53881 CAPLUS Full-text
DN 98:53881
OREF 98:8293a,8296a
TI Thiazole derivatives, medicaments containing them and their use
IN Ferrini, Pier Giorgio; Goeschke, Richard
PA Ciba-Geigy A.-G. , Switz.
SO Eur. Pat. Appl., 119 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 61425	A2	19820929	EP 1982-810111	19820312
	EP 61425	A3	19821215		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
	US 4451471	A	19840529	US 1982-355989	19820308
	FI 8200877	A	19820919	FI 1982-877	19820315
	DK 8201184	A	19820919	DK 1982-1184	19820317
	NO 8200881	A	19820920	NO 1982-881	19820317
	GB 2098203	A	19821117	GB 1982-7759	19820317
	GB 2098203	B	19850509		
	ZA 8201790	A	19830126	ZA 1982-1790	19820317
	HU 33130	A2	19841029	HU 1982-811	19820317
	HU 187684	B	19860228		
	AU 8281667	A	19820923	AU 1982-81667	19820318
	JP 57183767	A	19821112	JP 1982-41809	19820318
	IL 65285	A	19851129	IL 1982-65285	19820318
	DD 202705	A5	19830928	DD 1982-238479	19820326
	ES 533645	A1	19860216	ES 1984-533645	19840622
	ES 545147	A1	19861216	ES 1985-545147	19850712
PRAI	CH 1981-1838	A	19810318		
	US 1983-507419	A	19830624		
	US 1984-614612	A	19840529		
	US 1984-614615	A	19840529		
	US 1984-614617	A	19840529		

OS CASREACT 98:53881; MARPAT 98:53881
GI



I II

AB I [R, R1 = aryl, hydroxy- (or a derivative), mercapto- (or a derivative) (alkylamino)-, trifluoromethylaryl or heteroaryl, etc.; n = 0-2; R2 = alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, (alkylthio)alkyl, etc.] were prepared as antirheumatics (no data). Thus, 4-MeOC6H4CHBrCOC6H4OMe-4 was cyclized with P2S5 and the thiazole alkylated with BuLi and Me2S2 to give II.
IT 84263-99-0P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)
RN 84263-99-0 CAPLUS
CN Thiazole, 2-[(1,3-dithiolan-2-ylmethyl)thio]-4,5-bis(4-phenoxyphenyl)- (CA INDEX NAME)



L31 ANSWER 83 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1982:616161 CAPLUS Full-text
DN 97:216161
OREF 97:36285a,36288a
TI Thiazole compounds and medicinal composition containing them
IN Sakano, Isao; Yokoyama, Tatsuro; Kajiya, Seitaro; Okazaki, Yutaka; Tokuda, Hiroshi; Kawazura, Hiroshi; Kumakura, Mikio; Nakano, Takuo; Awaya, Akira
PA Mitsui Toatsu Chemicals, Inc. , Japan
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8202383	A1	19820722	WO 1982-JP12	19820113
	W: US				
	RW: CH, DE, FR, GB, NL				
	JP 57118572	A	19820723	JP 1981-2741	19810113
	JP 02055426	B	19901127		
	JP 57136578	A	19820823	JP 1981-6321	19810121
	JP 02055427	B	19901127		
	EP 69154	A1	19830112	EP 1982-900258	19820113
	EP 69154	B1	19861015		
	R: DE, FR, GB				
	US 4501750	A	19850226	US 1982-420257	19820913
PRAI	JP 1981-2741	A	19810113		
	JP 1981-6321	A	19810121		
	WO 1982-JP12	A	19820113		

OS CASREACT 97:216161; MARPAT 97:216161
GI



I Q

AB Title compds. I (R = H, halo, alkyl, alkoxy, (un)substituted PhO, NO2, cyano; R1 = H, alkyl, alkylthio; R2 = haloalkyl, Q), useful as inflammation inhibitors (data given) were prepared Thus, stirring 17.6 g 2-amino-4-phenylthiazole with 6.4 g ClCOCOCl in THF in the presence of 10 g Et3N gave 7.5 g I (R = R1 = H, R2 = Q).
IT 83766-21-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 83766-21-6 CAPLUS
CN Ethanediamide, N,N'-bis[4-[4-(4-chlorophenoxy)phenyl]-5-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L31 ANSWER 84 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1982:20116 CAPLUS Full-text
DN 96:20116
OREF 96:3354h,3355a
TI Herbicidally active 2-nitro-5-phenoxyphenyloxazoles, -oxazines, -imidazoles, -pyrimidines and -thiazoles and their use
IN Duerr, Dieter
PA Ciba-Geigy A.-G. , Switz.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 35475	A1	19810909	EP 1981-810065	19810227
	EP 35475	B1	19831130		
	R: AT, BE, CH, DE, FR, GB, IT, NL				
	AT 5478	T	19831215	AT 1981-810065	19810227
	US 4350519	A	19820921	US 1981-239721	19810302
	PL 126684	B1	19830831	PL 1981-229972	19810303
	CA 1161841	A1	19840207	CA 1981-372239	19810303

IL 62279	A	19840930	IL 1981-62279	19810303
AU 8168062	A	19810910	AU 1981-68062	19810304
AU 538588	B2	19840823		
ES 500071	A1	19820101	ES 1981-500071	19810304
ZA 8101425	A	19820331	ZA 1981-1425	19810304
DD 156664	A5	19820915	DD 1981-228050	19810304
SU 999969	A3	19830223	SU 1981-3260552	19810304
CS 225828	B2	19840213	CS 1981-1550	19810304
HU 29834	A2	19840228	HU 1981-545	19810304
JP 56154461	A	19811130	JP 1981-31907	19810305
US 4431439	A	19840214	US 1982-395770	19820706
PRAI CH 1980-1739	A	19800305		
EP 1981-810065	A	19810227		
US 1981-239721	A3	19810302		

OS MARPAT 96:20116
GI


I

II

III

AB The title compds. I [R1 - R3 independently = H, halo, CF3, NO2, cyano; X = O, S, NH optionally substituted (o.s.) with C1-4 alkyl; X1 = C2-3 alkylene o.s. with C1-4 alkyl or haloalkyl], useful as herbicides and plant growth regulators, were prepared Condensing benzoyl chloride II (R4 = Cl) with H2NCH2CH2OH gave the benzamide II (R4 = NHCH2CH2OH) which was converted to the chloride II (R4 = NHCH2CH2Cl) with SOCl2. Treating II (R4 = NHCH2CH2Cl) with Bu4N+Cl-, then powdered NaOH and refluxing 0.5 h, then stirring 10 h gave 79% oxazoline III. On preemergence testing, III, at 1 kg/ha, caused heavy damage to complete killing of 15 weeds with only slight damage to barley, wheat, corn, and rice.

IT [illegible]
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)

RN 80131-35-7 CAPLUS

CN Thiazole, 2-[5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-4,5-dihydro- (CA INDEX NAME)



L31 ANSWER 85 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1981:587138 CAPLUS Full-text
DN 95:187138
OREF 95:31229a,31232a
TI 2-Amino-4-phenylthiazole derivatives as anti-atherogenic agents
AU Kawamatsu, Yutaka; Sonda, Takashi; Imai, Yoshio
CS Chem. Res. Lab., Takeda Chem. Ind. Ltd., Jusohonmachi, Osaka, 532, Japan
SO European Journal of Medicinal Chemistry (1981), 16(4), 355-62
CODEN: EJMCA5; ISSN: 0009-4374
DT Journal
LA English
GI


I

AB Thiazoles I [R = (un)substituted benzyloxy, Ph, PhO, 4-ClC6H4O, PhCH2, PhCH2CH2O, 4-ClC6H4CO2, 4-ClC6H4CONHCH2CH2, 4-ClC6H4CH2NH, 4-ClC6H4CH2S, 3-pyridylmethoxy, 2-thienylmethoxy, cyclohexylmethoxy, 1-methyl-1-cyclohexylmethoxy, Me3CCH2O, Me(CH2)14CH2O; R1 = H, Me; R2 = H, CHO, acyl, Me, MeSO2, 4-MeC6H4SO2, allyl, cyclohexyl, Ph; R1R2 = (CH2)5] were prepared E.g. refluxing 4-ClC6H4CH2OC6H4COCH2Cl-4 with thiourea and NaOAc in H2O/EtOH gave 77.5% I (R = 4-ClC6H4CH2O, R1 = R2 = H). I.HCl (R = 4-FC6H4CH2O, R1 = R2 = H) showed pronounced antiatherogenic activity in rats.

IT 79615-33-1P 79615-34-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiatherogenic activity of)

RN 79615-33-1 CAPLUS

CN 2-Thiazolamine, 4-(4-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 79615-34-2 CAPLUS

CN 2-Thiazolamine, 4-[4-(4-chlorophenoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L31 ANSWER 86 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1981:103221 CAPLUS Full-text
DN 94:103221
OREF 94:16843a,16846a
TI Thiazole derivatives. III. Synthesis and pharmacological screening of 2-mercapto-4-arylthiazolyl-5-acetic acids and their ethyl esters
AU Zawadzka, Jadwiga; Szczycinski, Bohdan
CS Dep. Chem. Synth., Inst. Pharm. Ind., Warsaw, 01-793, Pol.
SO Acta Poloniae Pharmaceutica (1979), 36(5), 551-5
CODEN: APPHAX; ISSN: 0001-6837
DT Journal
LA Polish
OS CASREACT 94:103221
GI


I

AB Thiazole derivs. I (R = H, Cl, Br, F, OMe, Ph, OPh) were prepared in 40-75% yields by bromination in Et2O or CHCl3 of 4-RC6H4CO(CH2)2CO2Et and subsequent cyclization with H2NCS2NH4 in EtOH. I (R = H, Cl, Br, F) were hydrolyzed with 20% NaOH to yield the corresponding acids. Pharmacol. tests for antiphlogistic activity gave neg. results.

IT [illegible]
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 75449-14-8 CAPLUS

CN 5-Thiazoleacetic acid, 2,3-dihydro-4-(4-phenoxyphenyl)-2-thioxo-, ethyl ester (CA INDEX NAME)



L31 ANSWER 87 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1974:414549 CAPLUS Full-text
DN 81:14549
OREF 81:2355a,2358a
TI Infrared spectroscopic studies on high-temperature-stable fibers and textiles with ATR [attenuated total reflection] technique. II. Infrared spectra of high-temperature-stable fibers
AU Hummel, Dieter O.; Siesler, Heinz; Zoschke, Elsbeth; Vierling, Ilse; Morlock, Ute; Stadtlaender, Thomas
CS Inst. Phys. Chem. Kolloidchem., Cologne, Fed. Rep. Ger.
SO Melliand Textilberichte International (1973), 54(12), 1340-6
CODEN: MTXIAW; ISSN: 0375-9350
DT Journal
LA German
AB The use of ATR-ir spectra for identification of high temperature fibers was discussed and 27 representative spectra were given.

IT 52410-69-2
RL: USES (Uses)
(fiber, attenuated total reflection ir spectrum of)

RN 52410-69-2 CAPLUS

CN 1,3-Benzenedicarboxylic acid, polymer with 4-[2-[4-(4-aminophenoxy)phenyl]-4-thiazolyl]benzenamine (9CI) (CA INDEX NAME)

CM 1

CRN 26510-07-6
CMF C21 H17 N3 O S



CM 2

CRN 121-91-5
CMF C8 H6 O4



L31 ANSWER 88 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1971:529795 CAPLUS Full-text
DN 75:129795
OREF 75:20495a,20498a
TI Nematocidal thiazole derivatives
PA Burroughs Wellcome and Co. (U.S.A.) Inc.; Wellcome Foundation Ltd.
SO Brit., 7 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1246649		19710915	GB 1968-58060	19670922

AB Arylthiazole salts were prepared which were useful in treating nematode infections in warm-blooded animals. Thus, p-(dimethylamino)cinnamic acid in CHCl3 was mixed with SOCl2 and 25% aqueous methylamine at 10° to give N-methyl-p-(dimethylamino)cinnamamide which was refluxed 15 min with P2S5 in pyridine, to give N-methyl-p-(dimethylamino)thiocinnamamide (I). I was refluxed 2 hr with p-iodophenacyl chloride in EtOH to give S-(p-iododiphenacyl)-N-methyl-p-(dimethylamino)thiocinnamoimidate-HCl. The corresponding thioimidate hydroiodide was warmed with 5N HCl in excess NaOAc to give 2-[p-(dimethylamino)styryl]-4-p-iodophenyl-3- methylthiazolium iodide. Other thiazoles similarly prepared were 2-[p-(dimethylamino)-styryl]-3-ethyl-4-phenylthiazolium iodide and 2-[p-(dimethylamino)styryl]-4-p-methoxyphenyl-3-methylthiazolium bromide.
IT 24229-31-9P 24259-08-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24229-31-0 CAPLUS
CN Thiazolium, 2-[p-(dimethylamino)styryl]-3-methyl-4-(p-phenoxyphenyl)-, iodide (8CI) (CA INDEX NAME)



● I-

RN 24259-08-3 CAPLUS
CN Thiazolium, 2-[p-(diethylamino)styryl]-3-methyl-4-(p-phenoxyphenyl)-, iodide (8CI) (CA INDEX NAME)



● I-

L31 ANSWER 89 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1970:68047 CAPLUS Full-text
DN 72:68047
OREF 72:12445a,12448a
TI Aromatic polyamides with heterocyclic ring systems
AU Kuenzel, H. E.; Wolf, G. D.; Bentz, F.; Blankenstein, G.; Nischk, Guenther E.
CS Org.-Wiss. Lab., Farbenfabriken Bayer A.-G., Dormagen/Rh., Fed. Rep. Ger.
SO Makromolekulare Chemie (1969), 130, 103-44
CODEN: MACEAK; ISSN: 0025-116X
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB Aromatic diamines containing oxadiazole, triazole, thiadiazole, thiazole, hydantoin, quinazolone, and quinazolinedione ring systems were prepared and combined with aromatic dicarboxylic acid dichlorides to give the title polymers. The 1,3,4-oxadiazole derivs. were prepared by cyclizing nitro-substituted 1,2-diacylhydrazines and reducing the NO2 groups (compound and m.p. given): 2,5 - bis[4 - aminophenoxy)phenyl] - 1,3,4 - oxadiazole (I), 227-9°; 2 - (4 - aminophenyl) - 5 - [4 - (4 - aminophenoxy)phenyl]-1,3,4-oxadiazole, 228-30°; 1,3 - bis[5 - [3 - (4 - aminophenoxy)phenyl] - 1,3,4 - oxadiazol - 2 - yl]benzene, 222-5°; 2,5-bis[3-(4-aminophenoxy)phenyl]- 1,3,4-oxadiazole, 221-3°; 2,5-bis[4 - (4 - amino - 2 - chlorophenoxy)phenyl] - 1,3,4 - oxadiazole, 184°; 2,5-bis[4-(4-aminophenoxy) - 3-chlorophenyl]-1,3,4-oxadiazole, 156-8°; 2,5-bis[4-(4 - amino-2-chlorophenoxy) - 3-chlorophenyl] - 1,3,4 - oxadiazole, 179-82°; 2-(4 - aminophenyl)-5 - [3-(4 - aminophenoxy)phenyl] - 1,3,4 - oxadiazole, 254-6°; 2-(3-aminophenyl)-5-[3 - (4-aminophenylsulfonyl)phenyl] - 1,3,4-oxadiazole, 230-5°; 2-(4-aminophenyl)-5 -[3-(4-aminophenylsulfonyl)phenyl]-1,3,4-oxadiazole, 240-3°. The triazole derivs. were prepared by treating nitro-substituted hydrazides with benzimidoyl chlorides and then reducing (compound and m.p. given): 3-[3-(4-aminophenoxy)phenyl]-5- (3-aminophenyl)-4-phenyl - 1,2,4-triazole, 266-8°; 3-[4-(4 - aminophenoxy)phenyl]-5-(4 - aminophenyl)-4 - phenyl-1,2,4-triazole, 268-70°; 3 - [4 - (4 - aminophenoxy)phenyl] - 5-(3-aminophenyl) - 4 - phenyl-1,2,4-triazole, 250-2°; 3,5-bis-[4 - (4- aminophenoxy)phenyl]- 4 - phenyl-1,2,4-triazole, 243-5°; 3.5-bis[3-(4-aminophenoxy)phenyl]- 4 - phenyl - 1,2,4 - triazole, 272-4°; 3-[3-(4-aminophenylsulfonyl)phenyl]-5-(3-aminophenyl)-1,2,4 - triazole, 138-42°. 1,3,4 - Thiadiazoles were prepared by cyclodehydrating nitro-substituted diacylhydrazines in the presence of P2S5, while the thiazoles were prepd , from thioamides and bromomethyl ketones (compound and m.p. given): 2,5 - bis[4-(4-aminophenoxy)phenyl] - 1,3,4 - thiadiazole, 194-7°; 2,5 - bis[3 - (4 - aminophenoxy)phenyl]- 1,3,4-thiadiazole, 155-7°; 2 - [4-(4-aminophenoxy)phenyl] - 5 - (3-aminophenyl) - 1,3,4 - thiadiazole, 163-5°; 2 - [3 - (4 - aminophenoxy)phenyl] - 4 - (4 - aminophenyl)thiazole, 153-5°; 2 - [4-(4-aminophenoxy)phenyl] - 4 - (4-aminophenyl)thiazole, 170-2°; 2 - [4 - (4 - aminophenoxy)phenyl] - 4 - (3 -

aminophenyl)thiazole, 127-32°; 2-[4-(4-amino-2- chlorophenoxy)phenyl]-4 - (3 - aminophenyl)thiazole, 129-30°. The substituted 5,5-dimethylhydantoins were prepared by treating nitro-substituted α-aminoisobutyronitriles with nitro-substituted isocyanates, cyclodehydrating, and reducing (compound and m.p. given): 1,3 - bis-(4-aminophenyl)-5,5-dimethylhydantoin, 279-80°; 1 - [4-(4-aminophenoxy)phenyl] - 3 - (4-aminophenyl) - 5,5 - dimethylhydantoin, 258-9°; 1,3-bis[4-(4-aminop henoxy)phenyl]-5,5- dimethylhydantoin, 188-95°; 1,4 - bis[1-[4-(4-aminophenoxy)phenyl]- 5,5 - dimethylhydantoin - 3 - yl]phenoxy]benzene, 150-4°; 4,4'-bis[4 - [1-[4-(4-aminophenoxy)phenyl] - 5,5 - dimethylhydantoin-3 - yl]phenoxy]diphenyl sulfone, 173-81°; 1,4-bis[4-[3-[4-(4- aminophenoxy)phenyl] - 5,5-dimethylhydantoin - 1-yl]phenoxy]benzene, 300-3°; 1,4 - bis[4 - [3 - (4 - aminophenyl) - 5,5 - dimethylhydantoin - 1 - yl]phenoxy]benzene, 258-62°. Quinazolinediones were prepared similarly to the hydantoins by cyclodehydrating the reaction products of isocyanates and anthranilic acids, and then reducing the NO2 groups (compound and m.p. given): 3-(4-aminophenyl)-7-amino - 2,4(1H,3H) - quinazolinedione (II), >360°, 3-(4-aminophenyl)-6-amino - 2,4(1H,3H)-quinazolinedione, 340-5° (decompose); 3 - [4 - (4-aminophenoxy)phenyl] - 7 - amino-2,4(1H,3H)-quinazolinedione, 293-4°; 3,3'-m-phenylenebis[7- amino-2,4(1H,3H)-quinazolinedione), 322-9°; 1,4 - bis[4-(7-amino-2,4(1H,3H) - dioxoquinazolin - 3 - yl)phenoxy]benzene, >360°; 4,4'-bis[4 - (7-amino - 2,4(1H,3H)-dioxoquinazolin-3- yl)phenoxy]diphenyl sulfone, 262-5°. 4(3H) - Quinazolones were prepared by forming 3,1-benzoxazine-4-ones from anthranilic acids and Ac2O, treating with an aromatic nitro amine to give a quinazolone, and reducing the NO2 groups (compound and m.p. given): 3-(4-aminophenyl)-7-amino - 4(3H)-quinazolone, 285-8°; 3-[4-(4-aminophenoxy)phenyl - 7 - amino-4(3H)-quinazolone, 245-6°; 3 - [4 - (4-amino - 2 - chlorophenoxy)phenyl] - 7 - amino - 4(3H) - quinazolone, 280-3°; 3 - [3-(4-aminophenoxy)phenyl]-7-amino-2-methyl-4(3H)-quinazolone, 223-4°; 3 - (3 - aminophenyl)-6-amino-2-methyl-4(3H) - quinazolone, 237-8°; 1,4 - bis[4 - (7-amino-2-methyl-4(3H)-oxoquinazolin-3- yl)phenoxy]benzene, >360°; 4,-4'-bis[4-(7-amino-2-methyl-4(3H)- oxoquinazolin - 3-yl)phenoxy]-diphenyl sulfone, 313-20° 2 - [3 - (4 - aminophenoxy)phenyl]-7 - amino - 3 - phenyl - 4(3H) - quinazolone, 253-6°; 2-[4-(4-aminophenoxy)phenyl]-6-amino - 3-phenyl-4(3H)-quinazolone, 279-81°; 2 - [3-(4 - aminophenoxy)phenyl] - 6 - amino-3-phenyl - 4(3H)-quinazolone, 251-4°; 2 - [3 - (4 - aminophenoxy)phenyl] - 6-amino - 3 - ethyl - 4(3H) - quinazolone, 200-1°; 2-[3-(4-aminophenoxy)phenyl] - 6-amino-3 - methyl-4(3H)-quinazolone, 176-9°; 2-[4-(4-aminophenoxy)phenyl] - 6 - amino-3-methyl - 4(3H) - quinazolone, 214-15°; 2-[4 - (4 - aminophenoxy)phenyl]-7-amino-3-ethyl-4(3H)-quinazolone, 200-4°; 2 - [4 - (4 - aminophenoxy)phenyl] - 6 - amino-3-ethyl - 4(3H) - quinazolone, 212-14°; 2 - [4 - (4 - aminophenoxy)phenyl] - 7 - amino - 3 - methyl - 4(3H) - quinazolone, 216-17°; 2 - [4 - (4 - aminophenoxy)phenyl] - 6 - amino - 2 - (3-chlorophenyl) - 4(3H) - quinazolone, 258-9°; 2 - [4 - (4 - aminophenoxy)phenyl] - 7 - amino - 3 - (4 - chlorophenyl) - 4(3H) - quinazolone, 245-50°; 2 - [3-(4 - aminophenoxy)phenyl] - 7-amino-3-(4 - chlorophenyl) - 4(3H) - quinazolone, 210-14°; 2-[3-(4 - aminophenoxy)phenyl] - 6 - amino - 3 - (3-chlorophenyl)-4(3H) - quinazolone, 228-32°. These diamines were treated with isophthaloyl or terephthaloyl chlorides in AcNMe2 or N-methylpyrrolidone to give the title polyamides. Products soluble in the reaction solvents were obtained from oxadiazole, triazole, thiazole, or thiadiazole derivs. containing ≥1 ether or sulfone group, and optionally a halophenyl nucleus. Hydantoin, quinazolinedione, and quinazolone derivs. gave soluble products. Soluble polyamides containing oxadiazole rings and ≥1 ether group had good thermal stability and gave fibers having good tensile strength at room temperature, but were severely weakened at >200° and were easily flammable. The ether and trazole-, thiadiazole-, or thiazole-containing polyamides had much poorer thermal stability and low light resistance. Polymers containing quinazolone rings and ether groups had thermal stabilities comparable to that of oxadiazole-containing polymers. The quinazolinedione polymers had the best

properties. The product from II and isophthaloyl chloride had especially outstanding thermal stability and light resistance, good solubility, and good tensile strength which decreased only slightly with increasing temperature
IT 24689-96-1P 26507-11-9P 26510-06-5P
26510-07-6P 26810-10-1P 26615-62-3P
26655-99-2P 26656-00-9P 26656-01-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24689-96-1 CAPLUS
CN Thiazole, 2-[p-(4-amino-2-chlorophenoxy)phenyl]-4-(m-aminophenyl)- (8CI) (CA INDEX NAME)



RN 26507-11-9 CAPLUS
CN Thiazole, 2-(p-(p-aminophenoxy)phenyl]-4-(m-aminophenyl)- (8CI) (CA INDEX NAME)



RN 26510-06-5 CAPLUS
CN Thiazole, 2-[m-(p-aminophenoxy)phenyl]-4-(p-aminophenyl)- (8CI) (CA INDEX NAME)



RN 26510-07-6 CAPLUS
CN Benzenamine, 4-[2-[4-(4-aminophenoxy)phenyl]-4-thiazolyl]- (CA INDEX NAME)



RN 26510-10-1 CAPLUS
CN Thiazole, 2-[p-(p-nitrophenoxy)phenyl]-4-(p-nitrophenyl)- (8CI) (CA INDEX NAME)



RN 26615-62-3 CAPLUS
CN Terephthaloyl chloride, polyamide with 2-[p-(p-aminophenoxy)phenyl]-4-(m-aminophenyl)thiazole (8CI) (CA INDEX NAME)

CM 1

CRN 26507-11-9
CMF C21 H17 N3 O S



CM 2

CRN 100-20-9
CMF C8 H4 Cl2 O2



RN 26655-99-2 CAPLUS
CN 1,3-Benenedicarbonyl dichloride, polymer with 4-[2-[4-(4-aminophenoxy)phenyl]-4-thiazolyl]benzenamine (9CI) (CA INDEX NAME)

CM 1

CRN 26510-07-6
CMF C21 H17 N3 O S



CM 2

CRN 99-63-8
CMF C8 H4 Cl2 O2



RN 26656-00-8 CAPLUS
CN Isophthaloyl chloride, polyamide with 2-[p-(p-aminophenoxy)phenyl]-4-(m-aminophenyl)thiazole (8CI) (CA INDEX NAME)

CM 1

CRN 26507-11-9
CMF C21 H17 N3 O S



CM 2

CRN 99-63-8
CMF C8 H4 Cl2 O2



RN 26656-01-9 CAPLUS

CN Terephthaloyl chloride, polyamide with 2-[p-(4-amino-2-chlorophenoxy)phenyl]-4-(m-aminophenyl)thiazole (8CI) (CA INDEX NAME)

CM 1

CRN 24689-96-1
CMF C21 H16 Cl N3 O S



CM 2

CRN 100-20-9
CMF C8 H4 Cl2 O2



L31 ANSWER 90 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1970:3479 CAPLUS Full-text
DN 72:3479
OREF 72:639a,642a
TI Nematocidal 2-(p-dialkylaminostyryl)-4-(p-substituted-phenyl)thiazole alkyl halides
IN Phillips, Arthur Page; Burrows, Robert B.
PA Wellcome Foundation Ltd.
SO S. African, 22 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6805975		19690318	ZA	
	CA 961852			CA	
	CA 974173			CA	
	DE 1795380			DE	
	DE 1795381			DE	
	FR 1591630			FR	
	FR 7927			FR	
	FR 8213			FR	
	GB 1244961			GB	

US 3641012	19720208	US .	19680919
US 3883658	19750513	US 1971-146549	19710524

PRAI GB 19670922
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by the reaction of a (2-methyl-4-phenylthiazolyl)-alkyl halide and a p-dialkylaminobenzaldehyde in a polar solvent at 20° to b.p., with piperidine, an amine, alkali hydroxide or alkoxide as catalyst, or a p- dialkylaminocinnamoylthioalkyl-amide with a PhCOCH2X at 80-150° in the presence of HX. Thus, a mixture of 27.5 g p-PhC6H4COCH2Br and 10 g MeCSNH2 was heated 1-2 hr at 100° in 150 ml MeOH, then the mixture concentrated, treated with H2O and NH3, and the precipitate worked up to give 90-5% 2-methyl-4-p-biphenylylthiazole (II), m. 120-1°. A solution of 25 g II and 22 g MeI in 70 ml HCONMe2 was heated 6-8 hr at 100°, then treated with excess Et2O and cooled to give 75-80% 2-methyl-4-(p-biphenylyl)thiazole methiodide (III), m. 272-3°. A mixture of 79 g III and 4.5 g p-Me2NC6H4CHO in 90 ml MeOH containing 2 ml piperidine was heated 2 hr on a steam bath, and the precipitate worked up to give I (R = R1 = Me, Z = Ph, X = I) (IV), m. 253-6°. Similarly were prepared the following I (X = I) (NR2, R1, Z, and m.p. given): pyrrolidino (A), Me, H, 234-5°; A, Me, Cl, 219-20°; NMe2, Et, Ph, 233-5°; NEt2, Me, Ph, 208-9°; A, Me, Ph, 262-3°; A, Et, Ph, 264-5°; A, Me, Br, (0.5H2O) 211-13°; A, Et, Br, 223-5°; A, Me, PhO, (0.5H2O) 238-9°; A, Me, p-MeOC6H4, (0.5H2O) 279-80°; A, Me, F, 238-9°; A, Et, H, 228-30° (MeOH); A, Et, Cl, 217-18° (MeOH); also the following 4-substituted derivs. of 2-methylthiazole (substituent, salt and m.p. given): p-BrC6H4, ethiodide 209-10°; p-PhC6H4, ethiodide, 236-7°; p-PhOC6H4, methiodide, 261-2° [monohydrate m. 185-6°]; Ph, [m. 68-9° (MeOH)] ethiodide, 175-6° (MeOH-Et2O); p-ClC6H4, [m. 122-3° (MeOH or hexane)] ethiodide, 201-2° (MeOH-Et2O). A mixture of 25.1 g II, 100 ml HCONMe2, and 37.2 g p-MeC6H4SO3Me was heated 43 hr at 80-90°, and the precipitate worked up to give 2,3-dimethyl-4-p- biphenylylthiazolium p-toluenesulfonate (V), m. 180-2° (iso-PrOH), which was then converted to the p-toluenesulfonate analog, m. 248-54° (MeOH) of IV. Similarly prepared were the MeSO4- analogs of V, m. 235-40° (decomposition) (EtOH), and of IV, m. 210-25° or 240-5°. SOCl2 (31.25 g) was added to a stirred, cooled suspension of 47.75 g p-Me2NC6H4CH:CHCO2H in 500 ml. CHCl3 at 10°, stirring continued 30 min, the resultant solution added gradually with stirring to 400 ml 25% aqueous MeNH2 cooled to 0-5°, the mixture stirred 30 min more, and the organic layer worked up to give p-Me2NC6H4CH:CHCONHMe (VI), m. 165-6° (C6H6). A mixture of 20.4 g VI and 11.1 g P2S5 in 70 ml C5H5N was refluxed 15 min, then poured into 200 ml H2O and the precipitate worked up to give p-Me2NC6H4CH:CHCSNHMe (VII), m. 214-16° (EtOH). A solution of 8.8 g VII and 11.0 g p-PhC6H4CO-CH2Br in 400 ml Me2CO was refluxed and the precipitate worked up to give p-phenylphenacyl-N-methyl-(p- dimethylaminocinnamoyl)-thioimidate.HBr (VIII), m. 167-9°. A suspension of 5 g VIII in 50 ml H2O and 80 ml 48% HBr was warmed 5 min on a steam bath, then cooled, neutralized with aqueous NaOH, and the precipitate worked up to give the Br- analog, m. 253-5° (MeOH), of IV. Similarly were prepared the HCl analog of VIII, m. 145-50° (EtOH-E tOAc); the Cl- analog of IV, m. 251-3° (EtOHEtOAc); p- pyrrolidinocinnamoylmethylamide, m. 237-9° (EtOH), and the corresponding thioamide, m. 262-4° (C5H5N); and I (NR2 = pyrrolidino, R = Me, Z = H, X = Br), m. 236-7° (effervescence), iodide, m. 233-4° (effervescence). I are active against parasitic nematodes, especially hookworms, in the intestinal tract. Preferred is IV, LD50 (mice) 1650 mg/kg, at 5 mg/kg dose (cats and dogs).
IT 24840-62-8P 24840-67-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24840-62-8 CAPLUS
CN Thiazolium, 3-methyl-4-(p-phenoxyphenyl)-2-(p-1-pyrrolidinylstyryl)-, iodide (8CI) (CA INDEX NAME)





RN 24840-67-3 CAPLUS
CN Thiazolium, 2,3-dimethyl-4-(p-phenoxyphenyl)-, iodide (8CI) (CA INDEX NAME)

L31 ANSWER 91 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1969:524421 CAPLUS Full-text
DN 71:124421
OREF 71:23127a,23130a
TI Nematocidal 2-(p-dialkylaminostyryl)-3-alkyl-4-(p-substituted-phenyl)thiazolium halides
IN Phillips, Arthur Page; Burrows, Robert B.
PA Wellcome Foundation Ltd.
SO S. African, 16 pp.
CODEN: SFXXAB
DT Patent
LA Russian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ZA 6805976		19690318		
CA 961852			CA	
CA 974173			CA	
DE 1795380			DE	
DE 1795381			DE	
FR 1591630			FR	
FR 7927			FR	
FR 8213			FR	
US 3641012		19720208	US	19680919
US 3883658		19750513	US 1971-146549	19710524
PRAI GB		19670922		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by method B of S. African 68 05,975, and the same claims are made. Prepared were the following I (R, R1, R2, X, and

m.p. given): Me, Me, p-IC6H4, I (II), 228° (decomposition) (MeOH); Me, Et, p-MeOC6H4, Br, 219° (decomposition) (alc.); Me, Et, p-ClC6H4, I, 213-15°; Me, Me, p-PhOC6H4, I, 207-8°; Me, Me, p-MeOC6H4C6H4-p, I, 280-1°; Et, Et, Ph, I, 212-13°; Et, Me, p-MeOC6H4, I, 191-2°; Et, Me, β-naphthyl, I, 209-10°; Et, Me, p-PhOC6H4, I, 204-5°. Also prepared were p-Me2NC6H4CH:CHCONHEt, m. 157-8°, corresponding thioamide m. 198-200°; p-iodophenacyl N-methyl-p-(dimethylamino)thiocinnamimidat e-HCl, m. 176-7°; HI salt m. 173-4° (MeOH); phenyl N-ethyl-p-(dimethylamino)thiocinnamimidate-HBr(sic), m. 172-3°. A solution of 1 g. II in 20 ml. BuOH was heated 1.75 hrs. at 120°, cooled, treated with Et2O, and the precipitate dissolved in aqueous MeOH and treated with KI solution to give I (R = Me, R1 = Et, R2 = p-IC6H4, X = I), m. 193-5° (decomposition) (EtOH).
IT 24229-31-0P 24259-08-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24229-31-0 CAPLUS
CN Thiazolium, 2-[p-(dimethylamino)styryl]-3-methyl-4-(p-phenoxyphenyl)-, iodide (8CI) (CA INDEX NAME)



RN 24259-08-3 CAPLUS
CN Thiazolium, 2-[p-(diethylamino)styryl]-3-methyl-4-(p-phenoxyphenyl)-, iodide (8CI) (CA INDEX NAME)



L31 ANSWER 92 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1968:477164 CAPLUS Full-text
DN 69:77164
TI Thermal stability of some heterocyclic compounds
AU Gelus, Maurice; Bonnier, Jane Marie
CS Lab. Chim. Gen., Fac. Sci. Grenoble, St.-Martin-d'Heres, Fr.
SO Journal de Chimie Physique et de Physico-Chimie Biologique (1968), 65(2), 253-9
CODEN: JCPBAN; ISSN: 0021-7689

DT Journal
LA French
GI For diagram(s), see printed CA Issue.
AB The thermal stability of several aromatic and heterocyclic compds. was studied by a previously described method (R. Arnaud, et al., 1966). The synthesis of the compds. was described elsewhere (J. M. Bonnier, et al., 1965). The temps. of pyrolysis were determined by the isoteniscope method. The following values are reported: thiazole (I), 510°; 2,4-diphenylthiazole (II), 431°; 4-(4-biphenylyl)-2-phenylthiazole (III), 442°; 2-(4-biphenylyl)-4-phenylthiazole (IV), 452°; 2,4-bis(4-biphenylyl)thiazole, 510°; 2,2'-(p-phenylene)bis(4-methylthiazole), 403°; 4,4'-(p-phenylene)bis(2-phenylthiazole), 484°; 2,2'-(p-phenylene)bis(4-phenylthiazole), 495°; 4,4'-(p-phenylene)bis{[2-(4-biphenylyl)thiazole], 505°; 2,2'-(p-phenylene)bis[4-(4-biphenylyl)thiazole], 513°; 2,2'-oxydi-(p-phenylene)bis(4-(phenylthiazole), 476°; 2,2'-oxydi-(p-phenylene)bis[4-(4-biphenylyl]thiazole, 495°; imidazole (IVa), 590°; benzimidazole (V), 405°; 2-methylbenzimidazole (VI), 382°; 2-phenylbenzimidazole, 393°; 2,2'-diphenylimidazo[4,5:5'6']benzimidazole, (VII) 310°; 2,2'-(p-phenylene)bisbenzimidazole, 550°; 2,2'-oxydi-(p-phenylene)bisbenzimidazole, 535°; benzothiazole (VIII), 556°; 2-methylbenzothiazole (IX), 446°; 2-phenylbenzothiazole (X), 504°; 2,2'-(p-phenylene)bisbenzothiazole (XI), 495°; 2,2'-(biphenylylene)bisbenzothiazole, 423°; 2,2'-oxydi-(p-phenylene)bisbenzothiazole (XII), 409°. M.O. energies, resonance energies, and population indexes were calculated Dipole moments were determined for several compds. by the Guggenheim method. [compound and dipole moment (D.) given]: I, 1.04; II, 0.77; III, .apprx.0.7; (IV) 0.86; V, 3.89; VI, 4.66; VIII, 1.42; IX, 1.33; X, 0.94; XI, 0.50; and XII, 1.13. Charge distribution diagrams are given for I, IVa, V, and VIII. The resonance energies and the thermal stabilities of the studied compds. appear to increase with the dimensions of the mol. Isomers of equal resonance energies can, however, exhibit different thermal stabilities. 33 references.
IT 13355-37-8 14208-43-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(resonance energy and thermal stability of)
RN 13355-37-8 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-phenyl- (8CI) (CA INDEX NAME)



RN 14208-43-6 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-(4-biphenylyl)- (8CI) (CA INDEX NAME)



L31 ANSWER 93 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1968:100244 CAPLUS Full-text

DN 68:100244
OREF 68:19371a,19374a
TI Ultraviolet spectrophotometry of some heterocyclic compounds
AU Gelus, Maurice; Bonnier, Jane M.
CS Lab. Chim. Gen., Fac. Sci. Grenoble, Grenoble, Fr.
SO Journal de Chimie Physique (1967), 64(11-12), 1602-6
CODEN: JCPQAY
DT Journal
LA French
AB The uv spectra of thiazoles and benzimidazoles were studied and the M.O. energies calculated by a Hueckel method. The measured energy is a linear function dependent on the transition from the highest to the lowest orbital level occupied. The thiazole derivs. were studied in cyclohexane solution, the benzothiazoles in dioxane. Some of the thiazoles derivs. presented 2 absorption bands, 1 in the 250-70-mμ range, the other beyond 320 mμ; other derivs. had a single band at .apprx.290 mμ. The phenyl derivs. for example had a band at 252 mμ, the other at 320 mμ, this pattern of absorption corresponding to the transfer of one electron from a benzene orbital to a free orbital in the C:N group as shown by the calculated energy (3.93 ev.). The presence of 2 thiazoles rings shifted the spectra to 260 and 340 mμ in some derivs. while others kept their single band at 290 mμ. The benzimidazoles had 3 bands in the regions: 200, 245, and 280 mμ while imidazole presented a single band at 206 mμ. They were studied in EtOH solns. Introduction of a CH3 group in position 2 did not modify the spectrum while substitution by a phenyl group brought the appearance of a strong band around 315 mμ.
IT 13355-37-8 14208-43-6
RL: PRP (Properties)
(spectrum (uv) of, mol. orbitals in relation to)
RN 13355-37-8 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-phenyl- (8CI) (CA INDEX NAME)



RN 14208-43-6 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-(4-biphenylyl)- (8CI) (CA INDEX NAME)



L31 ANSWER 94 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1968:22805 CAPLUS Full-text
DN 68:22805
OREF 68:4439a,4442a
TI Thiazole polymers
IN Craven, James M.

PA du Pont de Nemours, E. I., and Co.
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3355426		19671128	US 1963-304686	19630826

PI US 3355426
GI For diagram(s), see printed CA Issue.
AB Thiazole polymers, prepared by the treatment of a difunctional α-haloketone with a difunctional thioamide in an inert solvent, are insol. in common organic solvents, have high thermal stability, can be dissolved in highly acidic solvents, and are useful as film-forming ingredients in lacquers and other coating compns. Thus, 4,4'-bis(m-chloroacetylphenyl) ether 16.159, 1,4-cyclohexanedithiocarboxamide 10.117, and HCO2H 200 parts were refluxed 72 hrs. and the resulting clear, yellow, viscous reaction mixture poured into 1000 parts water to give a white, solid polymer (I). A lacquer prepared by dissolving 15 parts I in 100 parts HCO2H was brushed on a metal plate and dried at 60° to give a clear, tough, durable, solvent-resistant film. Similarly prepared were II-VIII.
IT 32034-51-8 32034-52-9 32038-27-0
32038-28-1 32038-29-2
RL: USES (Uses)
(coatings of, on metals, heat- and solvent-resistant)
RN 32034-51-8 CAPLUS
CN Poly(2,4-thiazolediyl-1,4-phenyleneoxy-1,4-phenylene-4,2-thiazolediyl-1,4-phenyleneoxy-1,4-phenylene) (9CI) (CA INDEX NAME)



RN 32034-52-9 CAPLUS
CN Poly(4,2-thiazolediyl-1,4-phenylene-2,4-thiazolediyl-1,4-phenyleneoxy-1,4-phenylene) (9CI) (CA INDEX NAME)



RN 32038-27-0 CAPLUS
CN Poly(4,2-thiazolediyl-1,4-cyclohexanediyl-2,4-thiazolediyl-1,4-phenyleneoxy-1,4-phenylene) (9CI) (CA INDEX NAME)



RN 32038-28-1 CAPLUS
CN Poly(4,2-thiazolediyl-1,3-phenylene-2,4-thiazolediyl-1,4-phenyleneoxy-1,4-phenylene) (9CI) (CA INDEX NAME)



RN 32038-29-2 CAPLUS
CN Poly([2,2'-bithiazole]-4,4'-diyl-1,4-phenyleneoxy-1,4-phenylene) (9CI) (CA INDEX NAME)



L31 ANSWER 95 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1968:2510 CAPLUS Full-text
DN 68:2510
OREF 68:447a,450a
TI Thermal stability of heterocyclic compounds
AU Bonnier, Jane M.; Gelus, Maurice
CS Fac. Sci. Grenoble, Grenoble, Fr.
SO Revue de l'Institut Francais du Petrole et Annales des Combustibles Liquides (1967), 22(6), 1008-28
CODEN: RIFPA9; ISSN: 0370-5552
DT Journal
LA French
GI For diagram(s), see printed CA Issue.
AB The decomposition temps. of a number of heterocyclic compds. were determined and compared with the resonance energy and that of the highest and lowest free mol. orbitals for each compound A good correlation was found between thermal stability and the energy of the highest occupied orbital. Exptl. decomposition temps. determined by the change in pressure in a heated vessel containing the compound (the apparatus is described) are thiazole (I) 510°, 2,4-diphenylthiazole 431°, 2-phenyl-4-(4-biphenylyl)thiazole 442°, 4-phenyl-2-(4-biphenylyl)thiazole 452°, bis(4-biphenylyl)-2,4-thiazole 510°, 2,2'-p-phenylenebis(4- methylthiazole) 403°, 4,4'-p-phenylenebis(2-phenylthiazole)

484°, 2,2'-p-phenylenebis(4-phenylthiazole) 495°, 4,4'-p-phenylenebis[2-(4-biphenylyl)thiazole] 505°, 2,2'-p-phenylenebis[4-(4-biphenylyl)thiazole] 513°, 2,2'-oxydi(p-phenylene)bis(4-phenylthiazole) 476°, 2,2'-oxydi(p-phenylene)bis[4-(4-biphenylyl)thiazole] 495°, imidazole (II) 590°, benzimidazole (III) 405°, 2-methylbenzimidazole 382°, 2-phenylbenzimidazole 382°, 2-phenyl-2-phenylimidazo(4,5:5',6')benzimidazole (IV) 310°, 2,2'-p-phenylenebis(benzimidazole) 550°, 2,2'-oxido(p- phenylene)bis(benzimidazole) 435°, benzothiazole (V) 556°, 2-methylbenzothiazole 446°, 2-phenylbenzothiazole 504°, 2,2'-p-phenylenebis(benzothiazole) 495°, 2,2'-(biphenylyl)bis(benzothiazole) 423°, 2,2'-oxydi(p-phenylene)bis(benzothiazole) 409°. Orbital energies calculated by the method of Newton, et al. (CA 65: 1401c) showed that II had an energy of 85 kcal./mole greater than that of III for the highest occupied orbit, while the N-containing compds. showed the opposite effect, V being more stable than I and having 45 kcal./mole greater energy. 53 references.
IT 13355-37-8 14208-43-6
RL: PRP (Properties)
(thermal stability of)
RN 13355-37-8 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-phenyl- (8CI) (CA INDEX NAME)



RN 14208-43-6 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-(4-biphenylyl)- (8CI) (CA INDEX NAME)



L31 ANSWER 96 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1967:37815 CAPLUS Full-text
DN 66:37815
OREF 66:7203a,7206a
TI Thermal stability of thiazoles
AU Arnaud, Roger; Gelus, Maurice; Malet, Jean C.; Bonnier, Jane M.
CS Fac. Sci., Grenoble, Fr.
SO Bulletin de la Societe Chimique de France (1966), (9), 2857-61
CODEN: BSCFAS; ISSN: 0037-8968
DT Journal
LA French
AB Thiazoles were prepared by the reaction of α-halo ketones and thio amides according to the modified procedure of Mulvaney and Marvel (CA 55, 19902f). Thiazoles prepared were (% yield, m.p., and decomposition point given): thiazole -, -, 530°; 2,4-diphenylthiazole, 48, 93-3.5°, 431°; 2-phenyl-4-biphenylylthiazole, 49, 159-60°, 442°; 4-phenyl-2-biphenylythiazole, 50, 162-3°, 452°; 2,4-(bis(4-biphenylyl)thiazole 68.5, 207-8°, 510°; 2,2'-p-

phenylenebis[4-methylthiazole], 44, 169-70°, 403°; 4,4'-p-phenylenebis[2-phenylthiazole], 59.5, 232-3°, 484°; 2,2'-p-phenylenebis[4-phenylthiazole], 64.4, 230.5-31°, 495°; 4,4'-p-phenylenbis[2-biphenyl-4-ylthiazole], 44, 350°, 505°; 2,2'-p-phenylenebis[biphenyl-4-ylthiazole], 65, 350°; 513°; 2,2'-oxydi-p-phenylenebis[4-phenylthiazole], 63, 230-1°, 476°; 2,2'-oxydi-p-phenylenebis[4-biphenyl-4- ylthiazole], 62.3, 343-4.5°, 495°. In general, the thermal stability increased with increased mol. weight, and the Me derivs. were the least resistant. The presence of an ether linkage lowered the stability only slightly. Thio amides, p-RC6H4C(:NH)SH, were prepared by passing dry H2S into a soln. of the nitrile in pyridine and freshly distilled Et3N (Fairfull, et al., CA 46, 9530g) (R, yield, m.p. given): H, -, 117°; Ph, 58.5%, 207-8°; HS(HN:)C-, 57.5%, 263-5°; p-HS(HN:)CC6H4O-, 63%, 230-1.5°. p-PhC6H4COCH2Br, m. 124-5°, was prepared from Ph2 by a Friedel-Crafts reaction, while (p-BrC6H4)2O and CuCN gave (p-NCC6H4)2O.
IT 13355-37-8P 14208-43-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, spectrum (uv) and thermal stability of)
RN 13355-37-8 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-phenyl- (8CI) (CA INDEX NAME)



RN 14208-43-6 CAPLUS
CN Thiazole, 2,2'-(oxydi-p-phenylene)bis[4-(4-biphenylyl)- (8CI) (CA INDEX NAME)



L31 ANSWER 97 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1965:498923 CAPLUS Full-text
DN 63:98923
OREF 63:18274a-e
TI Heteroaromatic polymers. Polybithiazoles
AU Longone, Daniel T.; Un, Howard H.
CS Univ. of Michigan, Ann Arbor
SO Journal of Polymer Science, Part A: General Papers (1965), 3(9), 3117-30
CODEN: JPYAAK; ISSN: 0449-2951
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB cf. CA 63, 3058h. Gross properties of polymers obtained by condensation of a number of monomers of high structural d. were correlated with controlled structural variations, e.g. extent of conjugation, presence of flexible and heteroatom linkages, symmetry, etc. Bifunctional aryl bromomethyl ketones of the general formula BrCH2COACOCH2Br (.apprx. 3 millimoles) were condensed with dithiooxamide (3 millimoles) in HCONMe2, heated to reflux, giving within 15

min. a finely divided precipitate of I. After 1.5 hrs., the mixture was filtered hot, and the resulting solids were continuously extracted for 15 hrs. each with HCONMe2, absolute EtOH, and Et2O. The residual polymer was dried at 100°/0.2 mm. for 5 hrs. With p- bis(bromoacetyl)benzene as comonomer, the highly refractive, crystalline I (A = p-C6H4) (II), number-average mol. weight 12,000, was obtained in 88% yield. Polythiazoles based on biphenyl, diphenylmethane, and phenyl ether substrates were prepared; they resembled II closely. Uv spectra of model polymers and absorption in the uv region support polymer anal. evidence that bithiazole-containing recurring units are present in the polymers. Polymer thermal stabilities were examined in N by heating at 300, 350, 400, 500, and 600° consecutively for 1-hr. periods, samples predried at 140-50°/0.2 mm. for 30 min. At the end of each hr. heating, the sample was cooled under N and removed to determine weight loss. The polythiazoles showed unusual thermal stability, with gross structural changes between 500 and 600°, confirmed by x-ray powder patterns and uv spectra. On prolonged exposure to light, the initially yellow-brown surface of polymer samples became pink and, in one case, analysis of a sample after 3-month exposure showed a decrease in C content from 64.2 to 62.7%, implying that a photooxidation process was involved.

IT 4072-66-6
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 4072-66-6 CAPLUS
CN 2,2'-Bithiazole, 4,4'-bis(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 98 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1965:498922 CAPLUS Full-text
DN 63:98922
OREF 63:18274a
TI Inorganic polymers. I. Solid inorganic foam
AU Shaw, R. A.; Ogawa, Takeshi
CS Univ. London
SO Journal of Polymer Science, Part A: General Papers (1965), 3(9), 3343-51
CODEN: JPYAAK; ISSN: 0449-2951
DT Journal
LA English
AB Hexaaminocyclotriphosphazatriene (I), recrystd. from H2O or used without purification, forms a phospham as a powder. If the starting material is precipitated from aqueous solution by suitable organic solvents, a foamed material results. Evidence from x-ray powder photographs indicated a depression of m.p. of I through solid-solution rather than eutectic formation. No foaming was observed with octaaminocyclotetraphosphazatetraene, N4P4(NH2)8.
IT 4072-66-6
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 4072-66-6 CAPLUS
CN 2,2'-Bithiazole, 4,4'-bis(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 99 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1965:417175 CAPLUS Full-text
DN 63:17175
OREF 63:3058h,3059a
TI New thermally stable heteroaromatic polymers: polydithiazoles
AU Longone, Daniel T.; Un, Howard H.
CS Univ. of Michigan, Ann Arbor
SO Am. Chem. Soc., Div. Polymer Chem., Preprints (1963), 4(2), 49-56
DT Journal
LA English
AB The condensation of dithiooxamide with arylenebis(bromomethyl ketones) gives a new class of thermally stable polydithiazoles. These polymers are characterized by high crystallinity and decomposition temps. as well as low solubility in organic solvents. Polydithiazoles containing solely aromatic-heteroaromatic nuclei in the recurring units exhibit an appreciable weight loss only above 500°. The polycondensation reaction is of such a nature that requisite monomers of great structural diversity can be utilized. This allows correlation of gross polymer properties with controlled structural variations. The introduction of flexible polymethylene linkages in the polymer recurring unit affords polymers. of decreased crystallinity, mol. wts., and decomposition temps. as well as attendant increased solubilities.
IT 4072-66-6
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 4072-66-6 CAPLUS
CN 2,2'-Bithiazole, 4,4'-bis(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 100 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1965:417174 CAPLUS Full-text
DN 63:17174
OREF 63:3058f-h
TI New high-temperature aromatic polyamides
AU Preston, J.; Dobinson, F.
CS Chemstrand Res. Center, Durham, NC, USA
SO Journal of Polymer Science, Part B: Polymer Letters (1964), 2(12), 1171-4
CODEN: JPSBDU; ISSN: 0449-2986
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Polymerization of N,N'-m-phenylenebis(m-aminobenzamide) (I) with isophthaloyl chloride (II) gave III. The min. repeating unit in such polymers contains 4 rings. I, m. 213-14°; N,N'-p-phenylenebis(m- aminobenzamide), m. 289-91°; N,N'-m-phenylenebis(p-aminobenzamide), m. 227-8°; N,N'-p-phenylenebis(p-

aminobenzamide), m. 324-6°; and N,N'-dimethyl-p-phenylenebis(m-aminobenzamide) (IV), m. 231-3°, were conventionally polymerized with some or all of 4 aryl diacid chlorides including II, terephthaloyl chloride, 2,6-naphthalenedicarbonyl chloride, and 4,4'-bibenzoyl chloride to yield the polyamides. All the polymers were very high-melting except those derived from IV. The diamines were prepared by condensation of 2 equivs. of the suitable nitro aroyl chloride with 1 equivalent of the aromatic diamine followed by a conventional reduction of the nitro groups. Clear, tough films and crystalline fibers were prepared from the polyamides. III had inherent viscosity 1.83 (0.5 g. polymer/100 ml. AcNMe2 containing 5% LiCl at 30°).
IT 4072-66-6
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 4072-66-6 CAPLUS
CN 2,2'-Bithiazole, 4,4'-bis(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 101 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1961:121423 CAPLUS Full-text
DN 55:121423
OREF 55:22831b-f
TI Thiazolocarbocyanines with aryl radicals in the thiazole nucleus. VIII. Unsymmetrical thiazolocarbocyanines
AU Sych, E. D.
SO Ukrains'kii Khemichnii Zhurnal (1961), 27, 83-7
CODEN: UKHZAS; ISSN: 0372-4190
DT Journal
LA Russian
AB cf. CA 54, 13143i. The following compds. were prepared: 2-(2-acetylanilinovinyl)-3-ethyl-5-phenylthiazolium p-toluenesulfonate, m. 138°; 2-(2-acetylanilinovinyl)-3-ethylbenzothiazolium (I) iodide, m. 230°; 5-MeO derivative (II), m. 207°; 6-MeO derivative (III), m. 205°; 3-HOCH2CH2 analog (IV), m. 217°; 2-(2-anilinovinyl)-3- ethyl-6,7-benzobenzothiazole p-toluenesulfonate (V), m. 270°; 4,5-benzobenzothiazole isomer, m. 249°; 2-(2-anilinovinyl)-3-ethyl- 6-nitrobenzothiazolium p-toluenesulfonate (VI), m. 272°; and the 5-nitro isomer (VII), m. 292°. Cyanine dyes were prepared from these and salts of 5-substituted 3-ethyl-2-methylbenzothiazole (substituent in the thiazole ring, other reagent, anion if not iodide, λ in mμ of sym. tricyanine dye related to I-VII, λ of sym. tricyanine from thiazole used, λ of unsym. dye, hypsochromic effect over average of the 2 sym. compds., % yield, and m.p. of dye given): Ph, I, 558, 592, 572, 3, 30, 260°; p-MeOC6H4, I, 558, 612, 574, 11, 45.6, 240°; 2-C10H7, I, 558, 608, 582, 1, 27.7, 232°; p-O2NC6H4, I, 558, 650, 592, 12, 76, 252°; p-PhOC6H4, I, 558, 606, 570, 12, 46.8, 185°; Me2NC6H4 (3-Me not Et), I, 558, 625, 580, 11.5, 46, 253°; AcNHC6H4, I, 558, 608, 576, 7, 67, 280°; Ph, IV, ClO4-, 562, 592, 568, 9, 9.2, 235°; the isomer of last with substituents on N atoms interchanged, 558, 594, 575, 1, 62, 239°; Ph, II, ClO4-, 576, 592, 583, 1, 57.9, 239°; 2-C10H7, II, 576, 608, 591, 2, -, 232°; O2NC6H4, II, p-toluenesulfonate, 576, 650, 605, 8, -, 255°; Ph, III, 572, 592, 582, 0, 7.9, 290°; O2NC6H4, III, 572, 650, 605, 6, -, 265°; p-MeOC6H4, III, ClO4-, 572, 612, 582, 10, -, 230°; 2-C10H7, III, 572, 608, 590, 0, -, 184°; Ph, VII, 560, 592, 561, 15, 41, 282°; Ph, VI, 585, 592, 580, 8.5, 37, 273°; Ph, V, 597, 592, 1.5, -, -; p-MeOC6H4, V, 597, 612, 596, 9.5, 57.3,

215°; 2-C10H7, V, 597, 608, 597, 5.5, 60, 231°. The hypsochromic effect due to difference in basicity is rather small, but it appears that a NO2-group in the 5-position of benzothiazole has a greater effect on the thiazole ring than one in the 6-position.
IT 117373-09-8P, 3-Ethyl-2-[3-[3-ethyl-5-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]propenyl]benzothiazolium iodide
RL: PREP (Preparation)
(preparation of)
RN 117373-09-8 CAPLUS
CN 3-Ethyl-2-[3-[3-ethyl-5-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]propenyl]benzothiazolium iodide (6CI) (CA INDEX NAME)



● I⁻

L31 ANSWER 102 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1958:104223 CAPLUS Full-text
DN 52:104223
OREF 52:18377b-g
TI Thiazolocarbocyanines with aryl radicals in the thiazole rings. III. Methoxyarylthiazolocarbocyanines
AU Sych, E. D.
SO Ukrains'kii Khemichnii Zhurnal (1958), 24, 79-88
CODEN: UKHZAS; ISSN: 0372-4190
DT Journal
LA Russian
AB cf. C.A. 51, 372g. RCOCH2X (X = Cl or Br) (I) (from RAc and Br or RH and ClCH2COCl in presence of AlCl3) and MeCSNH2 form 4-substituted-2-methylthiazoles (II-4) and p-MeC6H4SO3Et derivs. (III-4). From I, via the (CH2)6N4 complexes, RCOCH2NH2 [HCl salt, R = 4-(p-MeOC6H4)C6H4 (IIIa), m. 272°] and their Ac derivs. (IV) were prepared IV and P2S5 form 5-substituted-2-methylthiazoles (II-5), p-MeC6H4SO3Et derivs. (III-5). III, CH(OEt)3, and a little Ac2O form trimethinecyanine dyes (V-4 and V-5), isolated as iodides. III and p-Me2NC6H4CHO form styrenes (VI-4 and VI-5), also isolated as iodides. The following are reported [R, X (m.p. of I), m.ps. of II-4, III-4, II-5, III-5, IV, V-4, V-5, VI-4, and VI-5, and λ (in mμ) of V-4, V-5, VI-4, and VI-5 given]: p-MeOC6H4, -(-), 69°, -, 143-4°, 145°, 111°, 240°, 190°, 198°, 245°, 560, 612, 485-90, 505; p-PhOC6H4, Cl (52°, b4 20°), 69° (b6 260-80°), -, 116°, 85°, 198°, 250-1°, 195°, 255°, 560, 606, 490, 508; IIIa, Cl (132°), Br (118-19°), 176°, 160°, 248-9°, -, 183°, 262°, 198-206°, 252°, 245°, 565, 612, 490, 510; 4-methoxy-1-naphthyl, Br (66°), 104-5°, -, 74-5°, 144-5°, 135°, 176°, 200°, -, -, 568, 580, -, -. I (X = Cl, R = IIIa) was accompanied by a more ligroine-soluble isomer, m. 117-20°, which was assumed to be the 2-MeO compound from an impurity in the RH. The following R1CH:CHCR1:CHCH:R2.2I (R1 and R2 = aryl-3-ethyl-2-thiazolyl and

-thiazolidinylidene, resp.) are reported as by-products in the preparation of V (aryl substituent, m.p., and λ, in mμ given) 5-IIIa, 190°, 638; 4-(p-PhOC6H4), 180°, 600; 4-methoxy-1-naphthyl, 247°, 605. 5-Substituted-3-ethylthiazolium compds. and 2-methylthio-3- ethylbenzothiazolium iodide form the following monomethinecyanines (VII) isolated as iodides (substituent, m.p., and λ in mμ given): p-MeOC6H4, 257°, 440; IIIa, 268°, 447; EtO, 222°, 425; H, 279°, 412; Ph, 277°, 437; p-PhC6H4, 244°, 444. II-5 (R = p-MeOC6H4) was heated with EtC(OEt)3 and MeC(OEt)3 to form R1CH:CR3CH:R2.ClO4 (VIII) (R1 and R2 as before): R3 = Et, m. 221°, λ 600 mμ; R3 = Me, m. 245° (as iodide), λ 600 mμ. Consideration of the λ of the tri- and monomethinecyanines shows that the bathochromic effect of an alkoxyl group is greatly reduced by an intervening benzene ring.

IT [illegible]
(Derived from data in the 6th Collective Formula Index (1957-1961))

RN 108627-72-1 CAPLUS

CN 2,2'-[3-[2-[3-Ethyl-4-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]ethylidene]propenylene]bis[3-ethyl-4-(p-phenoxyphenyl)thiazolium iodide] (6CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A

●2 I-

RN 122446-42-8 CAPLUS

CN 2-(p-Dimethylaminostyryl)-3-ethyl-5-(p-phenoxyphenyl)thiazolium iodide (6CI) (CA INDEX NAME)



● I-

RN 122446-46-2 CAPLUS

CN 2-(p-Dimethylaminostyryl)-3-ethyl-4-(p-phenoxyphenyl)thiazolium iodide (6CI) (CA INDEX NAME)



● I-

IT 108669-19-8P, 3-Ethyl-2-[3-[3-ethyl-4-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]propenyl]-4-(p-phenoxyphenyl)thiazolium iodide
108669-21-2P, 3-Ethyl-2-[3-[3-ethyl-5-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]propenyl]-5-(p-phenoxyphenyl)thiazolium iodide
302581-18-6P, Thiazole, 2-methyl-4-(p-phenoxyphenyl)-
860174-94-3P, Thiazole, 2-methyl-5-(p-phenoxyphenyl)-
RL: PREP (Preparation)
(preparation of)

RN 108669-19-8 CAPLUS

CN 3-Ethyl-2-[3-[3-ethyl-4-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]propenyl]-4-(p-phenoxyphenyl)thiazolium iodide (6CI) (CA INDEX NAME)



● I-

RN 108669-21-2 CAPLUS

CN 3-Ethyl-2-[3-[3-ethyl-5-(p-phenoxyphenyl)-4-thiazolin-2-ylidene]propenyl]-5-(p-phenoxyphenyl)thiazolium iodide (6CI) (CA INDEX NAME)



● I-

RN 302581-18-6 CAPLUS

CN Thiazole, 2-methyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 860174-94-3 CAPLUS

CN Thiazole, 2-methyl-5-(p-phenoxyphenyl)- (6CI) (CA INDEX NAME)



L31 ANSWER 103 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1955:49480 CAPLUS Full-text

DN 49:49480

OREF 49:9623b-h

TI Syntheses of thiazole derivatives containing a diphenyl ether nucleus. I

AU Tomita, Masao; Kumaoka, Hiroshi; Takase, Mumeaki

CS Univ. Kyoto

SO Yakugaku Zasshi (1954), 74, 850-3
CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Unavailable

AB Ph2O and ClCH2COCl in CS2 in the presence of AlCl3 give (4-ClCH2COC6H4)2O (I), prisms, m. 111° (from alc.); 1.52 g. (NH2)2CS in 10 ml. alc. at 60° treated dropwise with 3.23 g. I in 50 ml. alc., the mixture heated 30 min., stirred 1.5 hrs., and the alc. removed in vacuo gives 4.5 g. (p-RC6H4)2O.HCl (II) [R = 2-amino-4-thiazolyl (III)]; the free base, prisms, m. 241-2° (from tetrahydrofuran-Me2CO). Similarly, heating of 3.23 g. I and 1.5 g. MeCSNH2 in 60 ml. alc. gives 4.3 g. II [R = 2-methyl-4-thiazolyl (IIIa)] (IV); the free base of IV, leaves, m. 146-7° (from alc.). AlCl3 (20 g.) at 0° treated dropwise with 17 g. ClCH2COCl in 20 ml. CS2, then with 9.3 g. Ph2S in 30 ml. CS2, the mixture stirred 30 min. at 0°, heated 30 min. at 50°, the CS2 removed, the residue decomposed with ice water, and the product extracted with CHCl3 gives 8.3 g. (4-ClCH2COC6H4)2S (V), prisms, m. 106-7° (from CHCl3Me2CO); recrystn. from 250 ml. MeOH gives 6 g. V, m. 109°; 1.52 g. (H2N)2CS in 10 ml. alc. at 60° treated dropwise with 33.9 g. V in 50 ml. alc., the mixture heated 30 min., stirred 1.5 hrs., and the alc. removed in vacuo gives 4.5 g. (p-RC6H4)2S.HCl (VI) [(R = III (VII)]; the free base of VII, granules, m. 240° (from tetrahydrofuran-Me2CO). Similarly, 1.5 g. MeCSNH2 and 3.39 g. V in 60 ml. alc. give 4.6 g. VI [R = IIIa (VIII)]; the free base of VIII, leaves, m. 154-6° (from alc.-C6H6). (4-AcC6H4)2O (5 g.) in 30 ml. AcOH on a water bath treated dropwise with 4 g. Br in 20 min., the mixture stirred 40 min., the AcOH removed, and the residue extracted with Et2O and distilled gives 4.5 g. (4-BrCH2COC6H4)2O (IX), b3 190-2°; 0.47 g. (H2N)2CS in 10 ml. alc. treated dropwise with 1.8 g. IX in 30 ml. alc., stirred 1.5 hrs., and the product washed with dilute alc. and recrystd. from alc. gives 1.16 g. 2-amino-4-(p-phenoxyphenyl)thiazole (X), m. 117°; 0.42 g. MeCSNH2 in 10 ml. alc. treated with 1.6 g. IX in 30 ml. alc., stirred 1.5 hrs., made alkaline with NaOH, the alc., removed, and the residue extracted with Et2O and recrystd. from alc. gives the 2-Me analog of X, leaves, m. 71°. 4-H2NC6H4OPh.HCl (2.3 g.) in 10 ml. water and 2.3 g. NH4SCN in water evaporated to dryness, and the residue washed with a small amount of water and recrystd. from alc. give 2 g. 4-thioureidodiphenyl ether (XI), plates, m. 181°; 1.8 g. XI in 6 ml. water at 80° treated with 1 ml. ClCH2Ac, heated 20 min., made alkaline with NaOH, and the product filtered and recrystd. from 60 ml. 70% alc. gives 1.5 g. 2-(p-phenoxyphenylamino)-4-methylthiazole (XII), needles, m. 110.5-11.0°; picrate, m. 166.5°. XI (1.8 g.) in 5.5 ml. water treated with 1.3 ml. CH2ClCHClOEt, heated 30 min., and the product made alkaline with NaOH and recrystd. from 70% alc. gives 1.5 g. 2-(p-phenoxyphenylamino)thiazole, leaves, m. 128.5-9.0°; HCl salt, plates, m. 82.5-3.0°; picrate, needles, m. 187-8°. XII showed a strong antibacterial action toward human type tubercule bacilli; the other prepns. showed only a weak action against other bacteria, e.g., Bacillus dysentereae and Salmonella typhosa.

IT 105512-82-1P, Thiazole, 2-amino-4-(p-phenoxyphenyl)-
302581-18-6P, Thiazole, 2-methyl-4-(p-phenoxyphenyl)-
864260-01-2P, Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-amino-
899486-39-9P, Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-methyl-, hydrochloride 899495-46-9P, Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-methyl- 899496-53-0P, Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-amino-, hydrochloride
RL: PREP (Preparation)
(preparation of)

RN 105512-82-1 CAPLUS

CN 2-Thiazolamine, 4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 302581-18-6 CAPLUS
CN Thiazole, 2-methyl-4-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 854260-01-8 CAPLUS
CN Ether, bis[p-(2-amino-4-thiazolyl)phenyl] (4CI) (CA INDEX NAME)



RN 859480-38-9 CAPLUS
CN Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-methyl-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

RN 859480-46-9 CAPLUS
CN Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-methyl- (5CI) (CA INDEX NAME)



RN 859480-53-8 CAPLUS
CN Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-amino-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

L31 ANSWER 104 OF 104 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1946:19352 CAPLUS Full-text
DN 40:19352
OREF 40:3779f-i,3780a-h
TI Thiazoles
IN Simons, John K.
PA Libbey-Owens-Ford Glass Co.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2396893		19460319	US 1942-453987	19420807

AB Thiazoles are prepared which react with aldehydes to form thermosetting resins. Although 2,2'-diamino-4,4'-bithiazole does not form thermosetting resins with aldehydes, the general formulas for the compds. that form resins are: Ph-A1-(CH2)n-A2-Ph and R1-A1-B-A2-R2, where A1 and A2 are bivalent radicals from the 2-amino-4-thiazolyl group; n an integer not greater than 12; R1 and R2 are univalent radicals as H, Me, Et, Pr, iso-Pr, Ph; and benzyl; B is a bivalent radical as phenylene or substituted phenylene with no more than 4 univalent substituents, of which 3 may be Me and 2 may be MeO, EtO, -r1-O-r2-, and -r1-O-(CH2-CH2-O)x-r2-, where r1 and r2 are bivalent radicals as phenylene or substituted phenylene with no more than 2 univalent substituents as MeO and EtO; x is an integer not greater than 6. The 1st step consists of a Friedel-Crafts reaction between an aromatic compound and an acyl halide to prepare a dihalo ketone. In the 2nd step, the dihalo ketone is treated with thiourea (I) to give a hydrohalide, from which is liberated the organic compound on neutralization with a base. The general formula for the acyl halide is (R1)(X1)CH-CO(X2), where X1 and X2 may be Cl or Br and R1 as above. Thus 2 mols. ClCH2COCl (II) and 1 mol. PhOPh (III) are mixed and slowly added to a stirred suspension of 2 mols. anhydrous AlCl3 (IV) in 850 cc. CS2 in an ice bath. After the addition, warm on the water bath for 4 h., pour off the CS2, and hydrolyze the reddish oil with aqueous HCl. Crystallize the precipitate from alc. to produce 50% p,p'-bis(chloroacetyl)-diphenyl ether (V), white solid, m. 99 102°. In the 2nd step, heat 150 g. V on the H2O-bath with 250 g. I and 750 cc. H2O containing 4 cc. concentrated HCl until the HCl salt ppts. Dissolve the precipitate in 9 l. boiling H2O, filter, neutralize the hot solution with aqueous NaHCO3. Filter, wash, and recrystallize from the Me ether of ethylene glycol to obtain 44% of p,p'-bis(2-amino-4-thiazolyl)diphenyl ether, m. 246-8°. Dissolve 40 g. NaOH and 94 g. PhOH in 100 cc. H2O, add 100 cc. alc., and 94 g. (CH2Br)2. Reflux 16 h., filter, and cool. Recrystallize from alc. the ethylene glycol di-Ph ether (VI), m. 97°. The Friedel-Crafts reaction with 48 g. VI, 40 cc. II, and 60 g. IV in 300 cc. CS2 gives the di-Cl diketone (VII), m. 155-65°. VII (30 g.) and 16.5 g. I are dissolved in BuOH and boiled to precipitate the HCl salt, which is neutralized with NaHCO3 and ppts. ethylene glycol bis(2-amino-4-thiazolylphenyl) ether, m. 255-60°. Diethylene glycol di-Ph ether (VIII), m. 65-70°, is prepared from 72 g. (ClCH2CH2)2O instead of 94 g. (CH2Br)2. The Friedel-Crafts reaction is

conducted on 26 g. VIII, 18 cc. II, and 25 g. IV in 120 cc. CS2. Treat 16.5 g. di-Cl diketone with 10 g. I to obtain diethylene glycol bis(2-amino-4-thiazolylphenyl) ether, m. 178-9°. Prepare triethylene glycol di-Ph ether (IX), b15, 240° m. 42°, from 94 g. (CH2OCH2CH2Cl)2 instead of 94 g. (CH2Br)2. After 16 h. reflux, decant the supernatant liquid from the NaCl which seps. The oily layer obtained on cooling is dried with CaCl2, then distilled to give IX. The Friedel-Crafts reaction is conducted with 30 g. IX, 22 cc. II, and 35 g. IV in 200 cc. CS2. Treat 30 g. of the di-Cl diketone thus obtained with 20 g. I to obtain triethylene glycol bis(2-amino-4-thiazolylphenyl) ether sinters at 150°, m. 165°. In the Friedel-Crafts reaction with 15 g. anisole, 90 g. BrCH2COBr, and 40 g. IV in 230 g. CS2, the nonaq. hydrolyzate is extracted with Et2O; evaporation and addition of 70 cc. EtOH gives bis(bromoacetyl)anisole (X), m. 76-80°. From 3.3 g. X and 1.4 g. I in 30 cc. 60% EtOH after 2 h. heating on the H2O-bath, the HCl salt ppts. Dissolve the precipitate in 40 cc. hot H2O containing 1.5 g. NaHCO3 to precipitate bis(2-amino-4-thiazolyl)anisole, m. 205-8°. The Friedel-Crafts reaction with 120 g. sebacoyl chloride, 150 g. IV in 600 cc. benzene, after hydrolysis gives a white precipitate soluble in addnl. benzene. Wash with dilute Na2CO3 solution and dry over CaCl2; distil off the benzene; recrystn. from alc. gives 1,8-dibenzoyloctane (XI). XI (40 g.) and 180 cc. CCl4 are heated under reflux with dropwise addition of 40 g. Br. Distillation gives a concentrated solution, which crystallizes on cooling. Purifying the crystalline product by washing with petr. ether gives PhCOCHBr(CH2)6-CHBrCOPh (XII), m. 83°. XII (40.5 g.) and 12 g. I in 300 cc. 65% EtOH precipitate the HCl salt. Neutralization with Na2CO3 gives 36 g. 1,6-bis(2-amino-4-phenyl-5-thiazoyl)hexane, m. 202-4°. The Friedel-Crafts reaction with 16 g. MeCHClCOCl, 10 g; III, and 15 g. IV in 75 cc. CS2 gives p,p'-bis(α-chloropropionyl)diphenyl ether (XIII), m. 78-85°. XIII (11 g.) and 8 g. I in BuOH precipitate the HCl salt, which on neutralization with Na2CO3 ppts. p,p'-bis(5-methyl-2-amino-4-thiazolyl)diphenyl ether, m. 244-6°.

IT 854260-01-8P, Thiazole, 4,4'-(oxydi-p-phenylene)bis[2-amino-
857549-92-9P, Thiazole, 5,5'-(oxydi-p-phenylene)bis[2-amino-4-methyl-, hydrochloride 857549-94-1P, Thiazole, 5,5'-(oxydi-p-phenylene)bis[2-amino-4-methyl-
RL: PREP (Preparation)
(preparation of)

RN 854260-01-8 CAPLUS
CN Ether, bis[p-(2-amino-4-thiazolyl)phenyl] (4CI) (CA INDEX NAME)



RN 857549-92-9 CAPLUS
CN Thiazole, 5,5'-(oxydi-p-phenylene)bis[2-amino-4-methyl-, hydrochloride (4CI) (CA INDEX NAME)



● HCl

RN 857549-94-1 CAPLUS
CN Thiazole, 5,5'-(oxydi-p-phenylene)bis[2-amino-4-methyl- (4CI) (CA INDEX NAME)



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	549.02	1001.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-81.12	-84.24

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:16:55 ON 19 DEC 2007